NZ738636B2 - Method and compositions for cellular immunotherapy - Google Patents
Method and compositions for cellular immunotherapy Download PDFInfo
- Publication number
- NZ738636B2 NZ738636B2 NZ738636A NZ73863613A NZ738636B2 NZ 738636 B2 NZ738636 B2 NZ 738636B2 NZ 738636 A NZ738636 A NZ 738636A NZ 73863613 A NZ73863613 A NZ 73863613A NZ 738636 B2 NZ738636 B2 NZ 738636B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cells
- domain
- seq
- cell
- amino acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title description 51
- 238000009169 immunotherapy Methods 0.000 title description 22
- 230000001413 cellular Effects 0.000 title description 21
- 108020001747 chimeric receptor Proteins 0.000 claims abstract description 425
- 102100005826 CD19 Human genes 0.000 claims abstract description 177
- 101700087100 CD19 Proteins 0.000 claims abstract description 177
- 150000001413 amino acids Chemical group 0.000 claims abstract description 132
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 120
- 229920000023 polynucleotide Polymers 0.000 claims abstract description 108
- 239000002157 polynucleotide Substances 0.000 claims abstract description 108
- 235000001014 amino acid Nutrition 0.000 claims abstract description 96
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 92
- 230000004068 intracellular signaling Effects 0.000 claims abstract description 66
- 230000011664 signaling Effects 0.000 claims abstract description 65
- 229920001184 polypeptide Polymers 0.000 claims abstract description 59
- 230000000139 costimulatory Effects 0.000 claims abstract description 50
- 108020001756 ligand binding domains Proteins 0.000 claims abstract description 40
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000018417 cysteine Nutrition 0.000 claims abstract description 17
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 17
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims abstract description 12
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims abstract description 12
- 239000004475 Arginine Chemical group 0.000 claims abstract description 9
- 239000004471 Glycine Chemical group 0.000 claims abstract description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 9
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims abstract description 9
- 239000004473 Threonine Chemical group 0.000 claims abstract description 9
- 210000004027 cells Anatomy 0.000 claims description 431
- 102100019461 CD28 Human genes 0.000 claims description 115
- 101700033362 CD28 Proteins 0.000 claims description 115
- 102000005962 receptors Human genes 0.000 claims description 112
- 108020003175 receptors Proteins 0.000 claims description 112
- 102100009537 TNFRSF9 Human genes 0.000 claims description 88
- 101710040535 TNFRSF9 Proteins 0.000 claims description 88
- 230000014509 gene expression Effects 0.000 claims description 64
- 238000000338 in vitro Methods 0.000 claims description 57
- 210000004698 Lymphocytes Anatomy 0.000 claims description 43
- 239000003550 marker Substances 0.000 claims description 42
- 102100008254 SELL Human genes 0.000 claims description 40
- 101710038663 SELL Proteins 0.000 claims description 40
- 230000003834 intracellular Effects 0.000 claims description 23
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims description 9
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims description 9
- 230000003284 homeostatic Effects 0.000 claims description 2
- 210000001744 T-Lymphocytes Anatomy 0.000 description 438
- 102100017729 ROR1 Human genes 0.000 description 191
- 101710036428 ROR1 Proteins 0.000 description 190
- 101700058902 RORA Proteins 0.000 description 190
- 102100008191 CD8A Human genes 0.000 description 139
- 101700054655 CD8A Proteins 0.000 description 139
- 206010028980 Neoplasm Diseases 0.000 description 139
- 102100013077 CD4 Human genes 0.000 description 108
- 101700022938 CD4 Proteins 0.000 description 108
- 210000004881 tumor cells Anatomy 0.000 description 87
- 239000000427 antigen Substances 0.000 description 80
- 102000038129 antigens Human genes 0.000 description 80
- 108091007172 antigens Proteins 0.000 description 80
- 102000004965 antibodies Human genes 0.000 description 78
- 108090001123 antibodies Proteins 0.000 description 78
- 230000027455 binding Effects 0.000 description 65
- 230000035755 proliferation Effects 0.000 description 60
- 108091006028 chimera Proteins 0.000 description 55
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 50
- 230000000259 anti-tumor Effects 0.000 description 48
- 239000003446 ligand Substances 0.000 description 48
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 41
- 229920001850 Nucleic acid sequence Polymers 0.000 description 35
- 125000003275 alpha amino acid group Chemical group 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 35
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 description 34
- 201000010099 disease Diseases 0.000 description 34
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 33
- 206010008943 Chronic leukaemia Diseases 0.000 description 32
- 210000004379 Membranes Anatomy 0.000 description 30
- 239000012528 membrane Substances 0.000 description 30
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 29
- 230000004913 activation Effects 0.000 description 28
- 230000032823 cell division Effects 0.000 description 27
- 210000003283 T-Lymphocytes, Helper-Inducer Anatomy 0.000 description 23
- 230000016396 cytokine production Effects 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 22
- 230000000638 stimulation Effects 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 108010002350 Interleukin-2 Proteins 0.000 description 20
- 102000000588 Interleukin-2 Human genes 0.000 description 20
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 20
- 210000002443 helper T lymphocyte Anatomy 0.000 description 20
- 238000010186 staining Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 210000003071 memory T lymphocyte Anatomy 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- 206010025323 Lymphomas Diseases 0.000 description 18
- 206010025310 Other lymphomas Diseases 0.000 description 18
- 210000001185 Bone Marrow Anatomy 0.000 description 17
- 239000002609 media Substances 0.000 description 17
- 238000003384 imaging method Methods 0.000 description 16
- 230000028327 secretion Effects 0.000 description 16
- 238000010361 transduction Methods 0.000 description 16
- 230000026683 transduction Effects 0.000 description 16
- -1 LIGHT Proteins 0.000 description 14
- 210000003819 Peripheral blood mononuclear cell Anatomy 0.000 description 14
- 230000001461 cytolytic Effects 0.000 description 14
- 239000011886 peripheral blood Substances 0.000 description 14
- 101700025368 ERBB2 Proteins 0.000 description 13
- 102100016662 ERBB2 Human genes 0.000 description 13
- 102100016020 IFNG Human genes 0.000 description 13
- 101700086956 IFNG Proteins 0.000 description 13
- 230000001086 cytosolic Effects 0.000 description 13
- 230000004083 survival Effects 0.000 description 13
- 102100005832 CD69 Human genes 0.000 description 12
- 101700080416 CD69 Proteins 0.000 description 12
- 101700082799 IL2RA Proteins 0.000 description 12
- 101700015336 ISG20 Proteins 0.000 description 12
- 102100002950 ISG20 Human genes 0.000 description 12
- 101710037934 QRSL1 Proteins 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 12
- 230000009089 cytolysis Effects 0.000 description 12
- 108010045030 monoclonal antibodies Proteins 0.000 description 12
- 102000005614 monoclonal antibodies Human genes 0.000 description 12
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 11
- 238000004166 bioassay Methods 0.000 description 11
- 230000030833 cell death Effects 0.000 description 11
- 230000001976 improved Effects 0.000 description 11
- 230000001965 increased Effects 0.000 description 11
- 125000005647 linker group Chemical group 0.000 description 11
- 230000002934 lysing Effects 0.000 description 11
- 230000002688 persistence Effects 0.000 description 11
- 238000007619 statistical method Methods 0.000 description 11
- 230000003612 virological Effects 0.000 description 11
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 10
- 102100008151 CCR7 Human genes 0.000 description 10
- 229920001405 Coding region Polymers 0.000 description 10
- 229940022353 Herceptin Drugs 0.000 description 10
- 101700036258 MECOM Proteins 0.000 description 10
- 102100009534 TNF Human genes 0.000 description 10
- 210000003462 Veins Anatomy 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 102100005499 PTPRC Human genes 0.000 description 9
- 101700059076 PTPRC Proteins 0.000 description 9
- 230000029918 bioluminescence Effects 0.000 description 9
- 238000005415 bioluminescence Methods 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 210000004369 Blood Anatomy 0.000 description 8
- 102100014194 IL7R Human genes 0.000 description 8
- 101710025228 IL7R Proteins 0.000 description 8
- 210000000952 Spleen Anatomy 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 8
- 108091008153 T cell receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000005859 cell recognition Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000003379 elimination reaction Methods 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 210000004962 mammalian cells Anatomy 0.000 description 8
- 230000002062 proliferating Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000004450 types of analysis Methods 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 210000000170 Cell Membrane Anatomy 0.000 description 7
- 102100012223 KLRK1 Human genes 0.000 description 7
- 101710036390 KLRK1 Proteins 0.000 description 7
- 241000713666 Lentivirus Species 0.000 description 7
- 230000000875 corresponding Effects 0.000 description 7
- 230000001404 mediated Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000004366 CD4-Positive T-Lymphocytes Anatomy 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 6
- 102000003814 Interleukin-10 Human genes 0.000 description 6
- 108090000174 Interleukin-10 Proteins 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 210000001519 tissues Anatomy 0.000 description 6
- 210000003719 B-Lymphocytes Anatomy 0.000 description 5
- 102100000189 CD22 Human genes 0.000 description 5
- 101700020617 CD22 Proteins 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 206010024324 Leukaemias Diseases 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- 229940035295 Ting Drugs 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000003247 decreasing Effects 0.000 description 5
- 239000001963 growth media Substances 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 230000004936 stimulating Effects 0.000 description 5
- 230000001225 therapeutic Effects 0.000 description 5
- 101710043760 ANGPTL4 Proteins 0.000 description 4
- 101700056583 CD27 Proteins 0.000 description 4
- 102100019459 CD27 Human genes 0.000 description 4
- 102100019451 CD80 Human genes 0.000 description 4
- 101700080477 CD80 Proteins 0.000 description 4
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 4
- 108030007212 EC 3.4.21.79 Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 230000035693 Fab Effects 0.000 description 4
- 102100004391 GZMB Human genes 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 108060001084 Luciferase family Proteins 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- 101710040448 TNFRSF4 Proteins 0.000 description 4
- 102100013135 TNFRSF4 Human genes 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 210000003162 effector T lymphocyte Anatomy 0.000 description 4
- 101710024922 hyg Proteins 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000004073 interleukin-2 production Effects 0.000 description 4
- 238000001325 log-rank test Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000010445 mica Substances 0.000 description 4
- 229910052618 mica group Inorganic materials 0.000 description 4
- 238000006011 modification reaction Methods 0.000 description 4
- 108091007521 restriction endonucleases Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 206010059512 Apoptosis Diseases 0.000 description 3
- 210000000601 Blood Cells Anatomy 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 3
- 102100011842 CEACAM5 Human genes 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 102100010782 EGFR Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101700053597 FCER2 Proteins 0.000 description 3
- 102100014608 FCER2 Human genes 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 102100000165 MS4A1 Human genes 0.000 description 3
- 101710010909 MS4A1 Proteins 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 206010025650 Malignant melanoma Diseases 0.000 description 3
- 206010026798 Mantle cell lymphomas Diseases 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 102100009178 RUNX1T1 Human genes 0.000 description 3
- 101710034060 RUNX1T1 Proteins 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000735 allogeneic Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000003190 augmentative Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 3
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 230000001586 eradicative Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000003394 haemopoietic Effects 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 102000003735 mesothelin Human genes 0.000 description 3
- 108090000015 mesothelin Proteins 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000036457 multidrug resistance Effects 0.000 description 3
- 230000001717 pathogenic Effects 0.000 description 3
- 244000052769 pathogens Species 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000001177 retroviral Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000002463 transducing Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 2
- 102100007409 APRT Human genes 0.000 description 2
- 108010024223 Adenine Phosphoribosyltransferase Proteins 0.000 description 2
- 241000432074 Adeno-associated virus Species 0.000 description 2
- 102000009914 Adenosine deaminases Human genes 0.000 description 2
- 108091022188 Adenosine deaminases Proteins 0.000 description 2
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 2
- 101710040446 CD40 Proteins 0.000 description 2
- 102100013137 CD40 Human genes 0.000 description 2
- 102100008186 CD83 Human genes 0.000 description 2
- 101700013105 CD83 Proteins 0.000 description 2
- 101710038812 CS1 Proteins 0.000 description 2
- 102100005310 CTLA4 Human genes 0.000 description 2
- 101700054183 CTLA4 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- VDABVNMGKGUPEY-UHFFFAOYSA-N Carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Destomysin Chemical compound OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- 101700039191 EGFR Proteins 0.000 description 2
- 102100016692 ESR1 Human genes 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 101700036477 FOLH1 Proteins 0.000 description 2
- 102100008453 FOLH1 Human genes 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 229960002743 Glutamine Drugs 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 229940097277 Hygromycin B Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102100018760 IL3RA Human genes 0.000 description 2
- 101700029869 IL3RA Proteins 0.000 description 2
- 101710021997 ITPRID2 Proteins 0.000 description 2
- 210000000987 Immune System Anatomy 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 102100012225 KLRC2 Human genes 0.000 description 2
- 101710036391 KLRC2 Proteins 0.000 description 2
- 108010025815 Kanamycin Kinase Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 210000003141 Lower Extremity Anatomy 0.000 description 2
- 102100002232 MYOZ2 Human genes 0.000 description 2
- 101700029059 MYOZ2 Proteins 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 108020004999 Messenger RNA Proteins 0.000 description 2
- 101710036205 OXTR Proteins 0.000 description 2
- 101700008337 PSMA Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 108091008002 RAR-related orphan receptors Proteins 0.000 description 2
- 102100013504 RPL17 Human genes 0.000 description 2
- 108060007796 SPATA2 Proteins 0.000 description 2
- 210000000662 T-Lymphocyte Subsets Anatomy 0.000 description 2
- 101710040533 TNFRSF8 Proteins 0.000 description 2
- 102100009538 TNFRSF8 Human genes 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- 102000006646 aminoglycoside phosphotransferase family Human genes 0.000 description 2
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 101710006741 cys-17 Proteins 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 230000003211 malignant Effects 0.000 description 2
- 229920002106 messenger RNA Polymers 0.000 description 2
- 229960000060 monoclonal antibodies Drugs 0.000 description 2
- 101700004781 mor Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003370 receptor cell Anatomy 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 102000035402 transmembrane proteins Human genes 0.000 description 2
- 108091005683 transmembrane proteins Proteins 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- UHWYNRUUZORUJL-WOOOTXSOSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]am Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UHWYNRUUZORUJL-WOOOTXSOSA-N 0.000 description 1
- WLKSPGHQGFFKGE-UHFFFAOYSA-N 1-chloropropan-2-yl N-(3-chlorophenyl)carbamate Chemical compound ClCC(C)OC(=O)NC1=CC=CC(Cl)=C1 WLKSPGHQGFFKGE-UHFFFAOYSA-N 0.000 description 1
- 101700029306 ANG1 Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 240000000800 Allium ursinum Species 0.000 description 1
- 108010031480 Artificial Receptors Proteins 0.000 description 1
- 241000714230 Avian leukemia virus Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 102100016493 CD33 Human genes 0.000 description 1
- 101700017647 CD33 Proteins 0.000 description 1
- 102100016530 CD37 Human genes 0.000 description 1
- 101700044364 CD37 Proteins 0.000 description 1
- 102100005828 CD5 Human genes 0.000 description 1
- 101700066525 CD5 Proteins 0.000 description 1
- 102100016531 CD9 Human genes 0.000 description 1
- 101700017162 CD9 Proteins 0.000 description 1
- 101710043954 CEACAM3 Proteins 0.000 description 1
- 102100011836 CEACAM3 Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002676 Complementary DNA Polymers 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- 101700086219 DVA-1 Proteins 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- 102000004420 EC 2.7.3.2 Human genes 0.000 description 1
- 108010042126 EC 2.7.3.2 Proteins 0.000 description 1
- 102000000311 EC 3.5.4.1 Human genes 0.000 description 1
- 108010080611 EC 3.5.4.1 Proteins 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 102100001451 ESRRB Human genes 0.000 description 1
- 101710024869 ESRRB Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 101700079540 FAS Proteins 0.000 description 1
- 102100016439 FAS Human genes 0.000 description 1
- 102100015540 FCGR1A Human genes 0.000 description 1
- 101710003440 FCGR1A Proteins 0.000 description 1
- 102100015541 FCGR3A Human genes 0.000 description 1
- 101710044656 FCGR3A Proteins 0.000 description 1
- 101710044657 FCGR3B Proteins 0.000 description 1
- 102000018152 Frizzled domain Human genes 0.000 description 1
- 108050007261 Frizzled domain Proteins 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 108091006822 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 101710028361 MARVELD2 Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 102000003505 Myosin family Human genes 0.000 description 1
- 108060008487 Myosin family Proteins 0.000 description 1
- 102100016102 NTRK1 Human genes 0.000 description 1
- 101700043017 NTRK1 Proteins 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 208000010380 Tumor Lysis Syndrome Diseases 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 229920002533 WHP Posttrascriptional Response Element Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000001745 anti-biotin Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000005216 brain cancer Diseases 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003260 fluorescence intensity Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 101500002601 human Epidermal growth factor Proteins 0.000 description 1
- 229940116978 human epidermal growth factor Drugs 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 230000017307 interleukin-4 production Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001806 memory B lymphocyte Anatomy 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 101700040659 pgsA Proteins 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OFPTZWGZSRJCOT-MSPNRCMCSA-M potassium;2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-d Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O OFPTZWGZSRJCOT-MSPNRCMCSA-M 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Abstract
The invention relates to a nucleic acid encoding a chimeric receptor, the chimeric receptor comprising: (a) an extracellular domain consisting of: an extracellular ligand binding domain consisting of a single chain variable fragment (scFv) that binds to a CD19, wherein the scFv comprises a variable light chain (VL) domain comprising a CDRL1, a CDRL2, and a CDRL3 of the amino acid sequence encoded by SEQ ID NO:3, and a variable heavy chain (VH) domain comprising a CDRH1, a CDRH2, and a CDRH3 of the amino acid sequence encoded by SEQ ID NO:3; and an extracellular polypeptide spacer that is about 15 amino acids or less in length and comprises an amino acid sequence of X1PPX2P, wherein X1 is a cysteine, glycine, or arginine and X2 is a cysteine or a threonine (SEQ ID NO:1); (b) a transmembrane domain; and (c) an intracellular signaling domain that comprises a CD3ζ signaling domain and a costimulatory domain. Also provided is a nucleic acid encoding a chimeric receptor, the nucleic acid comprising: (a) a polynucleotide encoding a single chain variable fragment (scFv) that binds to CD19, wherein the scFv comprises: a variable light chain (VL) domain comprising a VL domain present in the amino acid sequence encoded by SEQ ID NO:3, and a variable heavy chain (VH) domain comprising a VH domain present in the amino acid sequence encoded by SEQ ID NO:3; or the amino acid sequence encoded by SEQ ID NO:3; (b) a polynucleotide encoding a transmembrane domain; (c) a polynucleotide encoding a polypeptide spacer located between the scFv and the transmembrane domain, wherein the polypeptide spacer is about 15 amino acids or less in length and comprises an amino acid sequence of X1PPX2P, wherein X1 is a cysteine, glycine, or arginine and X2 is a cysteine or a threonine (SEQ ID NO:1); and (d) a polynucleotide encoding an intracellular signaling domain that comprises a CD3ζ signaling domain and a costimulatory domain. Also provided are vectors that include the nucleic acids and methods of using the nucleic acids and vectors. le light chain (VL) domain comprising a CDRL1, a CDRL2, and a CDRL3 of the amino acid sequence encoded by SEQ ID NO:3, and a variable heavy chain (VH) domain comprising a CDRH1, a CDRH2, and a CDRH3 of the amino acid sequence encoded by SEQ ID NO:3; and an extracellular polypeptide spacer that is about 15 amino acids or less in length and comprises an amino acid sequence of X1PPX2P, wherein X1 is a cysteine, glycine, or arginine and X2 is a cysteine or a threonine (SEQ ID NO:1); (b) a transmembrane domain; and (c) an intracellular signaling domain that comprises a CD3ζ signaling domain and a costimulatory domain. Also provided is a nucleic acid encoding a chimeric receptor, the nucleic acid comprising: (a) a polynucleotide encoding a single chain variable fragment (scFv) that binds to CD19, wherein the scFv comprises: a variable light chain (VL) domain comprising a VL domain present in the amino acid sequence encoded by SEQ ID NO:3, and a variable heavy chain (VH) domain comprising a VH domain present in the amino acid sequence encoded by SEQ ID NO:3; or the amino acid sequence encoded by SEQ ID NO:3; (b) a polynucleotide encoding a transmembrane domain; (c) a polynucleotide encoding a polypeptide spacer located between the scFv and the transmembrane domain, wherein the polypeptide spacer is about 15 amino acids or less in length and comprises an amino acid sequence of X1PPX2P, wherein X1 is a cysteine, glycine, or arginine and X2 is a cysteine or a threonine (SEQ ID NO:1); and (d) a polynucleotide encoding an intracellular signaling domain that comprises a CD3ζ signaling domain and a costimulatory domain. Also provided are vectors that include the nucleic acids and methods of using the nucleic acids and vectors.
Description
METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY
This application is a divisional of New Zealand patent ation 705475,
which is the national phase entry in New d of PCT international application
(published as WO 2014//031687), and claims the t of
priority to U.S. patent application serial no. 61/691,117 filed on 20 August 2012, the
disclosure of which is incorporated herein by reference in its entirety.
Field of the Invention
The present invention relates to the field of biomedicine and specifically
methods useful for cancer therapy. In particular, embodiments of the invention relate
to s and compositions for carrying out cellular immunotherapy comprising T
cells ed with tumor targeting receptors.
Statement Regarding lly Sponsored Research
This invention was made with government support in the form of grants from
the United States ment of Health and Human Services and from the Leukemia
and Lymphoma y. The United States government has n rights in the
invention.
Background of the Invention
The adoptive transfer of human T lymphocytes that are engineered by gene
transfer to express chimeric antigen receptors (chimeric receptors) specific for
surface molecules expressed on tumor cells has the potential to effectively treat
advanced malignancies. ic receptors are synthetic ors that include an
extracellular ligand binding domain, most commonly a single chain variable
fragment of a monoclonal antibody (scFv) linked to intracellular signaling
components, most commonly CD3ζ alone or combined with one or more
costimulatory domains. Much of the research in the design of chimeric receptors has
focused on defining scFvs and other ligand binding ts that target malignant
cells without causing serious toxicity to essential normal tissues, and on defining the
optimal composition of intracellular signaling modules to activate T cell effector
functions. However, it is uncertain whether the variations in chimeric receptor
design that e superior in vitro function will translate reproducibly into
improved in vivo therapeutic activity in clinical applications of ic receptormodified
T cells.
There is a need to identify s for determining elements of chimeric
receptor design that are important for therapeutic activity and cell populations to
genetically modify and adoptively transfer that e enhanced survival and
efficacy in vivo. It an object of the present invention to go someway towards
meeting this need and/or to provide the public with a useful choice.
Summary of the Invention
In a first aspect the present invention provides a nucleic acid encoding a
chimeric or, the chimeric receptor comprising:
(a) an ellular domain consisting of:
an extracellular ligand binding domain consisting of a single chain variable
fragment (scFv) that binds to a CD19, wherein the scFv comprises a variable light
chain (VL) domain comprising a CDRL1, a CDRL2, and a CDRL3 of the amino
acid sequence encoded by SEQ ID NO:3, and a variable heavy chain (VH) domain
comprising a CDRH1, a CDRH2, and a CDRH3 of the amino acid sequence
encoded by SEQ ID NO:3; and
an extracellular polypeptide spacer that is about 15 amino acids or less in
length and comprises an amino acid ce of P, wherein X1 is a cysteine,
glycine, or arginine and X2 is a cysteine or a threonine (SEQ ID NO:1);
(b) a transmembrane domain; and
(c) an intracellular signaling domain that comprises a CD3ζ signaling
domain and a costimulatory domain.
In a second aspect the present invention provides a nucleic acid encoding a
chimeric or, the nucleic acid comprising:
(a) a polynucleotide encoding a single chain variable fragment (scFv)
that binds to CD19, wherein the scFv comprises:
the amino acid sequence encoded by SEQ ID NO:3;
(b) a polynucleotide encoding a transmembrane domain;
(c) a polynucleotide encoding a polypeptide spacer located between the
scFv and the transmembrane domain, n the polypeptide spacer is about 15
amino acids or less in length and comprises an amino acid sequence of X1PPX2P,
wherein X1 is a cysteine, glycine, or arginine and X2 is a cysteine or a threonine
(SEQ ID NO:1); and
(d) a polynucleotide encoding an intracellular signaling domain that
comprises a CD3ζ signaling domain and a costimulatory domain.
In a third aspect the present invention provides an expression vector,
comprising the nucleic acid of the first aspect.
In a fourth aspect the present invention provides an in vitro method for
ing an ed host cell, comprising:
introducing the nucleic acid of the first or second aspects or the sion
vector of the third aspect into cells of a lymphocyte population and culturing the
cells in the presence of anti-CD3 and/or anti-CD28, and at least one homeostatic
cytokine.
Also described are s and itions to confer and/or augment
immune responses mediated by cellular immunotherapy, such as by adoptively
erring tumor-specific, cally modified subsets of CD8+ or CD4+ T cells
alone, or in combination. The disclosure bes chimeric receptor nucleic acids,
and vectors and host cells ing such nucleic acids. The nucleic acid sequence
that encodes the chimeric receptor links together a number of modular components
that can be excised and replaced with other components in order to customize the
chimeric receptor for efficient T cell activation and recognition of a specific target
le or an epitope on the target molecule.
In embodiments described herein, a chimeric receptor nucleic acid
comprises a polynucleotide coding for a ligand binding domain, wherein the ligand
is a molecule expressed on malignant or infected cells, a polynucleotide coding for a
polypeptide spacer wherein the polypeptide spacer is about 200 amino acids or less,
a polynucleotide coding for a transmembrane domain; and a polynucleotide coding
for intracellular signaling domains. In embodiments, the polypeptide spacer
comprises a modified IgG4 hinge region containing an amino acid sequence
X1PPX2P that may be linked to other amino acid sequences including but not limited
to the CH2 and CH3 or CH3 only sequences of the Ig Fc. It has been surprisingly
found that the length of the spacer region that is presumed not to have signaling
capability affects the in vivo efficacy of the T cells modified to express the chimeric
receptor and needs to be ized for individual target molecules for optimal
tumor or target cell recognition.
Another aspect of the disclosure describes an isolated ic receptor
nucleic acid comprising: a polynucleotide coding for a ligand binding domain,
wherein the ligand is a tumor specific antigen, viral antigen, or any other molecule
sed on a target cell population that is suitable to e recognition and
elimination by a lymphocyte; a polynucleotide coding for a polypeptide spacer
wherein the ptide spacer is of a ized length that is specific for each
targeted ligand, wherein the spacer provides for enhanced T cell eration and/
or cytokine production as ed to a reference chimeric receptor; a
polynucleotide coding for a transmembrane domain; and a polynucleotide coding for
one or more intracellular signaling domains. In embodiments, a long spacer is
ed if the epitope on the target ligand is in a membrane proximal position and
a short spacer is employed if the epitope on the target ligand is in a membrane distal
position. The disclosure includes expression vectors and host cells comprising the
ed chimeric receptor as described herein.
Another aspect of the disclosure describes a chimeric receptor polypeptide
comprising a ligand g , wherein the ligand is a tumor specific antigen,
viral antigen or any other molecule that is expressed on a target cell population and
can be targeted to mediate recognition and elimination by lymphocytes; a
polypeptide spacer wherein the polypeptide spacer is about 10-229 amino acids; a
transmembrane domain; and one or more intracellular signaling domains. In
embodiments, the polypeptide spacer comprises a modified IgG hinge region
containing the amino acid ce X1PPX2P.
In another aspect, the present disclosure describes compositions to confer
and/or augment immune ses mediated by cellular immunotherapy, such as by
adoptively erring tumor-specific, subset specific genetically modified CD4+ T
cells, wherein the CD4+ T cells confer and/or augment the ability of CD8+ T cells to
n anti-tumor reactivity and increase and/or maximize tumor-specific
proliferation. In embodiments, the CD4+ cells are genetically modified to express a
chimeric receptor nucleic acid and/or chimeric receptor ptide as described
herein.
In another aspect, described are compositions to confer and/or augment
immune responses mediated by cellular immunotherapy, such as by adoptively
transferring tumor-specific, subset specific genetically modified CD8+ T cells. In
embodiments, the CD8+ cells express a chimeric receptor nucleic acid and/or
chimeric or polypeptide as described herein.
Also described is an adoptive cellular therapy composition having a
cally modified CD8+ cytotoxic T lymphocyte cell preparation to confer and/or
augment immune responses, wherein the cytotoxic T lymphocyte cell preparation
comprises CD8+ T cells that express a chimeric receptor comprising a ligand
binding domain for a ligand associated with the disease or er, a customized
spacer region, a transmembrane domain; and an ellular signaling domain of a T
cell or other receptors, such as a ulatory domain, and/or a genetically
ed helper T lymphocyte cell preparation, wherein the helper T lymphocyte
cell preparation has CD4+ T cells that express a chimeric receptor comprising an
antibody variable domain specific for the ligand associated with the disease or
disorder, a customized spacer region, a transmembrane domain; and one or more
intracellular ing domains.
Also described is a method of performing cellular immunotherapy in a
subject having a disease or er by administering to the subject a genetically
modified cytotoxic T lymphocyte cell preparation that provides a cellular immune
response, wherein the cytotoxic T lymphocyte cell preparation comprises CD8+ T
cells that have a chimeric receptor comprising a polynucleotide coding for a ligand
binding domain, wherein the ligand is a tumor specific antigen, viral antigen, or any
other molecule expressed on a target cell population that is suitable to mediate
recognition and elimination by a cyte; a polynucleotide coding for a
ptide spacer n the polypeptide spacer is of a customized length that is
specific for each targeted ligand, wherein the spacer provides for ed T cell
proliferation and/or cytokine production as compared to a reference chimeric
receptor; a polynucleotide coding for a embrane domain; and a
polynucleotide coding for one or more intracellular signaling domains. In
embodiment, the ligand binding domain is an extracellular antibody variable domain
specific for a ligand associated with the disease or disorder. An embodiment
includes a genetically ed helper T lymphocyte cell preparation that wherein
the helper T lymphocyte cell preparation comprises CD4+ T cells that have a
chimeric receptor comprising an a polynucleotide coding for a ligand g
domain, wherein the ligand is a tumor specific antigen, viral antigen, or any other
molecule expressed on a target cell population that is suitable to mediate recognition
and elimination by a lymphocyte; a polynucleotide coding for a polypeptide spacer
wherein the polypeptide spacer is of a customized length that is specific for each
targeted ligand, wherein the spacer provides for enhanced T cell proliferation and/or
cytokine production as compared to a reference chimeric receptor; a cleotide
coding for a transmembrane domain; and a cleotide coding for one or more
intracellular signaling s. In embodiments, the genetically modified CD8+
and genetically modified CD4+ cell tion are nistered. In ments,
the T cells are autologous or allogeneic T cells.
Various modifications of the above method are possible. For example, the
chimeric receptor that is expressed by the CD4+ T cell and the CD8+ T cell can be
the same or different.
Also described is a method of manufacturing an adoptive immunotherapy
composition by obtaining a chimeric receptor modified tumor-specific CD8+
cytotoxic T lymphocyte cell ation that elicits a cellular immune response and
ses an antigen-reactive chimeric receptor, wherein the modified cytotoxic T
lymphocyte cell preparation comprises CD8+ T cells that have a chimeric receptor
comprising a ligand binding domain, wherein the ligand is a tumor specific antigen,
viral antigen, or any other molecule expressed on a target cell population that is
suitable to mediate recognition and elimination by a lymphocyte; a polypeptide
spacer wherein the polypeptide spacer is of a customized length that is specific for
each targeted ligand, wherein the spacer provides for enhanced T cell eration
and/or cytokine tion as compared to a reference chimeric receptor; a
embrane domain; and one or more intracellular signaling domains.; and/or
obtaining a modified naïve or memory CD4+ T helper cell wherein the modified
helper T lymphocyte cell preparation comprises CD4+ cells that have a chimeric
receptor comprising a ligand binding domain, wherein the ligand is a tumor specific
antigen, viral antigen, or any other molecule expressed on a target cell population
that is le to mediate recognition and elimination by a lymphocyte; a
polypeptide spacer wherein the polypeptide spacer is of a customized length that is
specific for each targeted ligand, n the spacer provides for enhanced T cell
proliferation and/or cytokine production as compared to a nce ic
receptor; a transmembrane domain; and one or more intracellular signaling
domains.
These and other embodiments of the ion are described further in the
accompanying specification, gs and claims.
Brief Description of the Drawings
Figure 1 Library of spacer sequences. We constructed a plasmid library
that contain codon optimized DNA sequences that encode extracellular components
including of the IgG4 hinge alone, IgG4 hinge linked to CH2 and CH3 domains, or
IgG4 hinge linked to the CH3 domain. Any scFV sequence (VH and VL) can be
cloned 5’ to the sequences encoding this library of variable spacer s. The
spacer domains are in turn linked to CD28 transmembrane and intracellular
ing domains and to CD3 zeta. A T2A sequence in the vector separates the
ic receptor from a selectable marker encoding a truncated human epidermal
growth factor receptor (tEGFR).
Figure 2: In vitro xicity, cytokine tion, and proliferation of
T-cells modified to express 2A2 ROR1 ic receptors with modified spacer
. (A) Phenotype of purified CD8+ TCM-derived cell lines modified with each
of the 2A2 ROR1 chimeric receptors with long, intermediate and short spacer
domain. Staining with anti-F(ab) antibody that binds to an epitope in the 2A2 scFV
shows surface expression of ROR1 chimeric receptors with full length or truncated
spacer. (B) Cytolytic activity of T-cells expressing the various 2A2 ROR1 chimeric
receptors with long (●), intermediate (▲) and short spacer (♦), or a tEGFR control
lentiviral vector against ROR1+ (x) and control target cells. The bar diagram
summarizes cytotoxicity data from 3 independent experiments (E:T = 30:1)
normalized to cytolytic activity by 2A2 ROR1 chimeric receptor ‘long’ = 1, and
analyzed by Student’s t-test. (C) CFSE dye dilution was used to measure
proliferation of 2A2 ROR1 chimeric receptor and tEGFR control T-cells, 72 hours
after stimulation with Raji/ROR1 (left panel) and primary CLL cells (right panel)
without addition of exogenous cytokines. For analysis, triplicate wells were pooled
and the proliferation of live (PI-), CD8+ T-cells analyzed. Numbers above each
histogram indicate the number of cell divisions the proliferating subset underwent,
and the fraction of T-cells in each gate that underwent ≥4/3/2/1 cell divisions is
provided next to each plot. (D) Multiplex cytokine assay of supernatants obtained
after 24 hours from triplicate co-cultures of 5x104 T-cells expressing the various
2A2 ROR1 chimeric receptors with Raji/ROR1 and primary CLL cells. Multiplex
cytokine data from 3 ndent experiments were normalized (cytokine e by
2A2 ROR1 chimeric receptor ‘long’ = 1) and analyzed by Student’s t-test (right bar
diagram).
Figure 3. R11 chimeric or requires a long spacer for recognition of
ROR1+ tumor cells. The sequences encoding the scFV from the R11 monoclonal
antibody that is specific for an epitope in the ne proximal Kringle domain of
the orphan ne kinase receptor ROR1 were cloned upstream of IgG4 hinge only
(short), IgG4 hinge/CH3 (intermediate), and IgG4 hinge/CH2/CH3 ces in our
chimeric receptor library containing the 4-1BB costimulatory s and prepared
as lentiviral vectors. A). Human CD8+ T cells were transduced and the transduction
efficiency with each of the short, intermediate and long chimeric receptors was
determined by staining for the tEGFR marker. B). Transduced T cells expressing the
short (top), intermediate (middle), and long m) were assayed for lysis of K562
ia cells alone or transfected to express ROR1. Only the T cells expressing
the long spacer chimeric receptor efficiently killed ROR1+ K562 cells. C).
Transduced T cells expressing the short (top), intermediate (middle), and long
(bottom) were labeled with CFSE, stimulated with K562 cells expressing ROR1 or
CD19 (control) and d for cell proliferation over 72 hours. The T cells
sing the long spacer ic receptor proliferated specifically to the ROR1+
K562 cells. D). Transduced T cells expressing the short (top), intermediate (middle),
and long (bottom) were stimulated with Raji lymphoma cells and K562 cells that
expressed ROR1 or CD19 (control) and assayed for the secretion of interferon
gamma into the atant over 24 hours. The T cells expressing the long spacer
chimeric or proliferated and produced the highest levels of interferon gamma
in response to ROR1 positive target cells.
Figure 4: Design of ROR1 chimeric receptors with modified spacer
length and derived from the 2A2 and R12 scFV with different affinity. (A)
Design of lentiviral transgene inserts encoding a panel of ROR1 chimeric receptors
containing the 2A2 scFV, an IgG4-Fc derived spacer of ‘Hinge-CH2-CH3’ (long
spacer, 229 AA), -CH3’ (intermediate, 119 AA), or ’ only (short, 12
AA), and a signaling module with CD3ζ and CD28. Each chimeric receptor cassette
contains a truncated EGFR marker encoded downstream of a T2A element. (B)
Lentiviral transgene inserts encoding pecific chimeric receptors derived
from the R12 and 2A2 scFV with short IgG4-Fc ‘Hinge’ spacer (12 AA), and a
signaling module containing CD28 or 4-1BB and CD3ζ respectively : 4
constructs).
Figure 5: Anti-tumor reactivity of T-cells modified with ROR1 chimeric
receptors d from mAb R12 with higher affinity than 2A2. (A) tEGFR
expression on purified polyclonal CD8+ TCM-derived T-cell lines modified with each
of the R12 and 2A2 ROR1 chimeric receptors with short IgG4-Fc ‘Hinge’ spacer,
and CD28 or 4-1BB costimulatory domain. (B) Cytotoxicity against ROR1+ and
control target cells by T-cells expressing R12(28-▲; 4-1BB-∆) and 2A2 ROR1
chimeric receptors (28-●; 4-1BB○) or a tEGFR control vector (x). (C) Multiplex
cytokine assay of supernatants obtained after 24 hours from co-cultures of 5x104 T-
cells expressing the various ROR1 chimeric receptors with Raji/ROR1 tumor cells.
The /right bar diagrams show normalized multiplex data from 3 independent
experiments (cytokine release by ROR1 chimeric receptor 2A2 = 1) ed by
Student’s t-test. (D) Proliferation of ROR1 chimeric receptor T-cells and tEGFR
control s 72 hours after ation with Raji/ROR1 cells and without addition
of exogenous cytokines was assessed by CFSE dye dilution. Numbers above each
histogram indicate the number of cell divisions the proliferating subset underwent,
and the fraction of s in each gate that underwent ≥4/3/2/1 cell divisions is
provided above each plot.
Figure 6: Analysis of cytokine production and proliferation of CD4+ T-
cells lines ed with a ROR1 chimeric receptor derived from mAb R12
with higher affinity than 2A2. (A-B) The 2A2 and R12 ROR1 chimeric receptors
had the short spacer and a CD28 costimulatory domain. (A) Multiplex cytokine
analysis from atants obtained 24 hours after stimulation of 5x104 CD4+ T-
cells expressing the 2A2 and R12 ROR1 ic receptor with Raji/ROR1 tumor
cells. (B) Proliferation of CD4+ R12 and 2A2 ROR1 chimeric receptor T-cells and
tEGFR control T-cells 72 hours after stimulation with Raji/ROR1 cells and without
addition of ous cytokines was assessed by CFSE dye dilution. Numbers
above each histogram indicate the number of cell divisions the proliferating subset
ent, and the fraction of T-cells in each gate that ent ≥5/4/3/2/1 cell
divisions is provided above the histograms.
Figure 7: Recognition of primary CLL by T-cells modified with 2A2 and
R12 ROR1 chimeric receptors with optimal short spacer and 4-1BB
costimulatory domain or with a CD19-specific chimeric receptor. (A)
Expression of ROR1/CD19 on primary CLL, and CD80/86 on primary CLL and
Raji/ROR1 tumor cells (black dot plots) that can engage CD28 on chimeric receptor
T-cells (white histograms). Staining with matched isotype control mAbs is shown as
grey dot plots/histograms. (B) Cytolytic activity of T-cells expressing the 2A2(●)
and R12 ROR1 chimeric receptor (■), a CD19-specific ic receptor (▲) and
s modified with a tEGFR control vector (x) against primary CLL (left
diagram) and normal B cells (right m) analyzed by chromium release assay.
Cytotoxicity data against primary CLL from 4 independent experiments (E:T =
:1) were normalized (cytolytic activity by ROR1 chimeric receptor 2A2 = 1) and
analyzed by Student’s t-test (bar diagram). (C) Multiplex cytokine analysis after a
24-hour stimulation of 5x104 chimeric receptor T-cells with primary CLL cells.
ne release of unstimulated chimeric receptor s was below 3.6 pg/ml
(detection limit) (left bar diagram). ELISA for IFN-γ production by 5x104 2A2 and
R12 ROR1 chimeric receptor T-cells after a 24-hour co-culture with primary CLL.
O.D. of 1 corresponds to approximately 250 pg/ml (right bar m). (D)
Proliferation of CD8+ T-cells modified with the 2A2 ROR1, R12 ROR1 and a CD19
ic receptor, 72 hours after stimulation with primary CLL cells. Numbers
above each histogram indicate the number of cell divisions, and the fraction of T-
cells in each gate that underwent ≥3/2/1 cell divisions is provided next to each plot.
Figure 8: The function of ROR1-chimeric receptor and CD19-chimeric
receptor modified CD8+ T-cells against y CLL is augmented by chimeric
receptor-modified CD4+ helper T-cells. (A) ELISA for IL-2 tion from
triplicate co-cultures of 5x104 CD8+ and CD4+ s expressing the R12 ROR1
and CD19-chimeric receptor respectively, incubated with primary CLL for 24-hours.
O.D. of 1 corresponds to approx. 800 pg/ml. (B) Proliferation of ic receptor-
modified CD8+ T-cells in response to primary CLL is enhanced by addition of
chimeric receptor-modified CD4+ T-cells. CFSE-labeled CD8+ T-cells expressing
the 2A2 ROR1, R12 ROR1 and CD19-chimeric receptor respectively, were cocultured
with tumor cells and with 2A2 ROR1, R12 ROR1 and CD19-chimeric
receptor uced or control untranduced CD4+ T-cells (CD8+:CD4+ = 1:1).
Proliferation of the CD8+ subset was analyzed 72 hours after stimulation. Numbers
above each histogram indicate the number of cell divisions, and the fraction of T-
cells in each gate that underwent ≥3/2/1 cell divisions is provided above each plot.
Figure 9: In vivo umor efficacy of 2A2 ROR1, R12 ROR1 and
CD19 chimeric receptor T-cells. Cohorts of mice were inoculated with 0.5x106
JeKo-1/ffluc MCL via tail vein ion, and 5x106 2A2 ROR1, R12 ROR1 or
CD19 chimeric receptor T-cells, or s expressing a tEGFR control vector were
administered 7 days after tumor ation. All chimeric receptor constructs had the
short IgG4 ‘Hinge-only’ spacer and a 4-1BB costimulatory domain. (A, B) Serial
bioluminescence imaging of tumor in cohorts of mice treated with T-cells expressing
the 2A2 ROR1 chimeric receptor (▼), the high affinity R12 ROR1 chimeric
receptor (■), a pecific chimeric receptor (▲), with T-cells uced with
tEGFR alone (●), and ted mice. Bioluminescence imaging showed tumor
manifestations in the bone marrow and thorax and thus, signal intensity was
measured in regions of interest that encompassed the entire body and thorax of each
individual mouse. (C) Kaplan-Meier analysis of survival in individual treatment and
control groups. Statistical analyses were performed using the log-rank test. The data
shown in A-C are entative of results obtained in 2 independent experiments.
(D) Proliferation of 2A2 ROR1, R12 ROR1 and CD19 chimeric receptor T-cells in
vivo. Tumor bearing NSG/JeKo-1 mice received a single dose of 5x106 CFSE-
labeled 2A2 ROR1, R12 ROR1 or CD19 chimeric receptor T-cells on day 7 after
tumor inoculation, and 72 h later peripheral blood, bone marrow and spleen were
ted from each individual mouse. The frequency and proliferation of live (PI-),
CD45+ CD8+ tEGFR+ T-cells was analyzed. The frequency of 2A2 ROR1, R12
ROR1 and CD19 chimeric receptor T-cells respectively is provided on the left of
each histogram as percentage of live cells, and the fraction of T-cells that underwent
≥4/3/2/1 cell divisions is provided above each plot.
Figure 10 Expression of ROR1 and NKG2D ligands on epithelial cancer
cell lines. (A) Expression of ROR1 on the triple negative breast cancer cell lines
MDA-MB-231 and 468, and the renal cell cancer lines FARP, TREP and RWL
(black histograms). Staining with matched isotype control dy is shown as grey
histograms. (B) Expression of 6 and the NKG2D ligands MICA/B on MDAMB-231
and Raji/ROR1 tumor cells, and NKG2D ) on 2A2 and R12 ROR1-
chimeric receptor T-cells. Staining with matched isotype control mAbs is shown as
grey dot plots/histograms.
Figure 11: ROR1-chimeric or modified T-cells recognize ROR1+
epithelial tumor cells in vitro. (A) Chromium e assay to evaluate the
cytolytic activity of R12 ROR1-chimeric receptor modified T-cells (short spacer/4-
1BB costimulatory domain, closed s) and tEGFR l T-cells (open
symbols) against ROR1+ breast cancer and renal cell cancer lines. (A-D) The 2A2
and R12 ROR1-chimeric receptors had the optimal short spacer and a 4-1BB
costimulatory domain. (B) Multiplex cytokine analysis after stimulation of T-cells
expressing the 2A2 and R12 ROR1-chimeric receptor with MDA-MB-231 and
Raji/ROR1 tumor cells. (C) Proliferation of CD8+ T-cells modified with the 2A2 and
R12 himeric receptor 72 hours after stimulation with MDA-MB-231 tumor
cells. For analysis, triplicate wells were pooled and the proliferation of live (PI-),
CD8+ T-cells analyzed. Numbers above each histogram te the number of cell
divisions the proliferating subset ent, and the fraction of T-cells in each gate
that underwent /1 cell divisions is provided next to each histogram. (D)
ELISA for IL-2 tion by R12 ROR1-chimeric or T-cells after a 24-hour
co-culture with MDA-MB-231 in plain medium, and after addition of an antibody
cocktail blocking of the NKG2D pathway [anti-NKG2D (clone 1D11), anti-MICA/B
(clone 6D4) and anti-ULBP] or matched isotype control mAbs. O.D. of 0.6
corresponds to approximately 1900 pg/ml.
Figure 12. Effect of extracellular spacer length on recognition and
triggering of tumor cell lysis by CD8+ human T cells that express a HER2-
specific chimeric receptor. A.) Depiction of Herceptin Fab epitope location on
tumor cell membrane proximal epitope on human HER2, B.) Structural formats of
Herceptin scFv CAR spacer length variants as –T2A- linked polypeptides with the
carboxyl EGFRt marker transmembrane protein, C.) Western blot detection of short,
medium, and long spacer tin-CAR variant sion in human CD8+ CTL’s,
D.) Flow tric detection of EGFRt by transduced human CD8+ CTL’s
transduced with Herceptin CAR variants then immunomagnetically purified by
Herceptin-biotin, anti-biotin microbeads, E.) Distinct cytolytic function by T cells
transduced to express the Herceptin CAR variants (short – S; medium – M; and long
– L) against HER2+ Med411FH and D283 human medulloblastoma cell lines (D341
is a HER2- control medulloblastoma cell line, inset flow plots are tumor target lines
stained with anti-HER2 specific mAb). Green=full IgG4 (Long Spacer,▼),
Blue=IgG4hinge:CH3(Medium Spacer;▲), Red=IgG4hinge only (Short Spacer;■).
Figure 13: himeric or vectors and generation of CD19-
ic receptor T cells.
(A) Design of lentiviral transgene inserts encoding a panel of CD19-specific
chimeric ors that differ in extracellular spacer length and intracellular costimulation.
Each chimeric receptor encoded the CD19-specific single chain variable
fragment derived from the FMC63 mAb in a VL-VH orientation, an IgG4-derived
spacer domain of Hinge-CH2-CH3 (long spacer, 229 AA) or Hinge only (short
spacer, 12 AA), and a signaling module containing CD3ζ with CD28 or 4-1BB alone
or in tandem. Each chimeric receptor cassette contains a truncated EGFR marker
encoded downstream of a cleavable 2A t. (B, C) onal T cell lines
modified with each of the CD19-chimeric receptor ucts were prepared from
purified CD8+ CD45RO+ CD62L+ central memory T cells (TCM) of normal donors.
Following lentiviral transduction, transgene-positive T cells in each cell line were
purified using the tEGFR marker and expanded for in vitro and in vivo experiments.
(D) MFI after staining for the tEGFR marker shows equivalent transgene expression
in T cells modified with each of the CD19-chimeric receptors.
Figure 14: In vitro cytotoxicity, cytokine production, and proliferation
of T cells modified with distinct CD19-chimeric receptors. (A) Cytolytic activity
of T cells expressing the s CD19-chimeric receptors against CD19+ and
control target cells. (B) Multiplex cytokine assay of atants obtained after 24
hours from triplicate co-cultures of T cells expressing the various CD19-chimeric
receptors and K562 cells transfected with CD19, and CD19+ Raji cells. (C)
ison of cytokine production by T cells expressing the various CD19-
chimeric ors. Multiplex cytokine data from 6 independent experiments were
ized (cytokine release by CD19-chimeric receptor ‘short/CD28’ CTL = 1)
and analyzed by Student’s t-test. (D) CFSE dye on was used to measure
proliferation of CD19-chimeric receptor T cells 72 hours after stimulation with
K562/CD19 (upper panel) and CD19+ Raji tumor cells (lower panel) without
addition of exogenous cytokines. For analysis, triplicate wells were pooled and the
proliferation of live (PI-), CD8+ T cells analyzed. Numbers above each histogram
indicate the number of cell divisions the proliferating subset underwent, and the
fraction of T cells in each gate that underwent ≥4/3/2/1 cell divisions is provided in
the upper left of each plot. (E) PI staining was performed at the end of a 72-hour coculture
of T cells expressing the various CD19-chimeric receptors with Raji tumor
cells. The percentage of PI+ cells within in ic receptor T cell line (CD3+) is
provided in each histogram.
Figure 15: CD19-chimeric receptor T cells with a short extracellular
spacer domain eradicate Raji tumors in NOD/SCID mice. (A) Cohorts of mice
were inoculated with Raji-ffluc via tail vein ion, and T cells transduced with
CD19-chimeric receptors containing long and short spacer domains or with tEGFR
alone were administered 2 and 9 days after tumor inoculation by tail vein injection.
Tumor progression and distribution was evaluated by serial inescence
imaging after ion of luciferin substrate. (B) Serial bioluminescence imaging of
tumor in cohorts of mice either treated with T cells sing CD19-chimeric
ors with short spacer (‘short/CD28’ and ‘short/4-1BB’) and long spacer
(‘long/CD28’ and ‘long/4-1BB’) domains, with T cells transduced with the tEGFR
control vector, or ted. Each diagram representing cohorts of mice treated with
CD19-chimeric receptor or tEGFR uced T cells also shows the mean of tumor
progression in untreated mice for comparison (red triangles). (C) Kaplan-Meier
analyses of survival of untreated mice and mice d with T cells expressing
CD19-chimeric receptors with short spacer (‘short/CD28’ and ‘short/4-1BB’), long
spacer (‘long/CD28’ and ‘long/4-1BB’) domains, and with control tEGFR.
Statistical analyses were performed using the log-rank test. The data shown in B and
C are representative of results obtained in 3 independent experiments.
Figure 16: CD19-chimeric receptor T cells with a short spacer (short/4-
1BB) eradicate established Raji tumors in NSG mice in a ependent
manner. (A) Mice were inoculated with Raji-ffluc via tail vein injection and tumor
engraftment confirmed by inescence imaging on day 6. On day 7, mice
received a single i.v. injection of various doses of T cells transduced with the CD19-
chimeric receptor ‘short/4-1BB’ or with the tEGFR-control lentivirus. (B, C) Dose
dependent anti-tumor efficacy of T cells expressing the CD19-chimeric receptor
‘short/4-1BB’. A control cohort of mice received a single high dose of T cells
modified with tEGFR alone. (D) Persistence of CD19-chimeric receptor T cells
ing adoptive transfer into ji mice. Flow cytometric analysis of
peripheral blood (eye bleeds) in the cohort of mice treated with 2.5x106 CD19-
chimeric receptor ‘short/4-1BB’ T cells. The frequency of CD8+ tEGFR+ T cells is
shown as percentage of live peripheral blood cells.
Figure 17: T cells expressing CD19-chimeric ors with a short
spacer and either CD28 or 4-1BB are more effective against ished
lymphoma than those expressing CD19-chimeric receptors with a long spacer.
(A) NSG mice were inoculated with Raji-ffluc on day 0, and treated on day 7 with
one dose of 2.5x106 CD19 ic receptor T cells expressing short or long spacer
and either CD28 or 4-1BB costimulatory domain. (B) Kaplan-Meier es of
survival of mice in each of the treatment groups. Statistical analyses were performed
using the log-rank test. (C) inescence imaging of s of mice treated with
T cells expressing CD19-chimeric receptors with short spacers (‘short/CD28’ and
‘short/4-1BB’), and long spacers (‘long/CD28 and ‘long/4-1BB’). The mean tumor
burden observed in untreated mice at each time point is shown in each diagram for
comparison (triangles). (D) In vivo tence of T cells expressing CD19-chimeric
receptor with short spacer domain is enhanced compared to T cells expressing
CD19-chimeric ors with long spacer domain. The frequency of CD8+ tEGFR+
T cells in the peripheral blood obtained at day 3 and 10 after transfer was determined
by flow cytometry and is shown as percentage of live (PI-) peripheral blood cells.
Statistical analyses were performed by Student’s t-test. The data shown in B-D are
representative for results obtained in 3 independent experiments.
Figure 18: Increasing chimeric receptor T cell dose or augmenting
costimulatory signaling does not improve the anti-tumor efficacy of CD19-
chimeric receptors with a long spacer domain against established lymphoma.
(A) Cytolytic activity of T cells expressing ‘long/CD28’, ‘long/4-1BB’ and
‘long/CD28_4-1BB’ CD19 chimeric receptors against CD19+ and control target
cells. (B) Multiplex cytokine assay of supernatant obtained after 24 hours from
cate co-cultures of K562/CD19 and Raji tumor cells with T cells expressing the
various CD19-chimeric receptors. (C) Evaluation of proliferation of himeric
or T cells 72 hours after stimulation with CD19+ tumor cells (K562/CD19 –
left panel; Raji – right panel) by CFSE dye dilution. For analysis, triplicate wells
were pooled and the proliferation of live (PI-) CD8+ T cells ed. Numbers
above each histogram indicate the number of cell divisions the erating subset
underwent, and the fraction of T cells in each gate that underwent ≥4/3/2/1 cell
divisions is provided in the upper left of each plot. (D) Kaplan-Meier analyses of
survival of mice treated with T cells expressing CD19-chimeric receptors with short
(‘short/CD28’) and long spacer domain (‘long/CD28’ and ‘long/CD28_4-1BB’), or
T cells modified with a encoding control lentiviral vector. tical
analyses were performed using the log-rank test. (E) Bioluminescence imaging of
s of mice treated with T cells expressing CD19-chimeric receptors with short
spacer (‘short/CD28’), and long spacers (‘long/CD28 and ‘long/CD28_4-1BB’).
ms show mean tumor progression in untreated mice for ison (red
triangles). (F) In vivo persistence of T cells expressing the s CD19-chimeric
receptors. The frequency of CD8+ tEGFR+ T cells in the peripheral blood obtained at
day 3 and 10 after transfer was determined by flow cytometry and is shown as
percentage of live (PI-) peripheral blood cells. Statistical analyses were performed
by Student’s .
Figure 19: CD19-chimeric receptor T cells with a long spacer domain
are activated by tumor in vivo but fail to increase in cell number. (A)
Expression of CD69 and CD25 on T cells modified with each CD19-chimeric
receptor prior to transfer into NSG/Raji mice. (B) Cohorts of mice were inoculated
with Raji-ffluc tumor cells and 7 days later received CFSE-labeled CD19-chimeric
receptor transduced or control T cells. Bone marrow and spleens were harvested
from subgroups of mice 24 and 72 hours after T cell administration. (C, D)
Multiparameter flow cytometric analysis of bone marrow mononuclear cells
obtained 24 hours (C) and 72 hours (D) after T cell transfer. Dot plots show anti
CD3 and anti CD45 staining after gating on PI- cells to detect viable human T cells.
The CD3- CD45+ gate contains Raji tumor cells. Expression of CD25 and CD69 on
live (PI-) CD3+ CD45+ T cells is shown in the histograms. (E) Frequency of CD3+
CD45+ T cells in spleens ed 24 and 72 hours after T cell er. Dot plots are
gated on live PI- splenocytes and the percentage of CD3+ CD45+ T cells is shown in
each plot. (F) PI staining of bone marrow and splenocytes hours after T cell transfer
into NSG/Raji mice. The numbers in the rams indicate the percentage of PI+
cells within the CD3+ population. (G) inescence imaging of cohorts of mice
treated with T cells expressing CD19-chimeric receptors with short spacer
(‘short/CD28’ and ‘short/4-1BB’), long spacers (‘long/CD28 and ‘long/4-1BB’), or
control T cells.
Figure 20: T cells expressing CD19 chimeric receptors with 4-1BB and
CD3zeta and a modified IgG4-Fc hinge exhibit superior in vitro and in vivo on
compared to T cells expressing CD19 chimeric receptors with 4-1BB and CD3zeta and
a CD8 alpha hinge.A. Cytolytic activity of CD19 chimeric receptor modified T-cells with
IgG4 Fc hinge, CD8 alpha hinge and control T cells against Cr51-labeled K562 cells
transfected with CD19, Raji lymphoma cells that express CD19, and K562 control T cells.
Lysis is shown at different E/T ratios in a 4 hour Cr51 e assay. B. Interferon gamma
production by 5x104 T cells expressing a CD19 chimeric or with an IgG4 Fc hinge or
CD8 alpha hinge after a 24-hour coculture with Raji tumor cells. O.D. of 1 corresponds to
~500 pg/ml of interferon gamma. C. CFSE dye on assay to measure proliferation of T
cells expressing a CD19 chimeric receptor with an IgG4 Fc hinge or CD8 alpha hinge and T
cells that express tEGFR alone (control) after 72 hours coculture with CD19 positive Raji
lymphoma cells. Numbers above each histogram indicate the number of cell divisions the
erating cell subset underwent. The fraction of T cells in each gate that underwent
>3/2/1 cell divisions is provided next to the plot. D. In vivo antitumor activity of T cells
sing a CD19 chimeric receptor with an IgG4 Fc hinge (group 1) or CD8 alpha hinge
(group 2) and T cells that express tEGFR alone (group 3) in NSG mice inoculated with Raji
tumor cells expressing y luciferase (ffluc). Mice were imaged 17 days after tumor
inoculation and 10 days after T cell inoculation. The data shows greater tumor burden in
mice treated with control tEGFR T cells (group 3) or with CD19 chimeric receptor CD8
alpha hinge T cells (group 2) compared with mice treated with CD19 chimeric receptor
IgG4 Fc hinge T cells (group 1).
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have
the same meaning as ly understood by one of ordinary skill in the art to
which the invention pertains.
“About” as used herein when referring to a measurable value is meant to
encompass variations of ±20% or ±10%, more preferably ±5%, even more
preferably ±l%, and still more preferably ±0.1 % from the specified value.
"Activation", as used herein, refers to the state of a T cell that has been
iently stimulated to induce detectable cellular proliferation, cytokine
production or expression of cell surface s such as CD69 and CD25, or
detectable effector functions.
“Activation Induced cell death” as used herein refers to a state of a T cell that
is activated but is not able to proliferate for more than 2 generations and exhibits
markers of apoptosis.
"Antigen" or "Ag" as used herein refers to a molecule that provokes an
immune response. This immune response may involve either antibody production, or
the activation of specific immunologically-competent cells, or both. It is readily
apparent that an antigen can be generated synthesized, produced recombinantly or
can be derived from a biological sample. Such a biological sample can include, but
is not limited to a tissue sample, a tumor sample, a cell or a biological fluid.
"Anti-tumor effect" as used herein, refers to a biological effect, which can be
manifested by a decrease in tumor volume, a decrease in the number of tumor cells,
a se in the number of metastases, an se in life expectancy, or a decrease
of various physiological symptoms ated with the cancerous condition. An
"anti-tumor effect" can also be manifested by a decrease in recurrence or an increase
in the time before recurrence.
“Chimeric receptor” as used herein refers to a synthetically designed receptor
comprising a ligand binding domain of an antibody or other protein sequence that
binds to a molecule associated with the disease or er and is linked via a spacer
domain to one ore more intracellular signaling domains of a T cell or other
ors, such as a ulatory domain.
"Co-stimulatory ," as the term is used herein refers to a signaling
moiety that provides to T cells a signal which, in on to the primary signal
ed by for instance the CD3 zeta chain of the TCR/CD3 complex, mediates a T
cell response, ing, but not limited to, activation, eration, differentiation,
cytokine secretion, and the like. A co-stimulatory domain can e all or a portion
of, but is not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, , ICOS,
lymphocyte function-associated antigen-l (LFA-l), CD2, CD7, LIGHT, NKG2C,
B7-H3, and a ligand that specifically binds with CD83. In ments, the costimulatory
domain is an intracellular signaling domain that interacts with other
intracellular mediators to mediate a cell response including activation, eration,
differentiation and cytokine secretion, and the like.
"Coding for" are used herein refers to the property of specific sequences of
nucleotides in a polynucleotide, such as a gene, a cDNA, or an mRNA, to serve as
templates for synthesis of other olecules such as a defined sequence of
amino acids. Thus, a gene codes for a protein if transcription and ation of
mRNA corresponding to that gene es the protein in a cell or other biological
system. A "nucleic acid sequence coding for a polypeptide" includes all nucleotide
sequences that are degenerate versions of each other and that code for the same
amino acid sequence.
“Cytotoxic T lymphocyte “(CTL) as used herein refers to a T lymphocyte
that expresses CD8 on the surface thereof (i.e., a CD8+ T cell). In some
embodiments such cells are preferably "memory" T cells (TM cells) that are antigen-
experienced.
"Central memory" T cell (or "TCM") as used herein refers to an antigen
experienced CTL that expresses CD62L or CCR-7 and CD45RO on the surface
thereof, and does not express or has decreased expression of CD45RA as compared
to naive cells. In embodiments, l memory cells are positive for expression of
CD62L, CCR7, CD28, CD127, CD45RO, and CD95, and have decreased expression
of CD54RA as compared to naïve cells.
"Effector memory" T cell (or "TEM") as used herein refers to an antigen
experienced T cell that does not express or has decreased expression of CD62L on
the surface thereof as compared to central memory cells, and does not express or has
decreased expression of CD45RA as compared to naïve cell. In ments,
effector memory cells are negative for expression of CD62L 7, compared
to naïve cells or central memory cells, and have variable expression of CD28 and
CD45RA.
“Naïve “ T cells as used herein refers to a non antigen experienced T
lymphocyte that expresses CD62L and CD45RA, and does not express CD45RO- as
ed to central or effector memory cells. In some embodiments, naïve CD8+ T
lymphocytes are terized by the expression of phenotypic markers of naïve T
cells including CD62L, CCR7, CD28, CD127, and .
tor “ “TE” T cells as used herein refers to a antigen experienced
xic T cyte cells that do not express or have decreased expression of
CD62L, CCR7, CD28, and are positive for granzyme B and perforin as compared to
central memory or naïve T cells.
"Enriched" and "depleted" as used herein to describe amounts of cell types in
a mixture refers to the subjecting of the mixture of the cells to a process or step
which results in an increase in the number of the "enriched" type and a decrease in
the number of the "depleted" cells. Thus, depending upon the source of the original
population of cells subjected to the enriching process, a mixture or composition may
contain about 60, 70, 80, 90, 95, or 99 t or more (in number or count) of the
"enriched" cells and about 40, 30, 20, 10, 5 or 1 percent or less (in number or count)
of the "depleted" cells.
“Epitope” as used herein refers to a part of an n or molecule that is
recognized by the immune system including antibodies, T cells, and/ or B cells.
Epitopes usually have at least 7 amino acids and can be linear or conformational.
"Isolated," when used to be the various polypeptides sed herein,
means polypeptide or nucleic acid that has been identified and separated and/or
red from a component of its natural environment. Preferably, the isolated
polypeptide or nucleic acid is free of association with all components with which it
is naturally associated. Contaminant components of its natural environment are
materials that would typically interfere with diagnostic or therapeutic uses for the
polypeptide or nucleic acid, and may include enzymes, hormones, and other
proteinaceous or non-proteinaceous solutes.
“Intracellular signaling domain” as used herein refers to all or a portion of
one or more domains of a molecule (here the chimeric receptor molecule) that
provides for activation of a cyte. Intracellular domains of such molecules
mediate a signal by interacting with cellular mediators to result in proliferation,
differentiation, activation and other or functions. In embodiments, such
molecules e all or portions of CD28, CD3, 4-1BB, and combinations thereof.
“Ligand” as used herein refers to a substance that binds specifically to
r substance to form a x. Example of ligands include epitopes on
antigens, molecules that bind to receptors, substrates, inhibitors, hormones, and
activators. “Ligand binding domain” as used herein refers to substance or portion of
a substance that binds to a ligand. Examples of ligand binding domains include
antigen binding portions of antibodies, extracellular domains of receptors, and active
sites of enzymes.
"Operably linked" as used herein refers to functional e between a
regulatory sequence and a logous nucleic acid sequence resulting in
expression of the . For example, a first nucleic acid sequence is operably linked
with a second c acid sequence when the first nucleic acid sequence is placed in
a onal relationship with the second nucleic acid sequence. For ce, a
promoter is operably linked to a coding sequence if the promoter affects the
transcription or expression of the coding sequence. Generally, operably linked DNA
sequences are contiguous and, where necessary to join two protein coding regions,
in the same reading frame.
"Percent (%) amino acid sequence identity" with respect to the chimeric
receptor polypeptide sequences fied herein is defined as the percentage of
amino acid residues in a candidate sequence that are identical with the amino acid
residues in the reference ce for each of the ligand binding domain, spacer,
transmembrane domain, and/or the lymphocyte activating domain, after aligning the
sequences and introducing gaps, if necessary, to achieve the maximum percent
sequence identity, and not considering any conservative substitutions as part of the
ce identity. Alignment for purposes of determining percent amino acid
sequence identity can be achieved in various ways that are within the skill in the art,
for instance, using publicly ble er re such as BLAST, BLAST-2,
ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Those skilled in the art can
determine appropriate parameters for measuring alignment, including any algorithms
needed to achieve maximal alignment over the full-length of the sequences being
compared. For example, % amino acid sequence identity values generated using the
WU-BLAST-2 computer program [Altschul et al., Methods in Enzymology,
266:460-480 (1996)] uses several search parameters, most of which are set to the
default values. Those that are not set to default values (i.e., the adjustable
ters) are set with the following : overlap span=1, overlap
fraction=0.125, word threshold (T)=11 and scoring matrix=BLOSUM62. A %
amino acid sequence identity value is determined by dividing (a) the number of
matching identical amino acid residues between the each or all of the polypeptide
amino acid sequence of the reference chimeric receptor sequence provided in Table
2 and the comparison amino acid ce of st as determined by WUBLAST-2
by (b) the total number of amino acid residues of the polypeptide of
interest.
"Chimeric receptor variant polynucleotide" or "chimeric receptor variant
c acid sequence" as used herein refers to a polypeptide-encoding nucleic acid
molecule as defined below having at least about 80% c acid sequence identity
with the cleotide acid sequence shown in Table 1 or a specifically derived
nt thereof, such as polynucleotide coding for an antigen g domain, a
polynucleotide encoding a spacer domain, a polynucleotide coding for a
transmembrane domain and/ or a polynucleotide coding for a lymphocyte
stimulatory domain. Ordinarily, a chimeric receptor variant of polynucleotide or
nt thereof will have at least about 80% nucleic acid sequence identity, more
preferably at least about 81% nucleic acid sequence identity, more preferably at least
about 82% nucleic acid sequence identity, more ably at least about 83%
nucleic acid sequence identity, more preferably at least about 84% nucleic acid
ce ty, more preferably at least about 85% c acid sequence identity,
more preferably at least about 86% nucleic acid sequence identity, more preferably
at least about 87% nucleic acid sequence identity, more preferably at least about
88% nucleic acid sequence identity, more preferably at least about 89% nucleic acid
sequence identity, more preferably at least about 90% nucleic acid sequence identity,
more preferably at least about 91% nucleic acid sequence ty, more preferably
at least about 92% nucleic acid sequence identity, more preferably at least about
93% nucleic acid sequence identity, more preferably at least about 94% nucleic acid
sequence identity, more preferably at least about 95% nucleic acid sequence identity,
more preferably at least about 96% nucleic acid sequence identity, more preferably
at least about 97% nucleic acid sequence identity, more preferably at least about
98% nucleic acid sequence identity and yet more preferably at least about 99%
nucleic acid sequence identity with the nucleic acid sequence as shown in Table or a
derived fragment thereof. Variants do not ass the native nucleotide sequence.
In this regard, due to the degeneracy of the genetic code, one of ordinary skill in the
art will immediately recognize that a large number of chimeric receptor variant
polynucleotides having at least about 80% nucleic acid sequence identity to the
nucleotide sequence of Table 1 will encode a polypeptide having an amino acid
sequence which is identical to the amino acid sequence of Table 2.
antially purified" refers to a molecule that is essentially free of other
molecule types or a cell that is essentially free of other cell types. A substantially
purified cell also refers to a cell, which has been separated from other cell types with
which it is normally associated in its naturally occurring state. In some instances, a
population of substantially purified cells refers to a homogenous population of cells.
“Not ntially found” when used in reference the presence of a tumor
n or other molecules on normal cells refers to the percentage of a normal cell
type that has the antigen or molecule, and / or the density of the n on the cells.
In embodiments, not substantially found means that the antigen or molecule is found
on less than 50% of normal cell type and/or at a 50% less density as ed to the
amount of cells or antigen found on a tumor cell or other diseased cell.
"T cells" or "T lymphocytes" as used herein may be from any mammalian,
preferably primate, species, ing monkeys, dogs, and . In some
embodiments the T cells are allogeneic (from the same species but different donor)
as the recipient subject; in some embodiments the T cells are autologous (the donor
and the recipient are the same); in some embodiments the T cells arc syngeneic (the
donor and the recipients are different but are identical twins).
Modes of the sure
Described herein are chimeric receptor nucleic acids, and vectors and host
cells including such nucleic acids. The chimeric receptor c acid comprises a
number of modular components that can be excised and replaced with other
components in order to customize the chimeric receptor for a ic target
molecule. The disclosure describes that one of the modular components is the
spacer component. It has been surprisingly found that the length of the spacer
region that is presumed not to have signaling lity affects the in vivo
efficacy of the T cells modified to express the chimeric or and needs to be
customized for individual target molecules for ed therapeutic ty.
In one aspect, methods and nucleic acid constructs are described to design
a chimeric receptor that has improved tumor recognition, sed T cell
proliferation and/or cytokine production in response to the ligand as compared to
a reference chimeric or. In embodiments, a library of nucleic acids is
described, wherein each nucleic acid codes for a spacer region that differs from
the others in sequence and . Each of the nucleic acids can then be used to
form a chimeric receptor nucleic acid construct that can be tested in vivo (in an
animal model) and/or in vitro so that a spacer can be selected that es for
improved tumor recognition, increased T cell proliferation and/or cytokine
production in response to the ligand.
In embodiments, a chimeric receptor nucleic acid comprises a
polynucleotide coding for a ligand binding domain, wherein the ligand is a tumor
or viral specific antigen or molecule, a polynucleotide coding for a customized
polypeptide spacer, n the spacer provides for ed T cell proliferation;
a polynucleotide coding for a transmembrane domain; and a polynucleotide
coding for one or more intracellular signaling domains. In embodiments, a long
spacer is employed if the e of the target molecule is membrane proximal on
the target cell and a short spacer is employed if the epitope of the target le
is membrane distal on the target cell.
The design of a chimeric receptor can be customized depending on the
type of tumor or virus, the target antigen or molecule present on the tumor, the
affinity of the antibody for the target molecule, the flexibility needed for the
antigen binding domain, and/or the intracellular signaling domain. In
embodiments, a number of chimeric or constructs are tested in vitro and in
in vivo models to determine the ability of T cells modified with the receptor to
kill tumor cells in immunodeficient mice and to proliferate and persist after
adoptive transfer. In embodiments, a chimeric receptor is selected that provides
for capability of at least 30% of the cells to proliferate through at least two
generations in vitro and/or within 72 hours after introduction in vivo. In
embodiments, a chimeric receptor is not ed that results in greater than 50%
of the cells undergoing tion induced cell death (AICD) within 72 hours in
vivo in immunodeficient mice, and fails to eradicate tumor cells.
Depending on whether the target molecule is present on a subject’s tumor
cells, the chimeric receptor includes a ligand binding domain that specifically binds
to that target molecule. In embodiments, a subject’s tumor cells are characterized for
cell surface tumor molecules. The target molecule may be ed based on a
ination of its presence on a ular subject’s tumor cells. In embodiments,
a target le is selected that is a cell surface molecule found predominantly on
tumor cells and not found on normal tissues to any substantial . In
embodiments, an antibody is selected to bind to an epitope on the targeted cell
surface molecule. In some cases, the epitope is characterized with respect to its
proximity to the cell ne. An epitope is characterized as proximal to the
membrane when it is predicted or known by structural analysis to reside closer to the
target cell membrane than ative es that are predicted or known by
structural analysis to reside a greater distance from the target cell membrane. In
embodiments, the affinity of the antibody from which the scFV is constructed is
compared by binding assays, and antibodies with different affinities are examined in
chimeric receptor formats expressed in T cells to determine which affinity confers
optimal tumor recognition, based on superior cytotoxicity of target cells, and/or T
cell cytokine production and proliferation.
In addition, the spacer region of the chimeric receptor may be varied to
optimize T cell recognition of the ligand on the target cell. In embodiments, when an
antibody binds to an epitope on the target cell that is very al to the
membrane, a spacer is selected that is longer than about 15 amino acids. For
example, in embodiments, if the e or portion thereof on the target antigen is in
the first 100 amino acids of the linear sequence of the extracellular domain adjacent
to the transmembrane domain, a long spacer region may be selected. In
embodiments, when an antibody binds to an epitope on the target cell that is distal to
the membrane, a spacer is selected that is about 119 or 15 amino acids or less. For
example, in embodiments, when the e or portion thereof is found in the 150
amino acids of the linear sequence of the ellular domain from the terminus, a
short or inetermediate spacer may be utilized. In embodiments, a spacer comprises
an amino acid sequence X1PPX2P.
A variety of combinations of primary and costimulatory intracellular
signaling domain may be employed to enhance the in vivo efficacy of the chimeric
receptor. In embodiments, different constructs of the chimeric receptor can be tested
in an in vivo animal model to determine efficacy for tumor g. In embodiments,
a costimulatory intracellular signaling domain is selected from the group consisting
of CD28 and modified versions thereof, 4-1BB and modified versions thereof and
combinations thereof. Other costimulatory s, such as OX40 may be
incorporated.
CD8+ central memory T cells have an sic programming that allows
them to persist for extended periods after administration, which makes them a
preferred subset of CD8+ T cells for immunotherapy. In embodiments, CD19
specific chimeric receptor modified cytotoxic T cells prepared from sort purified
CD8+ central memory T cells are administered in the presence or absence of CD4+
CD19 ic chimeric receptor -modified T cells. In embodiments, tumor-specific
CD4+ T cells exert anti-tumor reactivity and provide help to tumor-specific CD8+ T
cells in vitro and in vivo. In a specific embodiment, tumor-specific CD4+ T cells or
CD4+ T cells selected from the naïve or the central memory subsets are utilized
alone or in combination with CD8+ TCM.
Nucleic Acids, Vectors, and ptides
Also described is a chimeric receptor nucleic acid useful for transforming or
transducing lymphocytes for use in adoptive therapy. In embodiments, the
nucleic acid contains a number of modular components that provide for easy
substitution of ts of the nucleic acid. While not meant to limit the scope of
the disclosure, it is believed that the chimeric receptor for each tumor antigen is
bly customized in terms of components in order to provide for in vivo efficacy
and efficient expression in mammalian cells. For example, in a ic embodiment,
for efficacy of a chimeric receptor comprising a scFV that binds to a ROR1 epitope
located in the ne distal Ig/Frizzled , a spacer that is about 15 amino
acids or less is employed. In another specific embodiment, for efficacy of a ic
receptor comprising a scFV that binds to a ROR1 epitope located in the membrane
proximal Kringle domain, a spacer that is longer than 15 amino acids is employed.
In another embodiment, for efficacy of a chimeric receptor comprising a scFV that
binds to CD19, a spacer that is 15 amino acids or less is employed.
In embodiments, an isolated chimeric receptor nucleic acid comprises a
polynucleotide coding for a ligand binding domain, wherein the target molecule is a
tumor specific antigen, a polynucleotide coding for a ptide spacer wherein the
polypeptide spacer is about 229 amino acids or less; a polynucleotide coding for a
transmembrane domain; and a cleotide coding for an intracellular signaling
. In embodiments, an expression vector comprises a chimeric nucleic acid as
described herein. Polypeptides encoded by all of or a portion of the ic
receptor nucleic acids are also included herein.
Ligand binding domain
In embodiments, the chimeric receptor nucleic acid comprises a
polynucleotide coding for a ligand binding domain. In embodiments, the ligand
binding domain specifically binds to a tumor or viral specific antigen. In
embodiments, the ligand binding domain is an antibody or fragment thereof. A
nucleic acid sequence coding for an antibody or antibody fragment can readily be
determined. In a specific embodiment, the polynucleotide codes for a single chain
Fv that specifically binds CD19. In other specific embodiments, the polynucleotide
codes for a single chain Fv that specifically binds ROR1. The sequences of these
antibodies are known to or can readily be determined by those of skill in the art.
Tumor antigens are proteins that are produced by tumor cells that elicit an
immune response. The selection of the ligand binding domain described herein will
depend on the type of cancer to be treated, and may target tumor antigens or other
tumor cell surface molecules. A tumor sample from a subject may be characterized
for the presence of certain biomarkers or cell surface markers. For example, breast
cancer cells from a subject may be positive or negative for each of Her2Neu,
Estrogen receptor, and/or the Progesterone receptor. A tumor antigen or cell surface
le is ed that is found on the individual subject’s tumor cells. Tumor
antigens and cell surface molecules are well known in the art and include, for
example, carcinoembryonic antigen (CEA), te specific n, PSMA,
Her2/neu, estrogen receptor, terone receptor, ephrinB2, CD19, CD20, CD22,
CD23, CD123, CS-1, ROR1, mesothelin, c-Met, GD-2, and MAGE A3 TCR. In
ments a target le is a cell e molecule that is found on tumor
cells and is not substantially found on normal tissues, or restricted in its expression
to tal normal tissues.
Other target molecules include but are not limited to antigens derived from
infectious ens such as HIV (human immunodeficiency virus), HBV itis
B virus), HPV (human papilloma virus) and Hepatitis C virus.
In one embodiment, the target molecule on the tumor comprises one or more
epitopes associated with a malignant tumor. Malignant tumors express a number of
proteins that can serve as target antigens for T cell receptor or chimeric receptor
mediated recognition. Other target les belong to the group of cell
transformation-related molecules such as the oncogene HER-2/Neu/ErbB2. In
embodiments, the tumor antigen is ively expressed or overexpressed on the
tumor cells as compared to control cells of the same tissue type. In other
embodiments, the tumor antigen is a cell surface polypeptide.
Once a tumor cell surface molecule that might be targeted with a chimeric
receptor is identified, an epitope of the target molecule is selected and terized.
In embodiments, an e is selected that is proximal to the tumor cell membrane.
In other embodiments, an epitope is selected that is distal to the tumor cell
membrane. An epitope is characterized as proximal to the membrane when it is
predicted or known by structural analysis to reside closer to the target cell membrane
than alternative es that are ted or known by structural analysis to reside
a r distance from the target cell membrane.
Antibodies that specifically bind a tumor cell surface molecule can be
prepared using methods of obtaining monoclonal antibodies, methods of phage
display, methods to generate human or humanized antibodies, or methods using a
transgenic animal or plant engineered to produce human antibodies. Phage display
libraries of partially or fully synthetic antibodies are available and can be screened
for an antibody or fragment thereof that can bind to the target molecule. Phage
display libraries of human antibodies are also available. In embodiments, antibodies
specifically bind to a tumor cell surface molecule and do not cross react with
nonspecific components such as bovine serum albumin or other unrelated antigens.
Once identified, the amino acid ce or polynucleotide sequence coding for the
antibody can be isolated and/or determined.
Antibodies or antigen binding fragments include all or a portion of
polyclonal antibodies, a monoclonal antibody, a human antibody, a humanized
dy, a synthetic antibody, a ic dy, a bispecific antibody, a
minibody, and a linear antibody. Antibody fragments" comprise a portion of an
intact antibody, preferably the antigen binding or variable region of the intact
antibody and can y be prepared. Examples of antibody fragments include Fab,
Fab', F(ab')2, and Fv fragments; diabodies; linear dies; single-chain antibody
molecules; and multispecific antibodies formed from dy fragments.
In ments, a number of different dies that bind to a particular
tumor cell surface molecules can be isolated and characterized. In ments, the
antibodies are characterized based on epitope specificity of the targeted molecule. In
addition, in some cases, antibodies that bind to the same e can be selected
based on the affinity of the antibody for that epitope. In embodiments, an antibody
has an affinity of at least 1 mM, and preferably <50 nM. In embodiments, an
antibody is selected that has a higher affinity for the epitope as compared to other
antibodies. For example, an antibody is selected that has at least a 2 fold, at least a 5
fold, at least a 10 fold, at least a 20 fold, at least a 30 fold, at least a 40 fold, or at
least a 50 fold greater affinity than a reference antibody that binds to the same
epitope.
In embodiments, target molecules are selected from the group consisting of
CD19, CD20, CD22, CD23, CD123, CS-1, ROR1, mesothelin, Her2, c-Met, PSMA,
GD-2, MAGE A3 TCR and combinations thereof.
In specific ments, the target antigen is CD19. A number of antibodies
specific for CD19 are known to those of skill in the art and can be readily
terized for sequence, epitope binding, and affinity. In a specific embodiment,
the chimeric receptor construct includes a scFV sequence from FMC63 antibody. In
other embodiments, the scFV is a human or humanized ScFv comprising a variable
light chain comprising a CDRL1 sequence of RASQDISKYLN, CDRL2 sequence
of SRLHSGV, and a CDRL3 sequence of GNTLPYTFG. In other embodiments, the
scFV is a human or humanized ScFv comprising a variable heavy chain comprising
CDRH1 ce of DYGVS , CDRH2 sequence of VIWGSETTYYNSALKS, and
a CDRH3 sequence of YAMDYWG. The disclosure also contemplates variable
regions that have at least 90% amino acid sequence identity to that of the scFv for
FMC63 and that have at least the same affinity for CD19. In embodiments, the
chimeric receptor has a short or intermediate spacer of 119 amino acids or less, or 12
amino acids or less. In a specific embodiment, the spacer is 12 amino acid or less
and has a sequence of SEQ ID NO:4.
In embodiments, CDR regions are found within antibody regions as
numbered by Kabat as follows: for the light chain; CDRL1 amino acids 24-
34;CDRL2 amino acids 50-56; CDRL3 at amino acids 89-97; for the heavy chain at
CDRH1 at amino acids 31-35; CDRH2 at amino acids 50-65; and for CDRH3 at
amino acids 95-102. CDR regions in antibodies can be readily determined.
In specific embodiments, the target antigen is ROR1. A number of antibodies
specific for ROR1 are known to those of skill in the art and can be readily
characterized for sequence, epitope binding, and ty. In a specific embodiment,
the chimeric receptor construct includes a scFV sequence from R12 antibody. In
other ments, the scFV is a human or humanized ScFv comprising a variable
light chain sing a CDRL1 sequence of ASGFDFSAYYM, CDRL2 sequence
of TIYPSSG, and a CDRL3 sequence of ADRATYFCA. In other embodiments, the
scFV is a human or humanized ScFv comprising a variable heavy chain comprising
CDRH1 sequence of , CDRH2 sequence of VQSDGSYTKRPGVPDR,
and a CDRH3 sequence of YIGGYVFG. The disclosure also contemplates variable
regions that have at least 90% amino acid sequence identity to that of the scFv for
R12 and that have at least the same affinity for ROR1. In embodiments, the chimeric
receptor has a short or ediate spacer of 119 amino acids or less, or 12 amino
acids or less. In a specific embodiment, the spacer is 12 amino acid or less and has a
sequence of SEQ ID NO:4.
In specific embodiments, the target antigen is ROR1. A number of antibodies
specific for ROR1 are known to those of skill in the art and can be readily
terized for sequence, epitope binding, and affinity. In a specific ment,
the chimeric receptor construct includes a scFV sequence from R11 antibody. In
other embodiments, the scFV is a human or humanized ScFv sing a le
light chain comprising a CDRL1 sequence of SGSDINDYPIS, CDRL2 sequence of
T, and a CDRL3 sequence of YFCARGYS. In other embodiments, the
scFV is a human or humanized ScFv comprising a variable heavy chain comprising
CDRH1 sequence of SNLAW, CDRH2 sequence of RASNLASGVPSRFSGS, and a
CDRH3 sequence of NVSYRTSF. The disclosure also contemplates variable
regions that have at least 90% amino acid sequence identity to that of the scFv for
R11 and that have at least the same affinity for ROR1. In embodiments, the chimeric
receptor has a long spacer of 229 amino acids or less. In a specific embodiment, the
spacer is 229 amino acids and has a sequence of SEQ ID NO:50.
In specific embodiments, the target antigen is Her2. A number of antibodies
specific for Her2 are known to those of skill in the art and can be readily
characterized for ce, epitope binding, and affinity. In a specific embodiment,
the chimeric receptor uct includes a scFV sequence from Herceptin antibody.
In other embodiments, the scFV is a human or humanized ScFv sing a
variable light chain comprising a CDRL1 sequence, CDRL2 sequence and a CDRL3
sequence of the Herceptin antibody. In other embodiments, the scFV is a human or
zed ScFv comprising a variable heavy chain comprising CDRH1 sequence,
CDRH2, and a CDRH3 sequence of Herceptin. The CDR sequences can readily be
determined from the amino acid sequence of Herceptin. The disclosure also
contemplates variable regions that have at least 90% amino acid sequence identity to
that of the scFv for tin and that have at least the same affinity for Her2. In
embodiments, the chimeric receptor has a long spacer of 229 amino acids or less. In
a specific embodiment, the spacer is 229 amino acids and has a sequence of SEQ ID
NO:50.
In embodiments, a polynucleotide coding for a ligand binding domain is
operably linked to a polynucleotide coding for a spacer region. In embodiments, the
polynucleotide coding for a ligand g domain may also have one or more
restriction enzyme sites at the 5’ and/or 3’ ends of the coding sequence in order to
provide for easy excision and replacement of the cleotide with another
polynucleotide coding for a ligand binding domain coding for a different antigen or
that has different binding characteristics. For example, a restriction site, NheI, is
encoded upstream of the leader sequence; and a 3’ RsrII d within the hinge
region allows subcloning of any desirable scFv into a chimeric receptor vector. In
embodiments, the polynucleotide is codon optimized for expression in mammalian
cells.
In embodiments, the cleotide coding for a ligand g domain is
operably linked to a signal peptide. In embodiments the signal peptide is a signal
peptide for granulocyte colony stimulating factor. Polynucleotides coding for other
signal peptides such as CD8 alpha can be utilized.
In embodiments, the polynucleotide coding for a ligand binding domain is
operably linked to a promoter. A promoter is selected that es for expression of
the chimeric antigen receptor in a mammalian cell. In a ic embodiment the
promoter is the elongation growth factor promoter (EF-1). Another example of a
suitable promoter is the immediate early cytomegalovirus (CMV) promoter
sequence. However, other constitutive promoter sequences may also be used,
ing, but not limited to the simian virus 40 (SV 40) early promoter, mouse
mammary tumor virus (MMTV), human immunodeficiency virus (HlV) long
terminal repeat (LTR) promoter, MuMoLV promoter, an avian leukemia virus
promoter, an Epstein-Barr virus immediate early er, a Rous sarcoma virus
promoter, as well as human gene promoters such as, but not limited to, the actin
promoter, the myosin promoter, the obin promoter, and the creatine kinase
promoter. ble promoters are also contemplated. Examples of inducible
promoters include, but are not limited to a metallothionine promoter, a
glucocorticoid promoter, a progesterone promoter, and a ycline promoter.
A specific embodiment of a polynucleotide coding for a ligand binding
domain is shown in Table 1 as the scFv from an antibody that specifically binds
CD19, such as FMC63. A polynucleotide encoding for a flexible linker including
the amino acids GSTSGSGKPGSGEGSTKG (SEQ ID NO:36)separates the VH and
VL chains in the scFV. The amino acid sequence of the scFv including the linker is
shown in Table 2.(SEQ ID NO:11) Other argeting dies such as SJ25C1
and HD37 are known. (SJ25C1: Bejcek et al. Cancer Res 2005, PMID 7538901;
HD37: Pezutto et al. JI 1987, PMID 2437199).
Spacer
In ments, the chimeric receptor nucleic acid comprises a
polynucleotide coding for a spacer region. It has been surprisingly found that the
length of the spacer region that is presumed not to have signaling capability affects
the in vivo efficacy of the T cells modified to express the chimeric receptor and
needs to be customized for individual target les for optimal tumor or target
cell recognition. In embodiments, the chimeric receptor nucleic acid comprises a
cleotide coding for a customizable spacer region ed from a library of
polynucleotides coding for spacer regions. In embodiments, a spacer length is
selected based upon the location of the epitope, affinity of the antibody for the
epitope, and/or the ability of the T cells expressing the ic or to
proliferate in vitro and/or in vivo in response to antigen recognition.
Typically a spacer region is found between the ligand binding domain and
the transmembrane domain of the chimeric receptor. In embodiments, a spacer
region provides for flexibility of the ligand binding domain, allows for high
sion levels in lymphocytes. A CD19-specific chimeric receptor having a
spacer domain of about 229 amino acids had less antitumor activity than a CD19-
specific chimeric receptor with a short spacer region comprised of the modified
IgG4 hinge only. Other chimeric receptors, such as those constructed from the R12
or 2A2 scFvs also require a short spacer for optimal triggering of T cell effector
functions, while a chimeric receptor constructed with the R11 ROR1 scFv es a
long spacer domain of about 229 amino acids for tumor recognition.
In embodiments, a spacer region has at least about 10 to 229 amino acids,
about 10 to 200 amino acids, about 10 to 175 amino acids, about 10 to 150 amino
acids, about 10 to 125 amino acids, about 10 to 100 amino acids, about 10 to 75
amino acids, about 10 to 50 amino acids, about 10 to 40 amino acids, about 10 to 30
amino acids, about 10 to 20 amino acids, or about 10 to 15 amino acids, and
including any integer between the endpoints of any of the listed . In
ments, a spacer region has about 12 amino acids or less, about 119 amino
acids or less, or about 229 amino acids or less.
In some embodiments, the spacer region is derived from a hinge region of an
immunoglobulin like le. In embodiments, a spacer region comprises all or a
portion of the hinge region from a human IgG1, human IgG2, a human IgG3, or a
human IgG4, and may contain one or more amino acid substitutions. Exemplary
sequences of the hinge s are provided in Table 8. In embodiments, a portion
of the hinge region includes the upper hinge amino acids found between the variable
heavy chain and the core, and the core hinge amino acids including a polyproline
region. Typically, the upper hinge region has about 3 to 10 amino acids. In some
cases, the spacer region comprises an amino acid sequence of X1PPX2P(SEQ ID
NO:1). In embodiments, X1 is a cysteine, glycine, or arginine and X2 is a cysteine or
a threonine.
In embodiments, hinge region sequences can be modified in one or more
amino acids in order to avoid undesirable structural interactions such as
dimerization. In a specific ment, the spacer region comprises a portion of a
modified human hinge region from IgG4, for example, as shown in Table 2 or Table
8(SEQ ID . A entative of a polynucleotide coding for a portion of a
modified IgG4 hinge region is provided in Table 1. (SEQ ID NO:4)In embodiments,
a hinge region can have at least about 90%, 92%, 95%, or 100% sequence identity
with a hinge region amino acid sequence identified in Table 2 or Table 8. In a
specific embodiment, a portion of a human hinge region from IgG4 has an amino
acid substitution in the core amino acids from CPSP to CPPC.
In some embodiments, all or a portion of the hinge region is combined with
one or more domains of a constant region of an immunoglobulin. For example, a
portion of a hinge region can be combined with all or a portion of a CH2 or CH3
domain or variant thereof. In embodiments, the spacer region does not include the
47-48 amino acid hinge region sequence from a or the spacer region
consisting of an extracellular n of the CD28 molecule.
In embodiments, a short spacer region has about 12 amino acids or less and
comprises all or a portion of a IgG4 hinge region sequence or variant thereof, an
intermediate spacer region has about 119 amino acids or less and comprises all or a
portion of a IgG4 hinge region sequence and a CH3 region or t thereof, and a
long spacer has about 229 amino acids or less and comprises all or a portion of a
IgG4 hinge region sequence , a CH2 region, and a CH3 region or variant thereof.
A polynucleotide coding for a spacer region can be readily prepared by
synthetic or inant methods from the amino acid sequence. In embodiments, a
cleotide coding for a spacer region is operably linked to a polynucleotide
coding for a transmembrane region. In embodiments, the polynucleotide coding for
the spacer region may also have one or more restriction enzyme sites at the 5’ and/or
3’ ends of the coding sequence in order to provide for easy on and replacement
of the polynucleotide with another polynucleotide coding for a different spacer
region. In embodiments, the cleotide coding for the spacer region is codon
optimized for expression in mammalian cells.
In embodiments, a library of polynucleotides, each coding for different
spacer region is described. In an embodiment, the spacer region is selected from the
group consisting of a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 or
portion thereof, a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 in
combination with all or a portion of a CH2 region or variant thereof, a hinge region
sequence from IgG1, IgG2, IgG3, or IgG4 in combination with all or a portion of a
CH3 region or t thereof, and a hinge region sequence from IgG1, IgG2, IgG3,
or IgG4 in combination with all or a portion of a CH2 region or variant thereof, and
a CH3 region or variant thereof. In embodiments, a short spacer region is a modified
IgG4 hinge sequence(SEQ ID NO:4) having 12 amino acids or less, an intermediate
sequence is a IgG4 hinge sequence with a CH3 sequence having 119 amino acids or
less(SEQ ID NO:49); or a IgG4 hinge sequence with a CH2 and CH3 region having
229 amino acids or less (SEQ ID NO:50)
In embodiments, a method of selecting a spacer region for a chimeric
receptor is described herein. Surprisingly some chimeric receptor ucts,
gh effective to activate T cells and direct their killing of tumor cells in vitro,
were not effective in vivo. In addition, the side effect profile of the chimeric receptor
modified T cells can be such as to result in more cells undergoing activation induced
cell death or causing an increase in in vivo cytokines. In ments, a method
comprises providing a plurality of chimeric or nucleic acids, wherein the
ic receptor nucleic acids differ only in the spacer region; introducing each of
the chimeric receptor nucleic acids into a separate T lymphocyte population;
expanding each separate lymphocyte population in vitro, and introducing each
lymphocyte population into an animal bearing a tumor to determine the anti-tumor
efficacy of each of the chimeric ors when expressed in T cells, and selecting a
chimeric receptor that es anti-tumor cy as compared to each of the other
te lymphocyte populations modified with each of the other chimeric receptors.
Animal models of different tumors are known. Anti-tumor efficacy can be
measured by identifying a se in tumor volume, by determining animal death,
persistence of the genetically modified T cells in vivo, tion of genetically
modified T cells (for example, by detecting an increase in expression of CD25
and/CD69), and/or proliferation of genetically modified T cells in vivo. In an
embodiment, a chimeric receptor is selected that provides for the best anti-tumor
efficacy in vivo as determined by one or more of these parameters. Lack of antitumor
efficacy can be determined by lack of tence of the genetically modified
lymphocytes in vivo, animal death, an increase in apoptosis as measured by an
increase in induction of e -3, and/or a decrease in proliferation of genetically
modified lymphocytes.
In other embodiments, a method for selecting a spacer comprises selecting an
epitope of a target molecule and characterizing the location of the e with
respect to the cell membrane, selecting a spacer region that is long or short
depending on the location of the epitope with respect to the cell membrane, selecting
an antibody or fragment thereof that has an affinity for the epitope that is higher or
lower as compared to a reference antibody, and determining whether the chimeric
receptor construct provides for enhanced T cell proliferation or cytokine production
in vitro and/or in vivo.
In some embodiments, if the target epitope or portion thereof is located
al to the membrane it is located in the first 100 amino acids of the linear
sequence of the extracellular domain adjacent to the transmembrane domain. If the
epitope is located proximal to the membrane, a long spacer (e.g. 229 amino acids or
less and greater than 119 amino acids) is selected. In some ments, if the
target epitope is located distal to the membrane, it is located in the first 150 amino
acids of the linear sequence of the extracellular domain terminus. If the epitope is
located distal to the membrane, an intermediate or short spacer is selected (e.g. 119
amino acids or less or 12-15 amino acids or less). Alternatively, whether the epitope
is proximal or distal to the membrane can be determined by modeling of the three
dimensional structure or based on is of the crystal structure,
In some embodiments, a chimeric receptor is selected that provides for at
least 30% of the cells proliferating through two generations in vitro and/or in vivo.
In other embodiments a chimeric or is not selected if it results in at least 50%
of the cells undergoing activation induced cell death in 72 hours. In ments, a
short spacer (e.g. 15 amino acids or less) is selected if the epitope is distal to the
membrane. In embodiments, a long spacer (e.g. 229 amino acid or less and greater
than 119 amino acids) is selected if the epitope is proximal to the membrane.
In embodiments, providing a ity of ic or nucleic acids,
n the chimeric receptor nucleic acids differ only in the spacer region
comprises providing a chimeric or construct comprising a polynucleotide
coding for a ligand binding domain, wherein the ligand is a tumor specific antigen,
viral antigen, or any other molecule expressed on a target cell population that is
suitable to mediate recognition and elimination by a lymphocyte; a polynucleotide
coding for a first polypeptide spacer having a defined restriction site at the 5’ and 3’
end of the coding sequence for the first polypeptide spacer; a cleotide coding
for a embrane domain; and a polynucleotide coding for one or more
intracellular signaling domains.
In embodiments, a method further comprises providing one or more
polynucleotides, each ng a different spacer region. In embodiments, the
different spacer regions are ed from the group consisting of a hinge region
sequence from IgG1, IgG2, IgG3, or IgG4 or variant thereof or portion thereof, a
hinge region sequence from IgG1, IgG2, IgG3, or IgG4 in combination with all or a
portion of a CH2 region or variant thereof, a hinge region sequence from IgG1,
IgG2, IgG3, or IgG4 in combination with all or a portion of a CH3 region or variant
thereof, and a hinge region sequence from IgG1, IgG2, IgG3, or IgG4 in
combination with all or a portion of a CH2 region or variant thereof and a CH3
region or variant thereof. In embodiments, CH2 or CH3 regions may be ed by
one or more deletions or amino acid tutions in order to provide for expression
in lymphocytes and/or in order to minimize ctions with other molecules. In
ments, a portion of a hinge region comprises at least the upper amino acids
and the core sequence. In embodiments, a hinge region comprises the sequence
X1PPX2P.
In embodiments, a method further comprises replacing the polynucleotide
coding for the spacer region with a polynucleotide ng a different spacer
region to form a chimeric receptor nucleic acid with a different spacer region. The
method can be repeated to form any number of chimeric receptor nucleic acids,
each differing in the spacer region. In embodiments, the chimeric receptor nucleic
acids differ from one another only in the spacer .
Transmembrane domain
In embodiments, the chimeric receptor nucleic acid comprises a
polynucleotide coding for a transmembrane domain. The transmembrane domain
provides for anchoring of the chimeric receptor in the membrane.
In an embodiment, the transmembrane domain that lly is associated
with one of the domains in the chimeric receptor is used. In some cases, the
transmembrane domain can be selected or modified by amino acid substitution to
avoid binding of such s to the transmembrane domains of the same or
different surface membrane ns to minimize interactions with other members of
the receptor complex.
The transmembrane domain may be derived either from a natural or a
synthetic source. When the source is natural, the domain may be derived from any
membrane-bound or transmembrane protein. Transmembrane regions comprise at
least the embrane region(s) of) the alpha, beta or zeta chain of the T-cell
receptor, CD28, CD3, CD45, CD4, CD8, CD9, CD16, CD22; CD33, CD37, CD64,
CD80, CD86, CD134, CD137 and CD154. In a specific embodiment, the
transmembrane domain ses the amino acid sequence of the CD28
transmembrane domain as shown in Table 2. A representative polynucleotide
sequence coding for the CD28 transmembrane domain is shown in Table 1(SEQ ID
NO:5).
A transmembrane domain may be tic or a variant of a naturally
occurring transmembrane . In embodiments, synthetic or variant
transmembrane domains comprise predominantly hydrophobic residues such as
leucine and valine. In embodiments, a embrane domain can have at least
about 80%, 85%, 90%, 95%, or 100% amino acid sequence identity with a
transmembrane domain as shown in Table 2 or Table 6. Variant transmembrane
domains preferably have a hydrophobic score of at least 50 as calculated by Kyte
Doolittle.
A polynucleotide coding for a transmembrane domain can be readily
prepared by synthetic or recombinant s. In embodiments, a polynucleotide
coding for a transmembrane domain is operably linked to a polynucleotide coding
for a intracellular signaling region. In embodiments, the polynucleotide coding for a
transmembrane domain may also have one or more ction enzyme sites at the 5’
and/or 3’ ends of the coding sequence in order to provide for easy excision and
replacement of the cleotide coding for a transmembrane domain with another
polynucleotide coding for a different transmembrane domain. In embodiments, the
polynucleotide coding for a transmembrane domain is codon optimized for
expression in mammalian cells.
Intracellular signaling domain
In embodiments, the chimeric receptor nucleic acid comprises a
polynucleotide coding for an intracellular signaling domain. The intracellular
signaling domain provides for activation of one function of the transduced cell
expressing the chimeric receptor upon binding to the ligand expressed on tumor
cells. In embodiments, the intracellular signaling domain contains one or more
intracellular ing domains. In embodiments, the intracellular signaling domain
is a portion of and/or a variant of an intracellular signaling domain that provides for
activation of at least one on of the transduced cell.
Examples of intracellular signaling domains for use in a chimeric receptor of
the disclosure include the cytoplasmic sequences of the CD3 zeta chain, and/or coreceptors
that act in concert to initiate signal transduction following chimeric
receptor engagement, as well as any derivative or variant of these sequences and any
synthetic ce that has the same functional capability. T cell activation can be
said to be mediated by two ct classes of cytoplasmic signaling sequence: those
that initiate n-dependent primary activation and provide a T cell receptor like
signal (primary cytoplasmic signaling sequences) and those that act in an antigenindependent
manner to provide a ary or co-stimulatory signal (secondary
cytoplasmic ing sequences). Primary cytoplasmic signaling sequences that act
in a stimulatory manner may n signaling motifs which are known as receptor
tyrosine-based activation motifs or ITAMs. es of ITAM containing primary
cytoplasmic signaling sequences include those derived from CD3 zeta, FcR gamma,
CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. In
embodiments, the primary signaling intracellular domain can have at least about
80%, 85%, 90%, or 95% sequence identity to CD3zeta having a sequence provided
in Table 2. In embodiments variants, of CD3 zeta retain at least one, two, three or
all ITAM regions as shown in Table 7.
In a preferred embodiment, the intracellular signaling domain of the chimeric
receptor can be ed to comprise the CD3-zeta signaling domain by itself or
combined with any other desired cytoplasmic domain(s). For example, the
intracellular signaling domain of the ic receptor can comprise a CD3zeta
chain and a costimulatory signaling region.
The costimulatory signaling region refers to a portion of the chimeric
or comprising the intracellular domain of a costimulatory molecule. A
costimulatory molecule is a cell e molecule other than an n receptor or
their ligands that is required for a response of cytes to an antigen. Examples
of such molecules include CD27, CD28, 4-1BB (CD 137), OX40, CD30, CD40,
cyte function-associated antigen-1 (LFA-l), CD2, CD7, LIGHT, NKG2C,
B7-H3, and a ligand that specifically binds with CD83. In embodiments, the
costimulatory signaling domain can have at least about 80%, 85%, 90%, or 95%
amino acid sequence identity to the intracellular domain of CD28 as shown in Table
or to 4-1BB having a sequence provided in Table 2. In an ment, a variant
of the CD28 intracellular domain comprises an amino acid substitution at positions
186-187, wherein LL is substituted with GG.
The intracellular signaling sequences of the chimeric receptor may be linked
to each other in a random or specified order. ally, a short oligo- or
polypeptide linker, preferably between 2 and 10 amino acids in length may form the
linkage. In one embodiment, the intracellular signaling domains comprises all or a
portion of the signaling domain of CD3-zeta or variant thereof and all or a portion of
the signaling domain of CD28 or a variant thereof. In another embodiment, the
intracellular signaling domain ses all or a portion of the signaling domain of
CD3-zeta or variant thereof and all or a portion of the signaling domain of 4-lBB or
variant thereof. In yet another embodiment, the intracellular signaling domain
comprises all or a portion of the signaling domain of CD3-zeta or variant thereof, all
or a portion of the signaling domain of CD28 or variant thereof, and all or a portion
of the signaling domain of 4-lBB or variant thereof. In a specific embodiment, the
amino acid sequence of the intracellular signaling domain comprising a variant of
CD3zeta and a portion of the 4-1BB intracellular signaling domain is ed in
Table 2. A entative nucleic acid sequence is ed in Table 1(SEQ ID
NO:6; SEQ ID NO:7).
In an embodiment, a polynucleotide coding for an intracellular signaling
domain comprises a 4-1BB intracellular domain linked to a portion of a CD3zeta
domain. In other embodiments, a 4-1BB ellular domain and a CD28
intracellular domain are linked to a portion of a CD3 zeta domain.
A polynucleotide coding for an intracellular signaling domain can be readily
prepared by synthetic or recombinant methods from the amino acid sequence. In
embodiments, the cleotide coding for an intracellular signaling domain may
also have one or more restriction enzyme sites at the 5’ and/or 3’ ends of the coding
sequence in order to provide for easy excision and replacement of the polynucleotide
coding for an intracellular signaling domain with another polynucleotide coding for
a different intracellular signaling domain. In embodiments, the polynucleotide
coding for an intracellular signaling domain is codon optimized for expression in
mammalian cells.
Marker sequences
In embodiments, the chimeric receptor nucleic acid optionally further
comprises a polynucleotide sequence coding for a marker sequence. A marker
sequence can provide for selection of transduced cells, and identification of
transduced cells. In embodiments, the marker sequence is operably linked to a
polynucleotide ce coding for a linker ce. In embodiments, the linker
sequence is a cleavable linker sequence.
A number of different marker sequences can be employed. Typically a
marker sequence has a functional characteristic that allows for selection of
uced cells and/or detection of transduced cells. In embodiments, the marker
ce is compatible with transduction of human lymphocytes.
The positive selectable marker may be a gene, which upon being introduced
into the host cell, expresses a dominant phenotype permitting positive selection of
cells ng the gene. Genes of this type are known in the art, and include, inter
alia, hygromycin-B phosphotransferase gene (hph) which confers resistance to
hygromycin B, the amino glycoside phosphotransferase gene (neo or aph) from Tn5
which codes for resistance to the antibiotic G418, the ofolate reductase
(DHFR) gene, the adenosine deaminase gene (ADA), and the multi-drug resistance
(MDR) gene.
In an embodiment, a chimeric or c acid further comprises a
polynucleotide coding for a marker sequence. In an embodiment, the marker
sequence is a truncated epidermal growth factor receptor as shown in Table 2. An
exemplary cleotide for the truncated epidermal growth factor or is
shown in Table 1. (SEQ ID NO:9)In embodiments, the polynucleotide coding for the
marker sequence is ly linked to a cleotide coding for a linker sequence.
In a specific embodiment, the linker sequence is a cleavable linker sequence T2A as
shown in Table 2. An exemplary polynucleotide sequence coding for the T2A linker
is provided in Table 1.(SEQ ID NO:8)
A polynucleotide coding for marker sequence can be readily prepared by
synthetic or recombinant methods from the amino acid sequence. In embodiments a
cleotide coding for a marker sequence is operably linked to a polynucleotide
coding for an ellular signaling domain. In embodiments, the polynucleotide
coding for a marker sequence may also have one or more restriction enzyme sites at
the 5’ and/or 3’ ends of the coding sequence in order to provide for easy excision
and ement of the polynucleotide coding for a marker sequence with another
polynucleotide coding for a different marker sequence. In ments, the
polynucleotide coding for a marker sequence is codon optimized for expression in
mammalian cells.
Vectors, Cells and Methods of transducing cells
ion and g of T lymphocyte populations
The compositions described herein provide for CD4+ and/or CD8+ T
cytes. T lymphocytes can be collected in accordance with known techniques
and enriched or depleted by known techniques such as ty binding to antibodies
such as flow cytometry and/or immunomagnetic selection. After enrichment and/or
depletion steps, in vitro expansion of the desired T lymphocytes can be carried out in
accordance with known techniques (including but not limited to those described in
US Patent No. 6,040,177 to Riddell et al.), or variations thereof that will be apparent
to those skilled in the art. In embodiments, the T cells are autologous T cells
obtained from the patient.
For example, the desired T cell population or subpopulation may be
expanded by adding an l T lymphocyte population to a e medium in vitro,
and then adding to the culture medium feeder cells, such as non-dividing peripheral
blood mononuclear cells (PBMC), (e.g., such that the resulting population of cells
contains at least about 5, 10, 20, or 40 or more PBMC feeder cells for each T
lymphocyte in the initial population to be expanded); and incubating the culture (e.g.
for a time sufficient to expand the numbers of T cells). The non-dividing feeder cells
can comprise gamma-irradiated PBMC feeder cells. In some embodiments, the
PBMC are irradiated with gamma rays in the range of about 3000 to 3600 rads to
prevent cell division. The order of addition of the T cells and feeder cells to the
culture media can be reversed if desired. The culture can lly be incubated
under conditions of ature and the like that are suitable for the growth of T
lymphocytes. For the growth of human T lymphocytes, for example, the temperature
will generally be at least about 25 degrees Celsius, preferably at least about 30
degrees, more preferably about 37 degrees.
The T lymphocytes expanded include CD8+ cytotoxic T lymphocytes (CTL)
and CD4+ helper T lymphocytes that may be specific for an n present on a
human tumor or a pathogen.
Optionally, the expansion method may further comprise the step of adding
non-dividing EBV-transformed lymphoblastoid cells (LCL) as feeder cells. LCL can
be ated with gamma rays in the range of about 6000 to 10,000 rads. The LCL
feeder cells may be provided in any suitable amount, such as a ratio of LCL feeder
cells to initial T lymphocytes of at least about 10:1.
Optionally, the expansion method may further comprise the step of adding
anti-CD3 and/or anti CD28 antibody to the culture medium (e.g., at a concentration
of at least about 0.5 ng/ml). Optionally, the expansion method may further comprise
the step of adding IL-2 and/or IL-15 to the culture medium (e.g., wherein the
concentration of IL-2 is at least about 10 units/m1).
After isolation of T cytes both cytotoxic and helper T lymphocytes
can be sorted into naïve, memory, and effector T cell subpopulations either before or
after expansion.
CD8+ cells can be ed by using standard methods. In some
embodiments, CD8+ cells are further sorted into naïve, central memory, and effector
memory cells by identifying cell surface ns that are associated with each of
those types of CD8+ cells. In embodiments, memory T cells are present in both
CD62L+ and CD62L- subsets of CD8+ peripheral blood lymphocytes. PBMC are
sorted into CD62L-CD8+ and CD62L+CD8+ ons after staining with anti-CD8
and anti-CD62L antibodies. In some embodiments, the expression of phenotypic
markers of central memory TCM include CD45RO, CD62L, CCR7, CD28, CD3, and
CD127 and are negative or low for granzyme B. In some ments, central
memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments,
effector TE are negative for CD62L, CCR7, CD28, and CD127, and ve for
me B and perforin. In some embodiments, naïve CD8+ T lymphocytes are
characterized by the expression of phenotypic markers of naïve T cells including
CD62L, CCR7, CD28, CD3, CD127, and CD45RA.
r a cell or cell population is positive for a particular cell surface
marker can be determined by flow cytometry using staining with a ic antibody
for the surface marker and an isotype matched control antibody. A cell population
ve for a marker refers to the absence of significant staining of the cell
population with the specific antibody above the isotype control, positive refers to
uniform staining of the cell population above the isotype control. In some
embodiments, a decrease in expression of one or markers refers to loss of 1 log10 in
the mean fluorescence intensity and/or decrease of percentage of cells that exhibit
the marker of at least about 20% of the cells, 25% of-the cells, 30% of the cells, 35%
of the cells, 40% of the cells, 45% of the cells, 50% of the cells, 55% of the cells,
60% of the cells, 65% of the cells, 70% of the cells, 75% of the cells, 80% of the
cells, 85% of the cells, 90% of the cell, 95% of the cells, and 100% of the cells and
any % between 20 and 100% when compared to a reference cell population. In
some embodiments, a cell population positive for one or markers refers to a
percentage of cells that exhibit the marker of at least about 50% of the cells, 55% of
the cells, 60% of the cells, 65% of the cells, 70% of the cells, 75% of the cells, 80%
of the cells, 85% of the cells, 90% of the cell, 95% of the cells, and 100% of the
cells and any % between 50 and 100% when compared to a reference cell
population.
CD4+ T helper cells are sorted into naïve, central memory, and effector cells
by fying cell populations that have cell surface antigens. CD4+ lymphocytes
can be obtained by standard methods. In some ments, naïve CD4+ T
lymphocytes are CD45RO-, CD45RA+, CD62L+, CD4+ T cells. In some
embodiments, central memory CD4+ cells are CD62L+ and CD45RO+. In some
embodiments, or CD4+ cells are CD62L- and CD45RO-.
In embodiments, populations of CD4+ and CD8+ that are n specific
can be obtained by stimulating naïve or antigen specific T lymphocytes with antigen.
For example, antigen-specific T cell lines or clones can be generated to
Cytomegalovirus antigens by isolating T cells from infected subjects and stimulating
the cells in vitro with the same antigen. Naïve T cells may also be used. Any
number of antigens from tumor cells may be utilized as targets to elicit T cell
responses. In some embodiments, the ve cellular immunotherapy
compositions are useful in the treatment of a disease or disorder including a solid
tumor, hematologic malignancy, breast cancer or melanoma.
Modification of T lymphocyte populations
In some embodiments it may be desired to uce onal genes into
the T cells to be used in immunotherapy in accordance with the present disclosure.
For example, the introduced gene or genes may e the efficacy of therapy by
promoting the viability and/or function of transferred T cells; or they may provide a
genetic marker to permit selection and/or evaluation of in vivo al or migration;
or they may incorporate ons that improve the safety of therapy, for
example, by making the cell susceptible to negative selection in vivo as described by
Lupton S. D. et al., Mol. and Cell Biol., 11:6 (1991); and Riddell et al., Human Gene
Therapy 3:319-338 (1992); see also the publications of PCT/US91/08442 and
PCT/US94/05601 by Lupton et al. describing the use of tional selectable
fusion genes derived from fusing a dominant positive selectable marker with a
negative selectable marker. This can be carried out in accordance with known
techniques (see, e.g., US Patent No. 6,040,177 to Riddell et al. at columns 14-17) or
ions thereof that will be apparent to those skilled in the art based upon the
present disclosure.
In embodiments, T cells are modified with chimeric receptors as described
herein. In some embodiments, the T cells are obtained from the subject to be
treated, in other ments, the lymphocytes are obtained from allogeneic human
donors, preferably healthy human donors.
In some embodiments, chimeric receptors comprise a ligand binding domain
that specifically binds to a tumor cell surface molecule, a polypeptide spacer region,
a transmembrane domain and an intracellular signaling domain as described herein.
In embodiments, the ligand binding domain is a single-chain antibody fragment
(scFv) that is derived from the variable heavy (VH) and variable light (VL) chains of
a monoclonal antibody (mAb). Costimulatory signals can also be provided through
the chimeric receptor by fusing the costimulatory domain of CD28 and/or 4-1BB to
the CD3ζ chain. Chimeric receptors are specific for cell surface les
ndent from HLA, thus overcoming the limitations of TCR-recognition
including HLA-restriction and low levels of HLA-expression on tumor cells.
Chimeric receptors can be constructed with a specificity for any cell surface
marker by utilizing antigen binding fragments or antibody le domains of, for
example, antibody molecules. The antigen binding molecules can be linked to one or
more cell signaling modules. In ments, cell signaling modules include CD3
transmembrane domain, CD3 ellular ing domains, and CD28
transmembrane domains. In ments, the intracellular signaling domain
comprises a CD28 transmembrane and signaling domain linked to a CD3 zeta
intracellular domain. In some embodiments, a chimeric receptor can also e a
transduction marker such as tEGFR.
In embodiments, the same or a different chimeric receptor can be introduced
into each of population of CD4+ and CD8+ T lymphocytes. In embodiments, the
chimeric receptor in each of these populations has a ligand binding domain that
specifically binds to the same ligand on the tumor or infected cell. The cellular
signaling modules can differ. In embodiments, the intracellular ing domain of
the CD8+ xic T cells is the same as the intracellular signaling domain of the
CD4+ helper T cells. In other embodiments, the intracellular signaling domain of the
CD8+ cytotoxic T cells is different than the intracellular signaling domain of the
CD4+ helper T cells.
In ments each of the CD4 or CD8 T lymphocytes can be sorted in to
naïve, central memory, effector memory or effector cells prior to transduction as
described . In alternative embodiments, each of the CD4 or CD8 T
lymphocytes can be sorted in to naïve, central memory, effector memory, or effector
cells after transduction.
Various transduction techniques have been developed which utilize
recombinant infectious virus les for gene delivery. This represents a currently
preferred approach to the uction of T lymphocytes described herein. The viral
vectors which have been used in this way include virus vectors derived from simian
virus 40, adenoviruses, adeno-associated virus (AAV), lentiviral vectors, and
retroviruses. Thus, gene transfer and expression methods are numerous but
essentially function to uce and express c material in mammalian cells.
Several of the above techniques have been used to transduce hematopoietic or
lymphoid cells, including calcium phosphate transfection, protoplast fusion,
electroporation, and infection with recombinant adenovirus, adeno-associated virus
and retrovirus vectors. Primary T lymphocytes have been successfully uced by
electroporation and by retroviral or iral infection.
Retroviral and lentiviral vectors provide a highly efficient method for gene
transfer into eukaryotic cells. Moreover, retroviral or lentiviral integration takes
place in a controlled fashion and results in the stable integration of one or a few
copies of the new c information per cell.
It is contemplated that overexpression of a stimulatory factor (for example, a
lymphokine or a cytokine) may be toxic to the d individual. Therefore, it is
within the scope of the present disclosure to include gene segments that cause the T
cells described herein to be susceptible to negative selection in vivo. By ''negative
selection" is meant that the infused cell can be eliminated as a result of a change in
the in vivo condition of the individual. The negative able phenotype may result
from the insertion of a gene that confers sensitivity to an administered agent, for
example, a compound. Negative selectable genes are known in the art, and e,
inter alia the following: the Herpes simplex virus type I thymidine kinase (HSV-I
TK) gene, which confers lovir sensitivity; the cellular hypoxanthine
phosphribosyltransferase (HPRT) gene, the cellular adenine
phosphoribosyltransferase (APRT) gene, and bacterial cytosine deaminase,
In some embodiments it may be useful to include in the T cells a positive
marker that enables the ion of cells of the negative selectable phenotype in
vitro. The positive selectable marker may be a gene that upon being introduced into
the host cell expresses a dominant ype permitting positive selection of cells
carrying the gene. Genes of this type are known in the art, and include, inter alia,
hygromycin-B phosphotransferase gene (hph) which confers resistance to
hygromycin B, the amino glycoside phosphotransferase gene (neo or aph) from Tn5
which codes for resistance to the antibiotic G418, the dihydrofolate reductase
(DHFR) gene, the adenosine deaminase gene (ADA), and the multi-drug ance
(MDR) gene.
A variety of methods can be employed for transducing T lymphocytes, as is
well known in the art. In embodiments, transduction is carried out using iral
vectors.
In embodiments, CD4+ and CD8+ cells each can separately be modified with
an expression vector encoding a chimeric or to form defined populations. In
embodiments, these cells are then further sorted into subpopulations of naïve, central
memory and effector cells as described above by sorting for cell surface antigens
unique to each of those cell populations. In addition, CD4+ or CD8+ cell
populations may be selected by their cytokine profile or erative activities. For
example, CD4+ T lymphocytes that have enhanced production of nes such as
IL-2, IL-4, IL-10, TNFα, and IFNγ as compared to sham transduced cells or
transduced CD8+ cells when stimulated with antigen can be selected. In other
embodiments, naïve or central memory CD4+ T cells that have enhanced production
of IL-2 and/or TNFα are selected. Likewise, CD8+ cells that have ed IFNγ
production are selected as compared to sham transduced CD8+ cells.
In embodiments, CD4+ and CD8+cells that proliferate in response to antigen
or tumor targets are selected. For e, CD4+ cells that proliferate vigorously
when stimulated with antigen or tumor targets as compared to sham transduced cells,
or CD8+ transduced cells are selected. In some embodiments, CD4+ and CD8+ cells
are ed that are cytotoxic for antigen bearing cells. In embodiments, CD4+ are
expected to be weakly xic as ed to CD8+ cells.
In a preferred embodiment, transduced lymphocytes, such as CD8+ central
memory cells, are selected that provide for tumor cell killing in vivo using an animal
model established for the ular type of cancer. Such animal models are known
to those of skill in the art and exclude human . As described herein, not all
chimeric receptor ucts transduced into lymphocytes confer the ability to kill
tumor cells in vivo despite the ability to become activated and kill tumor cells in
vitro. In particular, for some target molecules T cells having chimeric receptor
ucts with a long spacer region were less effective at killing tumor cells in vivo
as compared to T cells having a chimeric receptor with short spacer region. For other
target molecules, T cells having chimeric receptor constructs with a short spacer
region were less effective at killing tumor cells in vivo as compared to T cells
having chimeric receptors with a long spacer region.
In yet other embodiments, uced chimeric receptor expressing T cells
are selected that can persist in vivo using an animal model established for the
particular type of cancer. In embodiments, transduced chimeric receptor CD8+
central memory cells with a short spacer region have been shown to persist in vivo
after introduction into the animal for about 3 day or more, 10 days or more, 20 days
or more, 30 days or more, 40 days or more, or 50 days or more.
The disclosure contemplates that combinations of CD4+ and CD8+ T cells
will be utilized in the compositions. In one embodiment, combinations of chimeric
receptor transduced CD4+ cells can be combined with chimeric receptor transduced
CD8+ cells of the same ligand specificity or combined with CD8+ T cells that are
ic for a distinct tumor ligand. In other embodiments, chimeric receptor
transduced CD8+ cells are combined with chimeric receptor transduced CD4+ cells
specific for a different ligand expressed on the tumor. In yet another embodiment,
chimeric receptor ed CD4+ and CD8+ cells are combined. In embodiments
CD8+ and CD4+ cells can be ed in ent ratios for example, a 1:1 ratio of
CD8+ and CD4+, a ratio of 10:1 of CD8+ to CD4+, or a ratio of 100:1 of CD8+ to
CD4+. In embodiments, the combined population is tested for cell proliferation in
vitro and/or in vivo, and the ratio of cells that provides for proliferation of cells is
selected.
As described herein, the disclosure contemplates that CD4+ and CD8+ cells
can be further separated into subpopulations, such as naïve, central memory, and
effector memory cell populations. As described , in some embodiments, naïve
CD4+ cells are CD45RO-, +, CD62L+, CD4+ positive T cells. In some
embodiments, l memory CD4+ cells are CD62L positive and CD45RO
positive. In some embodiments, effector CD4+ cells are CD62L negative and
CD45RO ve. Each of these populations may be independently ed with a
chimeric receptor.
As described herein, in embodiments, memory T cells are present in both
CD62L+ and CD62L- s of CD8+ peripheral blood lymphocytes. PBMC are
sorted into CD62L-CD8+ and CD62L+CD8+ fractions after staining with anti-CD8
and anti-CD62L antibodies. In some embodiments, the expression of phenotypic
markers of central memory T cells (TCM) include CD62L, CCR7, CD28, CD3, and
CD127 and are negative or low for granzyme B. In some embodiments, l
memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments,
effector T cells (TE) are negative for CD62L, CCR7, CD28, and CD127, and positive
for granzyme B and perforin. In some embodiments, naïve CD8+ T lymphocytes are
characterized by CD8+, CD62L+, CD45RO+, CCR7+, CD28+ CD127+, and
CD45RO+. Each of these populations may be independently modified with a
chimeric receptor .
After transduction and/or selection for chimeric receptor bearing cells, the
cell populations are preferably expanded in vitro until a sufficient number of cells
are obtained to provide for at least one infusion into a human t, typically
around 104 kg to 109 cells/kg In embodiments, the transduced cells are ed
in the presence of antigen bearing cells, anti CD3, anti CD28, and IL 2, IL-7, IL 15,
IL-21 and combinations thereof.
Each of the subpopulations of CD4+ and CD8+ cells can be ed with
one another. In a specific embodiment, modified naïve or central memory CD4+
cells are combined with modified central memory CD8+ T cells to provide a
synergistic cytotoxic effect on antigen g cells, such as tumor cells.
Compositions
Also described is an adoptive cellular immunotherapy composition
comprising a genetically modified T lymphocyte cell preparation as described
herein.
In embodiments, the T lymphocyte cell preparation comprises CD4 + T cells
that have a chimeric receptor comprising an extracellular antibody variable domain
ic for a ligand associated with the disease or disorder, a izable spacer
region, a transmembrane domain, and an intracellular signaling domain of a T cell
receptor or other receptors as described herein. In other embodiments, an adoptive
cellular immunotherapy composition further ses a chimeric receptor modified
tumor-specific CD8+ cytotoxic T lymphocyte cell preparation that provides a
ar immune response, wherein the cytotoxic T lymphocyte cell preparation
comprises CD8+ T cells that have a chimeric receptor sing an ellular
single chain dy specific for a ligand associated with the disease or disorder, a
customizable spacer region, a transmembrane domain, and an intracellular signaling
domain of a T cell receptor as described herein. In embodiments, the chimeric
receptor modified T cell population of the disclosure can persist in vivo for at least
about 3 days or longer.
In some embodiments, an adoptive cellular immunotherapy composition
comprises a chimeric or modified tumor-specific CD8+ cytotoxic T
lymphocyte cell preparation that provides a cellular immune response, wherein the
xic T lymphocyte cell preparation comprises CD8+ T cells that have a
chimeric receptor comprising an ellular single chain antibody specific for a
ligand associated with the disease or disorder, a customizable spacer region, a
embrane domain, and an intracellular signaling domain of a T cell receptor, in
combination with an antigen-reactive chimeric receptor modified naïve CD4+ T
helper cell d from - CD62L+ CD4+ T cells, and a pharmaceutically
acceptable carrier.
In other embodiments, an adoptive cellular immunotherapy composition
comprises an antigen specific CD8+ cytotoxic T lymphocyte cell preparation that
provides a cellular immune response derived from the patient combined with an
antigen-reactive ic receptor modified naïve CD4+ T helper cell that augments
the CD8+ immune response, wherein the helper T lymphocyte cell preparation
comprises CD4 + T cells that have a chimeric receptor comprising an extracellular
antibody variable domain specific for the antigen associated with the disease or
disorder, a customizable spacer region, a transmembrane domain, and an
intracellular signaling domain of a T cell receptor.
In a further embodiment, an adoptive cellular immunotherapy composition
comprises an antigen-reactive ic receptor modified naïve CD4+ T helper cell
that augments the CD8+ immune response, wherein the helper T lymphocyte cell
preparation comprises CD4 + T cells that have a chimeric receptor comprising an
extracellular antibody variable domain ic for a ligand associated with a disease
or disorder, a customizable spacer , a transmembrane , and an
intracellular ing domain of a T cell receptor.
In embodiments, the CD4+ T helper lymphocyte cell is selected from the
group consisting of naïve CD4+ T cells, l memory CD4+ T cells, effector
memory CD4+ T cells, or bulk CD4+ T cells. In some embodiments, CD4+ helper
lymphocyte cell is a naïve CD4+ T cell, wherein the naïve CD4+ T cell comprises a
CD45RO-, CD45RA+, CD62L+ CD4+ T cell. In embodiments, the CD8+ T
cytotoxic cyte cell is selected from the group consisting of naïve CD8+ T
cells, central memory CD8+ T cells, effector memory CD8+ T cells or bulk CD8+ T
cells. In some embodiments, the CD8+ xic T lymphocyte cell is a central
memory T cell wherein the central memory T cell comprises a CD45RO+, CD62L+,
CD8+ T cell. In yet other embodiments, the CD8+ cytotoxic T lymphocyte cell is a
central memory T cell and the CD4+ helper T cyte cell is a naïve or central
memory CD4+ T cell.
Methods
Also described are methods of making adoptive immunotherapy
compositions and uses or methods of using these itions for performing
cellular immunotherapy in a subject having a disease or disorder. In embodiments,
the chimeric receptor ed T cells as described herein are able to persist in vivo
for at least 3 days, or at least 10 days. In embodiments, the chimeric receptor
modified T cells as described herein can proliferate in vivo through at least 2, or at
least 3 generations as determined by CFSE dye dilution. Proliferation and
persistence of the chimeric receptor modified T cells can be determined by using an
animal model of the disease or disorder and administering the cells and ining
persistence and/ or proliferative capacity of the transferred cells. In other
embodiments, proliferation and activation can be tested in vitro by going h
multiple cycles of activation with antigen bearing cells.
In embodiments, a method of cturing the compositions comprises
obtaining a modified naïve CD4+ T helper cell, wherein the modified helper T
lymphocyte cell preparation comprises CD4+ T cells that have a chimeric receptor
comprising a ligand binding domain specific for a tumor cell surface molecule, a
customized spacer domain, a transmembrane , and an ellular signaling
domain as bed herein.
In r embodiment, a method further comprises obtaining a modified
CD8+ cytotoxic T cell, wherein the modified cytotoxic T lymphocyte cell
preparation comprises CD8+ cells that have a chimeric receptor comprising a ligand
binding domain specific for a tumor cell surface molecule, a customized spacer
domain, a transmembrane domain, and an ellular signaling domain as
described herein.
In another embodiment, a method comprises obtaining a modified CD8+
cytotoxic T cell, wherein the modified cytotoxic T lymphocyte cell preparation
comprises CD8+ T cells that have a chimeric receptor comprising a ligand binding
domain specific for a tumor cell surface le, a customized spacer domain, a
transmembrane domain, and an intracellular ing domain as described herein,
and r comprising combining the modified CD8+ cytotoxic T cells with a
CD4+ helper cell lymphocyte cell preparation.
The preparation of the CD4+ and CD8+ cells that are modified with a
chimeric receptor has been described above as well as in the examples. Antigen
specific T lymphocytes can be ed from a patient having the disease or disorder
or can be prepared by in vitro stimulation of T lymphocytes in the presence of
antigen. Subpopulations of CD4+ and CD8+ T lymphocytes that are not selected for
antigen specificity can also be isolated as described herein and combined in the
methods of manufacturing. In embodiments, the combination of cell populations can
be ted for uniformity of cell surface makers, the ability to proliferate through
at least two generations, to have a uniform cell differentiation . Quality control
can be performed by coculturing an cell line expressing the target ligand with
chimeric receptor modified T cells to determine if the ic receptor modified T
cells recognize the cell line using xicity, proliferation, or cytokine production
assays that are known in the field. Cell differentiation status and cell surface markers
on the chimeric receptor modified T cells can be determined by flow cytometry. In
embodiments, the markers and cell differentiation status on the CD8+ cells include
CD3, CD8, CD62L, CD28, CD27, CD69, CD25, PD-1, CTLA-4, CD45RO, and
CD45RA. In embodiments, the markers and the cell differentiation status on the
CD4+ cells include CD3, CD4, CD62L, CD28, CD27, CD69, CD25, PD-1, CTLA-4
CD45RO, and CD45RA.
In ments, a method of selecting a spacer region for a chimeric
receptor is described herein. Surprisingly some chimeric receptor constructs,
although effective to te T cells in vitro, were not effective in vivo. In
embodiments, a method comprises providing a plurality of chimeric receptor nucleic
acids, wherein the chimeric receptor c acids differ only in the spacer ;
introducing each of the chimeric receptor nucleic acids into a te T
lymphocyte tion; expanding each separate lymphocyte population in vitro,
and introducing each lymphocyte population into an animal bearing a tumor to
determine the anti-tumor efficacy of each of the chimeric receptor modified T cells,
and selecting a chimeric receptor that provides anti-tumor efficacy as compared to
each of the other separate lymphocyte populations modified with each of the other
chimeric or modified T cells.
Animal models of different tumors are known. Anti-tumor efficacy can be
measured by identifying a decrease in tumor volume, by ining animal death,
persistence of the genetically modified T cells in vivo, activation of cally
modified T cells (for example, by detecting an increase in expression of CD25
and/CD69), and/or proliferation of genetically modified T cells in vivo. In an
embodiment, a chimeric or is selected that es for the best anti-tumor
efficacy in vivo as determined by one or more of these parameters. Lack of antitumor
efficacy can be determined by lack of persistence of the genetically modified
lymphocytes in vivo, animal death, an increase in apoptosis as measured by an
increase in induction of caspase -3, and/or a decrease in proliferation of genetically
modified cytes.
In embodiments, providing a plurality of chimeric receptor nucleic acids,
wherein the chimeric receptor nucleic acids differ only in the spacer region
comprises providing a chimeric receptor construct comprising a polynucleotide
coding for a ligand g domain, wherein the ligand is a tumor specific antigen,
viral antigen, or any other molecule expressed on a target cell population that is
suitable to mediate recognition and elimination by a lymphocyte; a polynucleotide
coding for a first polypeptide spacer having a defined restriction site at the 5’ and 3’
end of the coding sequence for the first polypeptide spacer; a polynucleotide coding
for a transmembrane ; and a polynucleotide coding for an intracellular
ing domain.
Also described are methods of performing cellular therapy in a
subject having a disease or er comprising: administering a ition of
lymphocytes expressing a chimeric receptor as described herein. In other
embodiments, a method comprises administering to the subject a cally
modified cytotoxic T lymphocyte cell preparation that provides a ar immune
se, wherein the cytotoxic T lymphocyte cell preparation comprises CD8 + T
cells that have a chimeric receptor sing a ligand binding domain specific for a
tumor cell surface molecule, a customized spacer domain, a transmembrane domain,
and an intracellular signaling domain as described , and a genetically modified
helper T lymphocyte cell preparation that elicits direct tumor recognition and
augments the genetically modified cytotoxic T lymphocyte cell preparations ability
to mediate a cellular immune response, wherein the helper T lymphocyte cell
preparation comprises CD4+ T cells that have a chimeric receptor sing a
ligand binding domain specific for a tumor cell surface molecule, a customized
spacer domain, a transmembrane domain, and an intracellular signaling domain as
described herein.
While not limiting the scope of the disclosure, it is believed by selecting the
chimeric receptor modified T cell population that can persist and proliferate in vivo
prior to administration may result in the ability to use a lower dose of T cells and
provide more uniform therapeutic activity. In embodiments, the dose of T cells can
be reduced at least 10%, 20%, or 30% or r. Reduction in the dose of T cells
may be beneficial to reduce the risk or tumor lysis syndrome and cytokine storm.
In another embodiment, a method of performing cellular therapy in
subject having a disease or disorder comprises: administering to the t a
genetically modified helper T lymphocyte cell preparation, wherein the modified
helper T lymphocyte cell preparation comprises CD4+ T cells that have a chimeric
receptor comprising a ligand binding domain specific for a tumor cell e
molecule, a customized spacer domain, a transmembrane , and an
intracellular signaling domain as described herein. In an ments, the method
further comprises administering to the subject a genetically modified cytotoxic T
lymphocyte cell preparation, wherein the modified cytotoxic T lymphocyte cell
ation comprises CD8+ cells that have a chimeric or comprising a ligand
binding domain specific for a tumor cell surface molecule, a customized spacer
domain, a transmembrane domain, and an intracellular signaling domain as
described herein.
Another embodiment describes a method of performing cellular
immunotherapy in a subject having a disease or disorder comprising: analyzing a
biological sample of the subject for the ce of a target molecule associated with
the disease or disorder and administering the ve immunotherapy compositions
described herein, n the chimeric receptor specifically binds to the target
molecule.
In some embodiments, the CD4+ T helper lymphocyte cell is ed prior
to introduction of the chimeric receptor from the group consisting of naïve CD4+ T
cells, central memory CD4+ T cells, effector memory CD4+ T cells or bulk CD4+ T
cells. In a specific embodiment, CD4+ helper lymphocyte cell is a naïve CD4+ T
cell, wherein the naïve CD4+ T cell comprises a CD45RO-, +, CD62L+
CD4+ T cell. In yet other embodiments, the CD8+ T cytotoxic lymphocyte cell is
selected prior to introduction of the chimeric receptor from the group consisting of
naïve CD8+ T cells, central memory CD8+ T cells, effector memory CD8+ T cells
or bulk CD8+ T cells. In a specific embodiment, the CD8+ cytotoxic T lymphocyte
cell is a l memory T cell wherein the central memory T cell comprises a
CD45RO+, CD62L+, CD8+ T cell. In a specific embodiment, the CD8+ xic T
lymphocyte cell is a central memory T cell and the CD4+ helper T lymphocyte cell
is a naïve CD4+ T cell.
In embodiments, the CD8+ T cell and the CD4+ T cell are both genetically
ed with a chimeric receptor comprising an antibody heavy chain domain that
specifically binds a tumor-specific cell e molecule. In other embodiments, the
intracellular signaling domain of the CD8 cytotoxic T cells is the same as the
intracellular signaling domain of the CD4 helper T cells. In yet other embodiments,
the intracellular signaling domain of the CD8 cytotoxic T cells is different than the
intracellular signaling domain of the CD4 helper T cells.
Subjects that can be treated by the methods bed herein are, in general,
human and other e subjects, such as monkeys and apes for veterinary
medicine purposes. The subjects can be male or female and can be any suitable age,
including infant, juvenile, adolescent, adult, and geriatric subjects.
The methods are useful in the ent of, for example, hematologic
malignancy, melanoma, breast cancer, and other epithelial malignancies or solid
tumors. In some embodiments, the le associated with the disease or disorder
is selected from the group consisting of orphan tyrosine kinase receptor ROR1,
Her2, CD19, CD20, CD22, mesothelin, CEA, and hepatitis B surface n.
Subjects that can be treated include subjects afflicted with cancer, including
but not limited to colon, lung, liver, breast, renal, te, ovarian, skin (including
melanoma), bone, and brain cancer, etc. In some embodiments the tumor associated
antigens or molecules are known, such as melanoma, breast , squamous cell
carcinoma, colon cancer, leukemia, myeloma, and prostate cancer. In other
embodiments the tumor associated molecules can be targeted with genetically
modified T cells expressing an engineered chimeric receptor. Examples include but
are not limited to B cell lymphoma, breast cancer, prostate cancer, and leukemia.
Cells prepared as described above can be ed in methods and
compositions for adoptive immunotherapy in accordance with known techniques, or
variations thereof that will be apparent to those skilled in the art based on the instant
disclosure.
In some embodiments, the cells are formulated by first harvesting them from
their culture medium, and then washing and trating the cells in a medium and
container system suitable for administration (a "pharmaceutically acceptable"
carrier) in a ent-effective amount. Suitable infusion medium can be any
isotonic medium formulation, typically normal saline, Normosol R (Abbott) or
Plasma-Lyte A r), but also 5% dextrose in water or 's lactate can be
utilized. The infusion medium can be supplemented with human serum albumin,
fetal bovine serum or other human serum components.
A treatment effective amount of cells in the composition is at least 2 cell
subsets (for example, 1 CD8+ central memory T cell subset and 1 CD4+ helper T
cell subset) or is more typically greater than 102 cells, and up to 106, up to and
including 108 or 109 cells and can be more than 1010 cells. The number of cells will
depend upon the ultimate use for which the composition is intended as will the type
of cells ed therein. For example, if cells that are ic for a ular
antigen are desired, then the population will contain r than 70%, generally
greater than 80%, 85% and 90-95% of such cells. For uses described herein, the cells
are generally in a volume of a liter or less, can be 500 mls or less, even 250 mls or
100 mls or less. Hence the density of the d cells is lly greater than 104
cells/m1 and generally is greater than 107 cells/ml, generally 108 cells/ml or greater.
The clinically relevant number of immune cells can be apportioned into multiple
infusions that tively equal or exceed 106, 107, 108, 108, 109, 1010 or 1011 cells.
In some embodiments, the lymphocytes described herein may be used to
confer immunity to individuals. By "immunity" is meant a lessening of one or more
physical symptoms associated with a response to infection by a pathogen, or to a
tumor, to which the lymphocyte response is directed. The amount of cells
administered is usually in the range present in normal individuals with immunity to
the pathogen. Thus, the cells are usually administered by infusion, with each
infusion in a range of from 2 cells, up to at least 106 to 3x1010 cells, preferably in the
range of at least 107 to 109 cells. The T cells may be administered by a single
infusion, or by multiple infusions over a range of time. However, since different
individuals are expected to vary in responsiveness, the type and amount of cells
infused, as well as the number of infusions and the time range over which multiple
infusions are given are determined by the attending physician, and can be
ined by routine examination. The generation of sufficient levels of T
lymphocytes ding cytotoxic T lymphocytes and/or helper T lymphocytes) is
readily able using the rapid expansion method described herein, as
exemplified herein. See, e.g., US Patent No. 6,040,177 to Riddell et al. at column 17.
In embodiments, the composition as described herein are stered
intravenously, intraperitoneally, intratumorly, into the bone marrow, into the lymph
node, and /or into cerebrospinal fluid. In ments, the chimeric or
engineered itions are delivered to the site of the tumor. Alternatively, the
compositions as described herein can be combined with a compound that targets the
cells to the tumor or the immune system compartments and avoid sites such as the
lung.
In embodiments, the compositions as described herein are administered with
chemotherapeutic agents and/or suppressants. In an embodiment, a patient is
first treated with a chemotherapeutic agent that inhibits or destroys other immune
cells followed by the compositions described herein. In some cases, chemotherapy
may be avoided entirely.
The present invention is illustrated further in the examples set forth below.
MENTAL
Example I. Customizing spacer domain length and scFv affinity for optimal
recognition of ROR1 with chimeric or modified T cells
We constructed chimeric receptors specific for the ROR1 molecule that is
expressed on a large number of human malignancies including chronic lymphocytic
leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and breast, lung
prostate, pancreas and ovarian . The ROR1 chimeric receptors were designed
from ROR1 specific scFVs with ent affinities and containing extracellular
IgG4-Fc spacer domains of different lengths. The ability of T-cells expressing each
ROR-1 specific chimeric receptor to recognize ROR1+ hematopoietic and epithelial
tumors in vitro, and to eliminate human mantle cell lymphoma engrafted into
deficient mice was analyzed.
Materials and Methods
Human subjects
Peripheral blood mononuclear cells (PBMC) were obtained from healthy
donors and patients after written ed consent on research protocols approved
by the Institutional Review Board of the Fred Hutchinson Cancer Research Center
(FHCRC).
Cell lines
The K562, Raji, JeKo-1, MDA-MB-231, MDA-MB-468, and 293T cell lines
were obtained from the American Type Culture Collection. Dr. Edus H. Warren
(FHCRC) kindly ed the renal cell cancer lines FARP, TREP and RWL.
OR1 and Raji/ROR1 were generated by lentiviral transduction with the fulllength
ROR1-gene. To derive /ffluc, native JeKo-1 cells were transduced
with a lentiviral vector encoding the firefly luciferase (ffluc)-gene upstream of a T2A
sequence and eGFP. The transduced JeKo-1 cells were sorted for eGFP expression,
and expanded for in vivo experiments.
Immunophenotyping
PBMC and cell lines were stained with the following conjugated mAbs:
CD3, CD4, CD5, CD8, CD19, CD28, CD45RO, CD62L, CD314 (NKG2D),
MICA/B and matched isotype controls (BD Biosciences). Propidium iodide (PI)
staining was performed for live/dead cell discrimination. Cell surface expression of
ROR1 was analyzed using a polyclonal goat anti-human-ROR1 antibody (R&D
Systems).
Surface expression of 2A2 ROR1chimeric receptor was analyzed using a
polyclonal goat anti-mouse-IgG antibody (Fab-specific) (Jackson ImmunoResearch).
Flow es were done on a FACSCanto®, urifications on a iaII®
(Becton Dickinson) and data analyzed using FlowJo® software (Treestar).
Vector uction and preparation of ic receptor encoding lentivirus
pecific and CD19-specific chimeric receptors were constructed using VL
and VH chain segments of the 2A2, R12, and R11 mAbs (ROR1) and FMC63 mAb
(CD19). (Variable region ces for R11 and R12 are provided in Yang et al,
Plos One 6(6):e21018, June 15, 2011) Each scFV was linked by a (G4S)3(SEQ ID
NO:12) peptide to a spacer domain derived from IgG4-Fc (Uniprot Database:
P01861,SEQ ID NO:13) comprising either ‘Hinge-CH2-CH3’ (229 AA, SEQ ID
NO:), ‘Hinge-CH3’ (119 AA,SEQ ID NO:) or ‘Hinge’ only (12 AA,SEQ. ID NO:4)
sequences (Figure 1). All spacers contained a SP substitution within the ‘Hinge’
domain located at position 108 of the native c protein, and were linked to the
27 AA transmembrane domain of human CD28 (Uniprot: P10747, SEQ ID NO:14)
and to a ing module comprising either (i) the 41 AA cytoplasmic domain of
human CD28 with an LLGG substitution located at positions 186-187 of the
native CD28 protein (SEQ ID NO:14)or (ii) the 42 AA cytoplasmic domain of
human 4-1BB (Uniprot: Q07011, SEQ ID , each of which was linked to the
112 AA cytoplasmic domain of isoform 3 of human CD3ζ (Uniprot: P20963, SEQ
ID NO;16). The construct encoded a T2A ribosomal skip element (SEQ ID
NO:8))and a tEGFR ce (SEQ ID NO:9) downstream of the ic receptor.
Codon-optimized nucleotide sequences encoding each transgene were synthesized
(Life Technologies) and cloned into the epHIV7 lentiviral vector
ROR1-chimeric receptor, himeric receptor or tEGFR-encoding
lentiviruses were produced in 293T cells using the packaging vectors pCHGP-2,
pCMV-Rev2 and pCMV-G, and Calphos® transfection reagent (Clontech).
Generation of T-cell lines expressing ROR1 and CD19-chimeric receptors
CD8+ CD45RO+ CD62L+ central memory T-cells (TCM) or bulk CD4+ T-
cells were sorted from PBMC of normal donors, activated with anti-CD3/CD28
beads (Life Technologies), and uced on day 3 after activation by
centrifugation at 800 g for 45 min at 32ºC with lentiviral supernatant (MOI = 3)
supplemented with 1 μg/mL polybrene (Millipore). T-cells were expanded in RPMI
with 10% human serum, 2 mM L-glutamine and 1% penicillin-streptomycin (CTL
medium), supplemented with recombinant human IL-2 to a final concentration of 50
U/mL. The tEGFR+ subset of each T-cell line was enriched by immunomagnetic
selection with biotin-conjugated anti-EGFR mAb (ImClone Systems) and
avidin-beads nyi). himeric receptor and tEGFR control T-cells
were expanded using a rapid ion protocol (Riddell SR, Greenberg PD,The use
of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human
n-specific T cells J Immunol Methods. 1990;128(2):189-201. Epub
1990/04/17.), and CD19-chimeric receptor modified T-cells were expanded by
stimulation with irradiated (8,000 rad) B-LCL at a T-cell:LCL ratio of 1:7. T-cells
were cultured in CTL medium with 50 U/mL IL-2.
xicity, cytokine secretion and proliferation assays
Target cells were labeled with 51Cr (PerkinElmer), washed and incubated in
triplicate at 1-2x103 well with effector chimeric receptor modified T-cells at
s effector to target (E:T) ratios. Supernatants were harvested for γ-counting
after a 4-hour incubation and specific lysis calculated using the rd formula.
For analysis of cytokine secretion, 5x104 T-cells were plated in triplicate with target
cells at an E:T ratio of 1:1 (primary CLL), 2:1 (Raji/ROR1; JeKo-1), 4:1
(K562/ROR1, K562/CD19 and K562) or 10:1 B-231), and IFN-γ, TNF-α
and IL-2 ed by ELISA or multiplex cytokine immunoassay (Luminex) in
supernatant removed after 24-h incubation. In experiments blocking NKG2D
signaling, anti-NKG2D (clone 1D11), anti-MICA/B (clone 6D4, all from BD) and
anti-ULBP (kindly provided by Dr. Veronika Groh, FHCRC) were used at ting
concentrations. For is of proliferation, T-cells were labeled with 0.2 μM
carboxyfluorescein succinimidyl ester (CFSE, Invitrogen), washed and plated in
triplicate with stimulator cells in medium without exogenous cytokines. After 72-h
incubation, cells were labeled with anti-CD8 mAb and PI, and analyzed by flow
cytometry to assess cell division of live CD8+ T-cells.
Experiments in NOD/SCID/γc-/- (NSG) mice
The Institutional Animal Chimeric receptor and Use Committee approved all
mouse experiments. Six- to 8-week old female -Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mice were obtained from the Jackson Laboratory or bred in-house. Mice
were injected with 6 JeKo-1/ffluc tumor cells via tail vein and received a
subsequent tail vein injection of chimeric receptor-modified or control T-cells.
For bioluminescence imaging of tumor growth, mice received intraperitoneal
injections of luciferin substrate (Caliper Life Sciences) resuspended in PBS (15 µg/g
body weight). Mice were anesthetized with isoflurane and imaged using an Xenogen
IVIS Imaging System (Caliper) 10, 12 and 14 minutes after the injection of luciferin
in small binning mode at an acquisition time of 1 s to 1 min to obtain unsaturated
images. Luciferase activity was analyzed using Living Image Software (Caliper) and
the photon flux analyzed within s of interest that encompassed the entire body
or the thorax of each individual mouse.
Statistical analyses
Statistical analyses were med using Prism re (GraphPad®).
Student’s t-test was performed as a two-sided paired test with a confidence al
of 95% and results with a p-value of p<0.05 were considered icant. Statistical
analysis of survival were done by log-rank testing and results with a p-value of
p<0.05 considered significant.
Results
Truncating the spacer domain of the 2A2 ROR1-chimeric receptor confers
superior recognition of ROR1+ tumors
We previously reported the design of a ROR1-specific chimeric receptor
using the 2A2 scFV, which binds to an epitope in the NH2-terminal, membrane
distal Ig-like/Frizzled portion of ROR1-1. The initial 2A2 ROR1-chimeric receptor
had a long 229 AA spacer that included the ‘Hinge-CH2-CH3’ region of IgG4-Fc,
and incorporated CD28 costimulatory and CD3ζ signaling domains (Hudecek M et
al. Blood, 2010). This chimeric receptor conferred specific recognition of ROR1+
, but we hypothesized that because of the membrane distal location of the
ROR1 epitope, ting the spacer domain might enhance tumor recognition and
T-cell signaling. Therefore, we constructed 2 onal chimeric ors in which
the IgG4-Fc spacer domain was sequentially deleted to derive ‘Hinge-CH3’ (119
AA, intermediate), and -only’ (12 AA, short) variants. Each of the new
receptors contained the identical 2A2 scFV, and CD28 and CD3ζ signaling modules.
The transgene cassette included a truncated EGFR (tEGFR) to serve as a
transduction, selection and in vivo tracking marker for chimeric receptor-modified
T-cells.
We transduced purified CD8+ TCM with the 2A2 ROR1-chimeric ors
containing full length or truncated IgG4-Fc spacers, and with a tEGFR control
vector. The mean uction efficiency was 15% (range 9-22%), and transgenepositive
T-cells were enriched to m purity (>90%) on day 10 by selection for
tEGFR expression, and expanded (Figure 2A). Surface expression of each of the
chimeric receptors was confirmed by staining with F(ab)-specific antibodies e
2A).
Analysis of the in vitro function of CD8+ T-cells modified to express each of
the 2A2 ROR1-chimeric receptors demonstrated that each receptor conferred
specific lysis of JeKo-1 MCL and primary CLL cells that naturally express ROR1,
and of K562 cells that had been transduced with ROR1, but did not confer
recognition of control ROR1- targets (Figure 2B). T-cells expressing the short
‘Hinge-only’ 2A2 ROR1-chimeric receptor had maximum cytolytic activity, and a
chy (short>intermediate>>long) of tumor lysis was clearly evident t all
ROR1+ tumor targets (Figure 2B), illustrating the importance of spacer domain
length on the recognition of ROR1+ tumor cells.
Anti-tumor efficacy of adoptive T-cell therapy correlates with proliferation
and al of erred T-cells, which could be altered by signaling through the
chimeric receptor. We used CFSE dilution assays to analyze proliferation of T-cells
modified with each of the 2A2 ROR1-chimeric receptors after engagement of
Raji/ROR1 or CLL, and found that the short spacer construct promoted the st
T-cell proliferation following stimulation e 2C). To ensure that the enhanced
proliferation was not associated with greater activation induced cell death (AICD),
we also analyzed the proportion of 2A2 ROR 1 chimeric receptor modified T-cells
that stained with propidium iodide (PI) after stimulation with OR1 and JeKo-
1 tumor cells. We detected a much lower frequency of PI+ CD8+ T-cells in the T-cell
line modified with the short (Raji/ROR1: 17.2%/JeKo-1: 20.2%) compared to the
intermediate /42.4%) and long (44.5%/48.5%) spacers.
Quantitative analysis of cytokine production in response to stimulation with
Raji/ROR1 and primary CLL cells showed production of IFN-γ, TNF-α and IL-2 by
T-cells expressing each of the 2A2 ROR1 chimeric receptors. As observed in
cytotoxicity assays, the short spacer uct was superior in mediating cytokine
secretion after tumor recognition (Figure 2D). Thus, this analysis shows that
ting the extracellular c spacer domain of the 2A2 ROR1-chimeric
receptor leads to a significant increase in cytotoxicity, eration and in vitro
effector functions after tumor recognition.
The R11 scFv that is specific for a membrane al epitope in the ROR1
Kringle domain requires a long extracellular spacer domain.
We transduced purified CD8+ T cells with ROR1-chimeric receptors
containing the R11 scFv that is specific for the Kringle domain of ROR1 and
containing full length or truncated IgG4-Fc spacers (CH3 and hinge only). The
uction efficiency with each of the short (IgG4 hinge only), intermediate (IgG4
hinge/CH3), and long (IgG4 hinge/CH2/CH3) vectors was comparable (45-51%) as
measured by EGFR expression. (Figure 3A). T cells transduced with each of the
vectors were d for cytolysis (Figure 3 B), proliferation (Figure 3C), and
cytokine production (Figure 3D) in response to leukemia or lymphoma cells that did
or did not express ROR1. As shown, only T cells transduced with the R11 chimeric
receptor containing a long spacer sequence were able to efficiently recognize
ROR1+ tumors and mediate effector functions.
ROR1 chimeric receptors derived from a mAb R12 with higher affinity than 2A2
mediate superior anti-tumor reactivity
We next examined whether increasing the affinity of the scFV used to
uct the ROR1 ic receptor might influence tumor recognition and T-cell
function. We generated ROR1-specific chimeric receptors from the mAb R12 that
like 2A2, binds to an epitope in the NH2-terminal Ig/Frizzled domain of ROR1 but
with >50-fold higher monovalent binding affinity.
R12 ROR1 chimeric receptors were constructed with both long and short
IgG4-Fc spacers to determine whether the optimal spacer design for this higher
affinity scFV differed from that for a lower affinity scFV. We found that similar to
2A2, the short spacer R12 ROR1 chimeric receptor conferred improved cytolytic
activity, cytokine secretion and proliferation (data not shown), ting that the
shorter spacer length provides superior spatial engagement of the T-cell and ROR1+
target cell for T-cell activation.
We then designed R12 and 2A2 ROR1 chimeric receptors that contained an
optimal (short) extracellular , and either a CD28 or 4-1BB costimulatory
domain in tandem with CD3ζ (4 constructs) for comparison (Figure 4A.B). These
ROR1-chimeric receptor ucts were expressed in ed CD8+ TCM of healthy
donors, and we confirmed lent ene expression by tEGFR staining
e 5A). T-cells ed with each of the 2A2 and R12 ROR1-chimeric
receptors specifically lysed K562/ROR1 and Raji/ROR1 tumor cells with
approximately equivalent efficiency (Figure 5B). However, analysis of cytokine
production showed that the high affinity R12 ROR1 chimeric receptors that
ned CD28 or 4-1BB conferred significantly higher IFN-γ, TNF-α and IL-2
production compared to the corresponding 2A2 constructs (Figure 5C). We found
that T-cells expressing chimeric receptors with a CD28 costimulatory domain
produced more IFN-γ, TNF-α and IL-2 compared to those with 4-1BB.
Experiments to analyze the proliferation of ROR1 chimeric receptor T-cells
showed a higher percentage of proliferating T-cells and a higher number of cell
divisions in T-cells expressing the high ty R12 ROR1 chimeric receptors with
CD28 and 4-1BB domain compared to T-cells expressing the tive 2A2
counterparts (Figure 4D). There was more vigorous proliferation in T-cells that
expressed chimeric receptors with a CD28 domain, consistent with higher IL-2
tion induced by these ors. There was a lower ncy of AICD as
measured by PI staining in T-cell lines modified with R12 compared to 2A2 ROR1-
chimeric receptors after stimulation with Raji/ROR1 and JeKo-1 tumor cells
tively (R12: 5.6%/6.9% vs. 2A2: 10%/9.65%). T-cell lines that expressed
chimeric ors with a CD28 domain also had lower AICD compared to 4-1BB in
se to Raji/ROR1 and JeKo-1 tumor cells respectively (R12: 16.4%/18.4% vs.
2A2 38.1%/39.6%).
To determine if the enhanced function observed with R12 ROR1 chimeric
receptors in CD8+ T-cells extended to CD4+ T-cells, we transduced bulk CD4+ T-
cells with the 2A2 and R12 ROR1 chimeric receptors containing the short spacer
and CD28 costimulatory domain. In response to Raji/ROR1+ tumor cells, CD4+ T-
cells that expressed the high affinity R12 scFV produced higher levels of IFN-γ,
TNF-α, IL-2, IL-4, and IL-10, and underwent greater proliferation than CD4+ T-cells
that expressed 2A2 (Figure 5A,B). Both cytokine production and proliferation was
superior in CD4+ compared to CD8+ T-cells modified with the same ROR1 chimeric
receptors. In summary, our data demonstrate that tailoring both the length of the
non-signaling extracellular chimeric or spacer domain and scFV affinity are
independent parameters that affect the function of ROR1-chimeric receptor T-cells.
D8+ T-cells modified with a high affinity ROR1 chimeric receptor have
comparable activity to a CD19 chimeric receptor against primary CLL in vitro
ROR1 and CD19 are both uniformly expressed on all primary CLL (Figure
6A), however the absolute number of ROR1-molecules per tumor cell is estimated to
be 10-fold lower than that of CD19, which has been successfully targeted in clinical
trials with CD19 chimeric receptor T-cells. We ed recognition of primary
CLL by CD8+ s sing the zed R12 and 2A2 ROR1 chimeric
receptors, and a CD19 chimeric receptor derived from the FMC63 scFV.
We used purified CD8+ TCM for chimeric or-modification to e a
uniform cell product and each chimeric receptor contained a short IgG4-Fc ‘Hingeonly
’ spacer and 4-1BB costimulatory domain. We confirmed our CD19 chimeric
receptor (IgG4 Hinge) was at least as and more effective in recognizing CD19+
tumors as a CD19 chimeric receptor with CD8a Hinge spacer and 4-1BB
costimulatory domain that is being used in ongoing clinical trials. (Figure 20). T
cells expressing CD19 chimeric receptors with 4-1BB and a and a modified
IgG4-Fc hinge exhibit superior in vitro and in vivo function compared to T cells
expressing CD19 chimeric receptors with 4-1BB and CD3zeta and a CD8 alpha
hinge. In Figure 20D, in vivo antitumor activity of T cells expressing a CD19
chimeric receptor with an IgG4 Fc hinge (group 1) or CD8 alpha hinge (group 2)
and T cells that s tEGFR alone (group 3) in NSG mice inoculated with Raji
tumor cells expressing y luciferase (ffluc) were compared. Mice were imaged
17 days after tumor inoculation and 10 days after T cell inoculation. The data shows
greater tumor burden in mice treated with control tEGFR T cells (group 3) or with
CD19 ic receptor CD8 alpha hinge T cells (group 2) compared with mice
d with CD19 chimeric receptor IgG4 Fc hinge T cells (group 1).
The cytolytic activity of R12 ROR1 ic receptor T-cells against
y tumor cells from multiple CLL patients (n=4) was higher ed to T-
cells modified with the lower affinity 2A2 ROR1 chimeric receptor, and equivalent
to the lysis observed with CD19 chimeric receptor s (Figure 6B). Multiplex
cytokine analysis showed nearly equivalent production of IFN-γ and TNF-α, but less
IL-2 production by CD8+ T-cells expressing the R12 ROR1 compared with those
expressing the CD19-chimeric receptor after co-culture with primary CLL (Figure
6C). 2A2 ROR1 chimeric receptor T-cells produced lower amounts of all cytokines
than R12 ROR1 ic receptor T-cells as noted previously. Cytokine production
by all of the chimeric or-transduced T-cells after ation with CLL was
substantially less than with Raji/ROR1, which unlike CLL expresses both CD80 and
CD86 that can engage CD28 expressed on chimeric receptor T-cells (Figure 6A, C).
We observed less proliferation of T-cells expressing the R12 and 2A2 ROR1
chimeric receptor compared to the CD19 chimeric receptor after stimulation with
CLL (CD19>R12>2A2) (Figure 6D). We hypothesized that proliferation of CD8+
ROR1 chimeric receptor T-cells in response to CLL may be augmented in the
presence of chimeric or-modified CD4+ s because of their higher
secretion of IL-2 compared to CD8+ TCM (Figure 4A; Figure 8A). To test this
ility, we performed in vitro co-culture experiments where CD4+ and CD8 TCM
were separately modified with the R12 ROR1, 2A2 ROR1 and CD19 ic
receptors respectively, enriched for chimeric receptor expression, and combined at a
1:1 ratio to ensure equivalent proportions of CD8+ and CD4+ T-cells modified with
each of the vectors. These cells were CFSE-labeled and stimulated with primary
CLL. We observed a dramatic increase in eration of CD8+ R12 ROR1 chimeric
receptor T-cells after addition of ic receptor-transduced, but not untransduced
CD4+ T-cells (Figure 8B). Notably, when provided with CD4-help, we observed
equivalent proliferation of R12 ROR1 and CD19 chimeric receptor CD8+ T-cells in
response to CLL, whereas proliferation of CD8+ T-cells expressing the lower
affinity 2A2 ROR1 chimeric receptor remained less. Collectively, our data show that
the high affinity R12 ROR1 chimeric receptor confers superior reactivity compared
to 2A2 against primary CLL cells in vitro.
ROR1-chimeric receptor T-cells mediate in vivo anti-tumor activity in a mouse
model of systemic mantle cell lymphoma
It remained uncertain whether the superior in vitro activity of T-cells
modified with the higher ty R12 chimeric receptor would translate into
improved anti-tumor activity in vivo, and how targeting ROR1 would compare to
targeting CD19. To address these questions, we ated cohorts of
immunodeficient NSG mice with the human MCL line JeKo-1/ffluc by tail vein
ion, and seven days later when tumor was disseminated, treated the mice with a
single intravenous dose of R12 ROR1, 2A2 ROR1 or CD19 chimeric receptor CD8+
T-cells. Control mice were treated with tEGFR T-cells or untreated. All chimeric
receptors had the optimal short spacer and the 4-1BB costimulatory domain.
Untreated Ko-1 mice developed a rapidly ssive systemic lymphoma
necessitating euthanasia approximately 4 weeks after tumor inoculation (Figure 9AC
We observed tumor regression and improved survival in all mice d with
R12 ROR1, 2A2 ROR1 and CD19 chimeric receptor s. Mice treated with R12
ROR1 chimeric receptor T-cells had a superior anti-tumor response and survival
compared to mice d with 2A2 ROR1 chimeric receptor T-cells (p<0.01), and
able anti-tumor activity to mice treated with CD19 chimeric receptor T-cells
(Figure 9A-C).
We analyzed the frequency of chimeric receptor T-cells in the peripheral
blood following adoptive transfer and detected higher numbers of tEGFR+ T-cells in
mice treated with the R12 ROR1 chimeric or compared to the 2A2 ROR1
chimeric receptor, suggesting more vigorous proliferation in vivo improved tumor
control. To confirm this, we administered CFSE-labeled CD19 chimeric receptor,
R12 and 2A2 ROR1 chimeric receptor T-cells to cohorts of NSG mice bearing
JeKo-1/ffluc, and analyzed T-cell proliferation in the peripheral blood, bone marrow
and spleen 72 hours after transfer. A higher percentage of the R12 and CD19
chimeric receptor T-cells proliferated and underwent a greater number of cell
divisions compared to 2A2 ROR1 chimeric receptor T-cells e 9D). The JeKo-
1 tumor eventually recurred in all mice treated with ROR1 or CD19 chimeric
receptor T-cells (Figure 9A-C). Tumor recurrence was not a result of the selection of
ROR1 or CD19 loss variants, as recurrent tumors were ve for both molecules.
For comparison, we analyzed anti-tumor efficacy of CD19 ic receptor
T-cells in NSG mice engrafted with Raji tumors and observed complete tumor
eradication, indicating the ence of JeKo-1 reflects ulty ating this
tumor (data not shown). In summary, this data is the first to show that ROR1
chimeric receptor T-cells have anti-tumor efficacy in vivo, and suggest that for B-
cell malignancies, an optimized ROR1 chimeric receptor such as R12 may be
effective and spare normal CD19+ s that lack ROR1 expression.
s expressing the R12 ROR1 chimeric receptor have superior reactivity
compared to 2A2 against ROR1+ lial tumor cells
ROR1 has been detected on many epithelial tumors, although it is unknown
whether ROR1 sion is sufficient for ition by ROR1 chimeric receptor
T-cells. Using flow cytometry, we confirmed ROR1 expression on breast cancer
lines MDA-MB-231 and 468, and on the renal cell carcinoma lines FARP, TREP,
and RWL (Figure 10A). We then ed tumor recognition by CD8+ T-cells
transduced with the R12 ROR1 chimeric receptors with the optimal short spacer and
4-1BB domain, and observed ent recognition of MDA-MB-231, MDA-MB-
468, FARP, TREP and RWL (Figure 11A). We analyzed cytokine secretion and
proliferation of T-cells modified with the R12 and 2A2 ROR1-chimeric receptors
after co-culture with MDA-MB-231, and observed greater cytokine production and
proliferation with the R12 ROR1 chimeric receptor (Figure 11 B, C). Similar to
what we ed with ROR1+ B cell malignancies, the superior tion of R12
ROR1 chimeric or T cells after stimulation with -231 was not
associated with increased AICD (R12: 9.8% vs. 2A2: .
Discussion
ROR1 has attracted interest as a potential target for cancer immunotherapy
due to its expression on the surface of many hoid and epithelial cancers,
including subsets of lung, colorectal and renal cell . We previously showed
that CLL and MCL were specifically recognized by s modified to express a
ROR1-specific chimeric receptor (Hudecek M, et al. Blood. 2010;116(22):4532-41.
Epub 2010/08/13). The design and function of ROR1-chimeric receptors has been
improved through modification of the extracellular spacer domain and deriving the
chimeric receptor from a scFV of higher affinity, and demonstrate that T-cells
modified with designed ROR1 chimeric receptors have in vivo activity t
ROR1+ B-cell lymphoma and in vitro activity against a wide range of epithelial
tumors.
We compared the function of T-cells modified with ROR1 chimeric
ors derived from the 2A2 mAb that contained either the original long IgG4-Fc
‘Hinge-CH2-CH3’ spacer that we have shown enables high level cell surface
expression, or truncated intermediate ‘Hinge-CH3’ and short ‘Hinge-only’ spacer
variants. We preserved the 12 AA Hinge domain in our short spacer construct based
on prior data that a flexible spacer was required for separating the scFV from the T-
cell ne and allowing antigen recognition on tumor cells ( Fitzer-Attas CJ, et
al.,Harnessing Syk family tyrosine kinases as signaling domains for ic single
chain of the variable domain receptors: optimal design for T cell activation. J
Immunol. 1998;160(1):145-54. Epub 1998/04/29.)
Our studies with the 2A2 ROR1 chimeric receptor show that T-cell cytokine
secretion and proliferation after tumor cell recognition are superior with the
ediate and short spacer constructs compared to the long spacer construct.
Staining with (ab) Abs showed equivalent chimeric receptor expression of all
three receptors, demonstrating the improved T-cell function with the short spacer
chimeric receptor was not due to differences in chimeric receptor density. This data
supports the principle that the design of extracellular spacers should be tailored for
each target molecule and epitope.
The affinity of the scFV selected for designing a ic or is an
additional parameter that could affect T-cell recognition. We generated and
characterized a panel of ROR1-specific mAbs of different affinities and ed the
R12 mAb, which recognizes an epitope in the Ig-like/Frizzled region as 2A2. R12
has a higher affinity for ROR1-protein due to a much slower dissociation. The R12
chimeric receptor, like the 2A2 chimeric receptor conferred optimal T-cell
recognition and function when designed with a short extracellular spacer. A direct
comparison of proliferation and cytokine production after tumor engagement by T-
cells modified with the 2A2 and R12 chimeric receptors demonstrated that the R12
chimeric receptor derived from the higher affinity mAb was superior. We were
ned that the slower dissociation of R12 from ROR1 could prolong T-cell
activation and confer an sed susceptibility to AICD. However, we detected a
lower rate of AICD in s modified with the R12 ROR1-chimeric receptor
compared to 2A2, demonstrating that the increased affinity of R12 had no
detrimental effect on T-cell survival in our preclinical models.
ROR1 has a potential advantage over CD19 as a target for CLL and MCL
since it is not expressed on normal mature naïve and memory B-cells. However,
there is a lower number of ROR1 molecules on B-cell tumors compared with CD19
and it is uncertain if an optimized ROR1 chimeric receptor would be as effective as
a CD19 chimeric receptor similar in design to those being used in the clinic.
Unfortunately, B-cell tumor aft models used previously in NSG mice to
evaluate the function of CD19 chimeric receptor T-cells including Raji, Daudi and
Nalm-6, are not derived from CLL or MCL and do not constitutively express ROR1.
Thus, to compare targeting CD19 and ROR1 in vivo, we used the JeKo-1 MCL cell
line, which lly expresses both CD19 and ROR1 and engrafts in NSG mice. To
make our model clinically relevant, we ated JeKo-1 lymphoma cells
intravenously to generate systemic tumors, and d mice with T-cell products of
uniform consistency once tumors were established. We found that T-cells sing
the high affinity R12 chimeric receptor conferred equivalent anti-tumor activity in
vivo as CD19 chimeric receptor T-cells. Consistent with our in vitro analysis, the
R12 ROR1 chimeric receptor also mediated superior activity in vivo compared to the
optimal 2A2 ROR1-chimeric receptor. These results should be interpreted cautiously
since murine tumor models may not predict the cy of ve therapy in
clinical settings. However, the results suggest that ROR1 warrants consideration as
an alternative to CD19, or to e an additional target to minimize the potential
for CD19 loss variants to emerge.
ROR1 appears to play a decisive role in survival of some epithelial tumors.
Thus, an advantage of targeting ROR1 is that a single chimeric or may be
useful to treat patients with a large number of hematopoietic and non-hematopoietic
tumors.
Our data shows for the first time that T-cells that express a designed ROR1
chimeric receptor efficiently recognize epithelial cancers in vitro. Cytokine secretion
and T-cell eration induced by ROR1+ breast cancer cells were higher than that
induced by leukemia cells, despite the absence of the CD80/86 costimulatory ligand.
The studies reported here demonstrate that the design of the extracellular spacer
domain and chimeric receptor ty are parameters that can be modulated to
enhance the recognition of ROR1+ hematologic and epithelial tumors in vitro and in
vivo by himeric receptor modified T-cells. The development of ROR1-
chimeric receptors with enhanced tumor vity provides the opportunity for
clinical applications in a variety of human cancers.
Example 2
Effect of ellular spacer domain length on triggering of tumor cell lysis
with a Her2-specific chimeric receptor that recognizes an epitope located
proximal to the tumor cell membrane.
The effect of CAR spacer length on recognition and triggering of tumor cell
recognition by CD8+ human T lymphocytes that expressed a HER2-specific
chimeric receptor was examined using similar methods to those described above for
ROR1. HER2-specific chimeric receptors were constructed using VL and VH chain
segments of a HER2-specific mAb that recognized a membrane proximal epitope on
HER2 e 12A), and the scFVs were linked to IgG4 CH2/CH3, IgG4
hinge/CH3, and IgG4 hinge only extracellular spacer domains and to the CD28
transmembrane domain, 4-1BB and CD3 zeta signaling domains (Figure 12B).
Primary CD8+ T cells were transduced with each of the HER2 chimeric receptors
and selected for sion of the EGFR transducton marker (Figure 12D).
Expression of the HER2 chimeric receptors and the size of each receptor was
confirmed by Western Blot (Figure 12C). The T cells were then expanded with anti
CD3 mAb and feeder cells and examined for their y to ize HER2+ tumor
cells. As observed with the R11 ROR 1 specific chimeric receptor, the HER2
chimeric receptor that contained a long ellular spacer domain conferred
superior T cell recognition of HER2+ tumor cells (Figure 12E).
Discussion
This example of the effect of extracellular spacer length on chimeric receptor
modified T cell recognition of tumor cells used a ic receptor comprising a
scFv built from the VH+L ces of the tin chimeric mAb. Studies by Cho
et al (Nature 421:756, 2003) localized to epitope location of Herceptin to a
membrane proximal location on the HER2 (ERRB2) extracellular domain e
12A). Based on our understanding of the structure of human IgG4 hinge:Fc
variants (Figure 12B), we esize that a membrane proximal location of the
targeting e on an extracellular tumor cell antigen would best recognized by
effector T cells that express a chimeric or ng a long spacer. Our data
demonstrating a nt of cytolytic activity from near back ground activity by T
cells expressing a short spacer Herceptin chimeric receptor, to intermediate activity
by T cells expressing a medium length spacer chimeric receptor, and maximal lysis
by T cells that expressed the long spacer chimeric receptor. Thus, the extracellular
spacer has definitive effects on tumor recognition by T cells, and this data provides
further support for the need to tailor chimeric receptor design based on epitope
location of tumor expressed target molecules.
e 3 –
Customizing spacer length and sequence for optimal recognition and in vivo
efficacy of CD19 with chimeric receptor modified T cells.
Materials and Methods
Human subjects
Blood samples were obtained from healthy donors who provided written
informed consent to participate in research protocols approved by the Institutional
Review Board of the Fred Hutchinson Cancer Research Center (FHCRC). Peripheral
blood mononuclear cells (PBMC) were isolated by centrifugation over Ficoll-
Hypaque (Sigma, St.Louis, MO), and cryopreserved in RPMI, 20% human serum
and 10% dimethyl sulfoxide.
Cell lines
The K562, Raji, JeKo-1, and 293T cell lines were obtained from the
American Type Culture Collection (Manassas, VA) and cultured as directed. A
lentivirus ng the ffluc-gene am of a T2A sequence and eGFP was
ed in 293T cells and used to transduce Raji and JeKo-1 tumor cells. Raji, and
JeKo-1 cells were expanded after iral transduction and the eGFP positive
subset sort-purified.
Immunophenotyping
PBMC and T-cell lines were stained with one or more of the following
conjugated onal antibodies: CD3, CD4, CD8, CD25, , CD45RO,
CD62L, CD69 and matched isotype controls (BD Biosciences). Staining with
propidium iodide (PI, BD Biosciences) was performed for live/dead cell
discrimination as directed by the manufacturer. Flow analyses were done on a
FACSCanto, sort-purifications on a FACSAriaII (Becton Dickinson) and data
analyzed using FlowJo software (Treestar).
Vector construction and preparation of CD19 chimeric receptor encoding
lentivirus
CD19 specific chimeric receptors were constructed using: (1) the VL and VH
chain segments of the CD19-specific mAb FMC63 (SEQ ID NO:3), linked by a
(G4S)3 linker (SEQ ID NO:12)peptide (VL-linker-VH); (2) a spacer domain derived
from IgG4-Fc (Uniprot Database: P01861, (SEQ ID NO:13)) comprising either the
Hinge-CH2- CH3 portion (229 AA, (SEQ ID NO:)) or Hinge only (12 AA; (SEQ ID
NO:4)). Both spacers contained a S → P substitution within the Hinge domain
located at position 108 of the native IgG4-Fc protein; the 27 AA transmembrane
domain of human CD28 (Uniprot Database: P10747, (SEQ ID NO:14)); (4) a
signaling module comprising either (i) the 41 AA cytoplasmic domain of human
CD28 with an LL → GG substitution located at position 186-187 of the native CD28
protein (SEQ ID NO:14) ; and/or (ii) the 42 AA cytoplasmic domain of human 4-
1BB (Uniprot se: , (SEQ ID ); linked to (iii) the 112 AA
cytoplasmic domain of isoform 3 of human CD3ζ (Uniprot se: P20963, (SEQ
ID NO:16)); the self cleaving T2A sequence (SEQ ID NO:8); and (6) a truncated
epidermal growth factor receptor (EGFR)sequence (SEQ ID NO:9).
Codon-optimized nucleotide sequences encoding each trans gene were
synthesized (LifeTechnologies, Carlsbad, CA) and cloned into the epHIV7 lentiviral
vector using NheI and Not1 ction sites. The epHIV7 lentiviral vector had been
derived from the pHIV7 vector by replacing the galovirus er of
pHIV7 with an EF-1 er.
CD19 chimeric receptor or tEGFR-encoding lentivirus was produced in 293T
cells co-transfected with the lentiviral vector and the ing vectors pCHGP-2,
pCMV-Rev2 and pCMV-G using Calphos transfection reagent (Clontech). Medium
was changed 16 h after transfection, and lentivirus collected after 24, 48 and 72 h.
Generation of T -cell lines expressing the CD19 chimeric receptors
Sort-purified CD8+ CD45RA- CD45RO+ CD62L + central memory T -cells
(TCM) of normal donors were activated with anti-CD3/ CD28 beads (Life
Technologies) according to the manufacturer's ctions, and transduced with
lentiviral supernatant (MOI = 3) supplemented with 1 μg/mL polybrene pore)
on day 3 after activation by centrifugation at 2,100 rpm for 45 min at 32°C. T cells
were expanded in RPMI, 10% human serum, 2 mM L-glutamine and 1 % llinstreptomycin
(CTL medium), supplemented with recombinant human (rh) lL-2 to a
final concentration of 50 U/mL every 48 h. After expansion, an aliquot of each
transduced T cell line was stained with biotin-conjugated anti-EGFR (epithelial
growth factor receptor) antibody and streptavidin-beads (Miltenyi), and tEGFR+ T
cells isolated by immunomagnetic selection.
The tEGFR+ T-cell subset was then stimulated with irradiated (8,000 rad)
TM EBV-LCL at a T cell: LCL ratio of 1 :7, and expanded for 8 days in CTL
medium with addition of 50 U/mL rh IL-2 every 48 h.
Chromium e, cytokine secretion and CFSE proliferation assays
Target cells were labeled with 51Cr (PerkinElmer) overnight, washed and
incubated in triplicate at 1-2x l03 cells/well with effector T cells at various or
to target (E:T) ratios. Supernatants were harvested for γ counting after a 4-hour
incubation and specific lysis calculated using the standard a. For analyses of
cytokine secretion, target and effector cells were plated in triplicate wells at an E:T
ratio of 2: 1 (Raji) or 4: 1 (K562/CDI9 and K562), and INF-γ, TNF-α, IL-2, IL-4,
IL-6 and IL-10 ed by multiplex cytokine immunoassay ex) in
supernatant removed after a 24-hour incubation.
For analysis of proliferation, T cells were labeled with 0.2 μM
carboxyfluorescein succinimidyl ester (CFSE, Invitrogen), washed and plated in
triplicate wells with stimulator cells at a ratio of 2: 1 (Raji) or 4: 1 (K562/CD19 and
K562) in CTL medium without exogenous cytokines. After 72 h of incubation, cells
were labeled with anti-CD3 mAb and propidium iodide (PI) to exclude dead cells
from analysis. Samples were analyzed by flow cytometry and cell division of live
CD3+ T-cells assessed by CFSE dilution.
Experiments in NOD/SCID and NOD/SCID/γc-/- (NSG) mice
All mouse experiments were approved by the FRCRC Institutional Animal
Chimeric receptore and Use Committee. Six- to 8-week old female NOD.CBI7-
Prkdcscid /J (NOD/SCID) and NOD.Cg-Prkdcscid Il2rgtmlWjl/SzJ (NSG) mice were
obtained from the Jackson Laboratory or bred se (FRCRC. Mice were injected
intravenously (i. v.) with 0.5 x l06 Raji-ffluc tumor cells via tail vein injection, and
received injections of chimeric or-modified T cells, control T cells, or PBS via
tail vein injection as indicated.
For bioluminescence imaging, mice received eritoneal (i.p.) injections
of freshly prepared rin substrate (Caliper Life Sciences, MA) resuspended in
PBS (15 μg/g body ) and were then anesthetized with isoflurane in an
ion r. After induction of deep esia, mice were imaged using an
Xenogen IVIS In Vivo Imaging System (Caliper Life Sciences, MA) at 10, 12 and
14 s post i.p. injection of luciferin at an acquisition time of 1 second to 1
minute in small binning mode to obtain unsaturated images. Luciferase activity was
analyzed using Living Image Software (Caliper Life Sciences, MA) and the photon
flux analyzed within regions of interest that encompassed the entire body of each
individual mouse.
Statistical analyses
Statistical analyses were performed using Prism Software Pad, CA).
Student's t-test was performed as a two-sided test with a confidence interval of 95%
and results considered significant with a p-value of p<0.05. Statistical analysis of
survival were done by Log-rank testing and results considered significant with a pvalue
of p<0.05.
Results
Preparation of polyclonal CD8+ TCM-derived cell lines that express CD19 chimeric
receptors with long and short extracellular spacers
We constructed individual lentiviral vectors encoding a panel of codon-
optimized CD 19 chimeric receptor genes to examine the influence of extracellular
spacer length on the in vitro function and in vivo antitumor activity of CD19
chimeric receptor-modified T cells. Each chimeric receptor was comprised of a
single chain variable fragment corresponding to the sequence of the pecific
mAb FMC63 (scFv: , a spacer derived from IgG4-Fc including either the
'Hinge-CH2-CH3' domain (229 AA, long spacer) or the 'Hinge' domain only (12
AA, short spacer), and a signaling module of CD3ζ with membrane al CD28
or 4-1 BB costimulatory domains, either alone or in tandem (Figure 13A). The
transgene te included a truncated EGFR (tEGFR) downstream from the
chimeric receptor gene and ted by a cleavable T2A element, to serve as a
transduction, selection and in vivo tracking marker for chimeric receptor-modified T
cells.
We isolated a CD8+ CD45RO+ CD62L+ central memory T cell (TCM) cell
population by cell sorting from the blood of normal donors for transduction and
expansion, because of the superior ability of TCM to persist in vivo after adoptive
transfer. CD8+ T cells were stimulated with anti CD3/28 beads, transduced with
each of the lentiviral vectors, and expanded in culture for 18 days before being used
for in vitro and in vivo experiments. (Figure 13B) Similar transduction efficiencies
were achieved with each of the iral vectors (mean 25%) and transgene-positive
T cells were enriched to uniform purity by immunomagnetic selection using a
biotinylated anti-EGFR mAb and streptavidin beads. ing tEGFR-enrichment,
each of the CD19 chimeric receptor T cell lines were ed by a single
stimulation with CD19+B-LCL, without apparent differences in in vitro growth
cs n T cell lines expressing the various CD 19 ic receptor
constructs. After expansion, the tEGFR marker was expressed at equivalent levels
on >90% of the T cells transduced with each of the vectors (Figure 13C).
CD19 ic receptors with long and short extracellular spacer domain confer
specific anti-tumor reactivity in vitro
We compared the effector function of rived T cell lines modified to express
CD19 chimeric receptors with CD28 and 4-1BB costimulatory signaling moieties,
and either a short ('short/CD28';'short/4-1BB') or long /CD28'; 'long/4-1BB')
extracellular spacer domain respectively. T cells expressing each of the 4 CD19
chimeric receptor constructs conferred specific cytolytic activity against CD19+ Raji
and JeKo-l lymphoma cells, and against K562 cells that had been stably transfected
with CD19, but not native CD19- K562 cells (Figure 14A). Quantitative analyses of
cytokine production in response to stimulation with K562/CD19 or Raji tumor cells
by multiplex cytokine assay (Luminex) showed production of IFN-γ, TNF-α, IL-2,
IL-4, IL-6, and IL-10 by T cells expressing each of the CD19 chimeric receptors
(Figure 14B). T cells sing CD19 chimeric receptors with a CD28
costimulatory domain produced significantly higher levels of IFN-γ, TNF-α, IL-2
and IL-10 compared to the corresponding constructs with a 4-1BB ulatory
domain (Figure 14B, C). There was significantly higher IFN-y production and
significantly less IL-4 production by T cells expressing the CD19 'long/CD28'
chimeric receptor compared with those expressing the 'short/CD28' chimeric
or. Amongst the CD19 chimeric receptors with 4-1BB costimulatory signaling
module, we detected significantly higher levels of IFN-γ, TNF -α, IL-2, IL-4, and
IL-10 secretion in T cells expressing the uct with the short spacer domain
e 14B, C).
We used CFSE dye dilution to analyze proliferation of T cells modified with
each of the CD 19 chimeric receptors after engagement of CD 19+ tumor cells.
Specific and vigorous proliferation of each of the CD19 chimeric or T cell
lines was observed 72 hours following stimulation with either D19 or Raji.
The average number of cell divisions was higher for CD19 chimeric receptor T cells
with a CD28 costimulatory domain compared to those with 4-1BB, consistent with
greater IL-2 production by T cells expressing a CD28 containing chimeric receptor
(Figure 14B-D). We also analyzed the tion of ic receptor T cells that
underwent activation induced cell death after stimulation with K562/CD19 and Raji
tumor cells at the end of the 72-hours by costaining the culture with CD3+ and PI.
We detected a higher frequency of CD3+ CD8+ PI+ T cells in the CD 19 chimeric
receptor cell line 'long/4-1 BB', but few PI+ cells were observed with the other
CD19 chimeric ors. (Figure 14E).
This analysis of in vitro effector functions was consistent with prior s
that have compared CD28 and 4-1BB costimulatory domains, and did not reveal
differences in T cell function that would suggest that a particular CD19 chimeric
receptor construct from this panel would lack anti-tumor efficacy in vivo.
T cells expressing CDI9 chimeric receptors with short extracellular spacer
domains but not long extracellular spacer s eradicate Raji tumors in
immunodeficient mouse models
We next evaluated the in vivo antitumor cy of T cells modified with
each of the CD19 chimeric receptors in deficient CID) mice
engrafted with firefly luciferase transfected Raji cells (Raji-ffluc), which enables
sequential quantitative analyses of tumor burden and distribution using
bioluminescence imaging. NOD/SCID mice inoculated with 0.5x106 Raji-ffluc cells
via tail vein injection ped disseminated lymphoma, which if untreated led to
hind limb paralysis after approximately 3.5 weeks, necessitating euthanasia. Tumor
bearing mice were treated with 2 doses of CD8+ TCM-derived T cells modified with
each of the CD19 chimeric receptors or with a tEGFR control vector administered
on day 2 and day 9 after tumor inoculation e 15A).
Surprisingly, only T cells modified to express CD19 chimeric receptors with
short extracellular spacer domain ('short/CD28' and 'short/4-1BB') eradicated Raji
tumors in this model, whereas mice treated with T cells expressing CD19 chimeric
receptors with long spacer ('long/CD28' and 4-1BB') developed systemic
lymphoma and hind limb paralysis with nearly identical kinetics as ted mice
or mice d with control tEGFR+ T cells (Figure 15B, C). The striking difference
in mor activity between CD19 chimeric receptors with short and long spacer
domains was highly significant and reproducible in multiple experiments with
chimeric receptor T cell lines generated from 3 different normal donors.
The NOD/SCID ma model may be suboptimal for predicting antitumor
ty in a clinical setting because of the short interval between tumor
inoculation and T cell administration and the greater resistance to engraftment of
human cells compared to more immunodeficient mouse strains such as
NOD/SCID/γc-/- (NSG). Thus, we evaluated antitumor ty of adoptive therapy
in a more clinically relevant model in which Raji-ffluc lymphoma was established in
NSG mice, and the CD19 chimeric receptor T cells were administered after 7 days
when the tumor was readily detectable in the bone marrow by inescence
imaging (Figure 16A). We performed initial dose titration experiments to ine
the minimal dose of T cells transduced with the CD19 /4-1BB' chimeric
receptor that was required for eradication of established Raji tumors. A single dose
of 2.5x106 T cells expressing CD19-chimeric receptor 'short/4-1BB' promoted
complete regression of established Raji tumors and resulted in long-term tumor-free
survival in 100% of mice (Figure 16B,C). At the 2.5x106 dose level, the T-cells were
easily detected in the eral blood of NSG mice for at least 3 weeks ing
adoptive transfer and tumor eradication. Thus, this model enabled comparative
studies both of antitumor activity and persistence of T cells modified with each of
the CD19-chimeric receptors in our panel (Figure 16D).
We then treated cohorts of NSG mice that were engrafted with Raji
lymphoma with PBS alone, with a single dose of 2.5x106 T cells expressing each of
the CD19 chimeric ors or with T cells modified with a tEGFR encoding
l vector (Figure 17A). In this model of established lymphoma, T cells
expressing CD19 chimeric receptors with a short extracellular spacer domain and
either 4- 1BB or CD28 costimulatory domains (‘short/CD28' and 'short/4-1BB')
mediated complete tumor regression over 7-10 days and all mice survived tumor
free for >56 days. By contrast, mice treated with T cells modified to express CD19
chimeric receptors with a long spacer domain ('long/CD28' and 'long/4-1BB')
exhibited tumor ssion and had to be sacrificed at a similar time as mice that
had received control tEGFR T cells (Figure 17B, C). The lack of in vivo antitumor
activity of the chimeric receptor constructs with long spacers was unexpected given
the ability of T cells expressing these constructs to lyse tumor cells in vitro, and the
enhanced IL-2 production and proliferation after engagement of T cells expressing
the 'long/CD28' CD19 chimeric receptor compared to the 4-1BB ucts.
To provide insight into the basis for the lack of efficacy, we performed
sequential flow try on peripheral blood samples of mice at intervals after the
T cell infusion. All mice treated with T cells expressing the 'short/CD28' and
'short/4-1BB' CD19 chimeric receptors had icantly higher levels of transferred
T cells in the blood at all time points after adoptive transfer, compared to mice
treated with T cells that expressed corresponding CD19 chimeric ors with long
extracellular spacer (p<0.01) (Figure 17D). We did not observe significant
differences in T-cell persistence in the peripheral blood of mice that had received T
cells expressing CD19 chimeric receptors with CD28 or 4-1BB co-stimulatory
domains and short spacer domains (Figure 17D).
The in vivo anti-tumor cy of CD19 chimeric ors with long spacers is
not improved by increasing T cell dose or providing an additional ulatory
domain
The lack of in vivo anti-tumor efficacy and the lower level of persisting
chimeric receptor T cells in mice treated with T cells modified with CD19 chimeric
receptors with long spacer s suggested that cy might be improved by
increasing the chimeric receptor T cell dose or by including both CD28 and 4- IBB
domains into the chimeric receptor to augment costimulatory signaling. To te
this possibility we modified CD8+ TCM with 'long/CD28', 'short CD28', and
'long/CD28_ 4-1BB' CD19 chimeric receptor vectors and med that the
long/CD28_ 4-1BB' CD19 chimeric receptor conferred specific lysis and cytokine
production in vitro after recognition of CD19+ target cells (Figure .
Consistent with previous studies of CD19 chimeric receptors, the level of cytokine
production and proliferation in vitro in T cells expressing the CD28_ 4-IBB' CDI9
chimeric receptor was inferior compared to the identical construct with CD28 alone,
and superior to T cells expressing the 'long 4-IBB' CD19 chimeric receptor e
18B, C).
Groups of NSG mice with established Raji tumors were then treated with a
high dose of T cells (10 x106 ) T cells expressing the 'long/CD28' CD19 chimeric
receptor, the 'long/CD28_ 4-IBB' CDI9 chimeric receptor, the 'short/CD28' CD19-
chimeric receptor, and tEGFR alone. Tumor burden was measured by
bioluminescence imaging and serial flow cytometric analyses of peripheral blood
samples performed to determine the frequency of erred T cells. tent
with the results of our prior experiments using much lower doses of T cells, Raji
tumors were completely eradicated in mice d with T cells expressing the
'short/CD28' CD19-chimeric receptor. However, even with a 4-fold higher T cell
dose, treatment with T cells expressing the 'long/CD28' CD19 chimeric receptor or
the 'long/CD28_ 4-1BB' CD19 chimeric or did not provide a discernible
antitumor effect (Figure 18D,E).
Thus, increasing the chimeric receptor T cell dose and adding a 4-1BB
ulatory domain to CD19 chimeric receptors failed to overcome the negative
impact of the longer spacer domain on mor activity in vivo. Thus, in this
model, anti-tumor reactivity of CD19 chimeric receptors is dictated to a great extent
by the length of the extracellular spacer domain, and not by the intracellular
costimulatory signaling modules.
T cells modified with CD19 chimeric receptors that possess long extracellular
spacers undergo activation induced cell death in vivo
We sought to determine ial mechanisms underlying the inferior in vivo
antitumor activity of T cells that express CD19 chimeric receptors with long spacer
domains. Because lower numbers of transferred T cells modified to express CD19
chimeric receptors with long spacer domains were present in the blood, we
ered the possibility that the T cells were not efficiently activated by tumor
cells in vivo or sely, that they underwent activation induced T cell death in
vivo. Therefore, we labeled CD19 chimeric receptor modified and corresponding
control T cells with CFSE and administered these T cells to tumor bearing NSG/Raji
mice to examine activation, proliferation and survival of T cells modified with each
of the CD19 chimeric receptor constructs at tumor sites in vivo (Figure 19A). At the
end of their in vitro expansion and immediately prior to CFSE labeling and infusion
into NSG mice bearing established Raji tumors, T cells transduced with each of the
CD19 chimeric receptors sed low levels of the activation markers CD69 and
CD25 e 19B).
Bone marrow was ed from subgroups of mice 24 and 72 hours after the
T cell on to examine the frequency, activation and proliferation of transferred
T cells. At 24 hours, tumor cells (CD45+ CD3-) were present in the bone marrow in
all treatment groups and a large fraction of chimeric receptor T cells, but not control
T cells, had upregulated CD69 and CD25. There was no measurable on of
CFSE in the transferred chimeric receptor T cells. (Figure 19C) Both CD69 and
CD25 were expressed in a higher proportion of T cells modified with 'long '
CD19 chimeric receptors, suggesting these cells may have received a stronger
stimulus compared to T cells with 'short spacer' CD19 chimeric receptors (Figure
__C). Despite evidence of T cell activation at 24 hours there were significantly
lower numbers of ic receptor T cells in the bone marrow of mice treated with
T cells modified with the CD28 and 4-IBB 'long spacer' constructs compared to
those ed with the CD28 and 4-IBB 'short spacer' constructs, or with the
control tEGFR vector (Figure 19C, E).
At 72 hours after T cell transfer, T cells expressing the 'short/CD28' and
'short/4-lBB' CD19 chimeric receptors had increased 3 to > 10 fold in ncy in
the bone marrow and , and had undergone several cell divisions (Figure
19D,E). Control tEGFR+ T cells remained present in the bone marrow and spleen at
72 hours at a level r to that observed at 24 hours, and had not divided as
measured by CFSE dilution. By contrast, the numbers of T cells expressing the
'long/CD28' and 'long/4-IBB' CD19 chimeric receptors had not increased in the bone
marrow and spleen. (Figure 19D, E) Consistent with lower cell numbers, is of
CFSE ng in viable PI- 'long/CD28' and 'long/4-IBB' CDl9 chimeric receptor T
cells demonstrated these cells had undergone a much lower number of cell divisions
compared with 'short/CD28' and /4-IBB' CDl9 chimeric receptor T cells.
(Figure 19D)When the flow data was analyzed to e PI+ T cells, we detected a
much higher frequency of PI+ CD3+ T cells in bone marrow and spleen of mice that
received CD19 chimeric receptor T cells with 'long spacer' domains, demonstrating
that a significant proportion of T cells, despite being activated by tumor in vivo had
one cell death (Figure 19F). Consistent with the bioluminescence imaging,
CD45+ CD3- Raji tumor cells were present in greater numbers in the bone marrow
of mice treated with T cells expressing CD19 chimeric receptors with long spacer
domains or expressing tEGFR only compared to mice treated with CD19 chimeric
receptors with short spacer domains (Figure 19D,E, G).
Collectively, the data provides ce that CD19 chimeric ors with
long extracellular spacer domain, despite mediating equivalent or superior effector
function in vitro and recognizing tumor in vivo, induce a high level of activation
induced cell death in vivo and fail to eradicate established lymphoma.
Discussion
Chimeric receptors are artificial receptors that include an extracellular
antigen-binding scFv, a spacer domain that provides separation of the scFv from the
cell membrane and an intracellular ing module that mediates T cell activation.
Chimeric receptors that contain a scFv derived from the CD19-specific FMC63 mAb
d here, have advanced to testing in clinical trials in patients with B-cell
ancies. Antitumor activity and T cell persistence have varied substantially in
different trials. Each of these clinical trials differed in potentially critical variables,
including different gene transfer s, cell culture methodologies, and
conditioning regimens prior to CD19 chimeric receptor T cell er.
We examined the possibility that the extracellular spacer domain of CD19
chimeric receptors may be an important determinant of anti-tumor activity in vivo,
independent of the ulatory signaling provided by the chimeric receptor. We
derived spacer s from IgG4-Fc, which enables high levels of chimeric
receptor cell surface sion and is less likely to provoke recognition by innate
immune cells compared to other IgG isotypes. We used the IgG4 ‘Hinge-CH2-CH3’
in the design of the long (229 AA) spacer constructs and the IgG4 ‘Hinge’ domain in
our short (12 AA) spacer chimeric receptors. To compare the individual ic
receptor constructs, we used purified (>90%) chimeric receptor positive CD8+ TCM–
derived T cells to remove differences in the cellular composition and transduction
frequency as a potential source of bias in the analysis of in vitro and in vivo
function. CD8+ TCM have been shown to have superior traits for adoptive
immunotherapy, compared with other more ent T cell subsets in blood that
t poorly and are ineffective in tumor therapy. The CD19 chimeric or T
cells were generated using a standardized e protocol that is similar to that used
to derive chimeric receptor T cells for clinical trials. Our data show that CD19
chimeric receptors with a short IgG4 ‘Hinge’ spacer conferred potent umor
reactivity in vitro and in vivo, whereas corresponding CD19 chimeric receptors with
a long spacer of IgG4 ‘Hinge-CH2-CH3’, despite equivalent or superior reactivity in
vitro, failed to confer significant umor effects in murine lymphoma .
Surprisingly, the length of the spacer domain proved to be a decisive element for in
vivo antitumor activity, and the lack of efficacy of the ‘long spacer’ chimeric
receptor could not be overcome by increasing the T cell dose.
We also observed major differences in cytokine secretion and proliferation in
vitro between T cells expressing CD19 chimeric receptors containing CD28 and 4-
1BB costimulatory domains, with CD28 ting secretion of IFN-γ, IL-2, and
TNF-α compared with 4-1BB. CD19 chimeric receptors that possessed a tandem
CD28_4-1BB also produced higher levels of these cytokines compared to chimeric
receptors encoding 4-1BB only. However, our data shows that these differences in in
vitro on were not predictive of in vivo anti-tumor efficacy, since CD19
chimeric receptors with either CD28 or 4-1BB costimulatory domain and a short
spacer were similarly effective at eradicating advanced established Raji tumors in
NSG mice. In contrast, CD19 chimeric receptors with suboptimal spacer length and
CD28, 4-1BB, or both costimulatory domains, despite conferring similar in vitro
function as the identical chimeric or construct with a short spacer domain,
lacked significant anti-tumor ty in vivo, demonstrating the contribution of
spacer length to in vivo function of chimeric receptor T cells.
Our studies provide insight into the mechanism sible for the lack of in
vivo efficacy of CD19 chimeric receptors with long spacer domains. T cells
expressing CD19 chimeric receptors with both long and short spacer domains could
be ed in the bone marrow and spleen after adoptive transfer into NSG mice
bearing established Raji lymphoma, and the majority were activated as trated
by upregulation of CD25 and CD69. r, T cells modified to express a CD19
chimeric receptor with a long spacer domain exhibited a steep decline in cell
number, in contrast to the marked in vivo expansion of T cells expressing CD19
chimeric receptors with a short spacer domain. The e in T cell number was a
consequence of much higher levels of cell death in the first 72 hours after adoptive
transfer compared with T cells with short spacer s, and control T cells that
did not express a CD19 chimeric receptor. Collectively, these data indicate that
recognition of tumor cells in vivo resulted in death of T cells sing CD19-
chimeric receptors with long spacer domains. A similar mechanism may explain the
short duration and low levels of T cell persistence in the clinical trials that employed
long spacer CD19-chimeric receptors (14).
The studies reported here are the first to show that the spacer domains of
CD19 chimeric receptors that lack intrinsic signaling properties have dramatic
effects on in vivo antitumor activity independent of ulatory signaling, and
identify the importance of analyzing the optimal composition of this region in the
design of chimeric receptors for clinical applications.
The term “comprising” as used in this specification and claims means
“consisting at least in part of”. When interpreting statements in this specification,
and claims which include the term ising”, it is to be understood that other
features that are onal to the features prefaced by this term in each statement or
claim may also be present. Related terms such as “comprise” and ised” are
to be interpreted in similar manner.
In this specification where nce has been made to patent specifications,
other external documents, or other sources of ation, this is generally for the
purpose of providing a t for discussing the features of the invention. Unless
specifically stated otherwise, reference to such external documents is not to be
construed as an admission that such documents, or such sources of information, in
any jurisdiction, are prior art, or form part of the common general knowledge in the
art.
In the description in this specification reference may be made to subject
matter that is not within the scope of the claims of the current application. That
subject matter should be y identifiable by a person skilled in the art and may
assist in putting into practice the invention as defined in the claims of this
application.The ing is illustrative of the present invention, and is not to be
construed as limiting thereof. The invention is defined by the following claims, with
equivalents of the claims to be included therein. All references and documents
referred to herein are hereby incorporated by reference.
Table 1
ce of anti-CD19 short spacer chimeric receptor
GMCSFRss-CD19scFv-IgG4hinge-CD28tm-41BB-Zeta-T2A-EGFRt
Atgctgctgctggtgaccagcctgctgctgtgcgagctgccccaccccgcctttctgctgatcccc
(GMCSFRss) (SEQ ID NO:2)
Gacatccagatgacccagaccacctccagcctgagcgccagcctgggcgaccgggtgaccatcagctgccggg
ccagccaggacatcagcaagtacctgaactggtatcagcagaagcccgacggcaccgtcaagctgctgatctac
cacaccagccggctgcacagcggcgtgcccagccggtttagcggcagcggctccggcaccgactacagcctgac
catctccaacctggaacaggaagatatcgccacctacttttgccagcagggcaacacactgccctacacctttggc
ggcggaacaaagctggaaatcaccggcagcacctccggcagcggcaagcctggcagcggcgagggcagcacc
aagggcgaggtgaagctgcaggaaagcggccctggcctggtggcccccagccagagcctgagcgtgacctgca
ccgtgagcggcgtgagcctgcccgactacggcgtgagctggatccggcagccccccaggaagggcctggaatg
gctgggcgtgatctggggcagcgagaccacctactacaacagcgccctgaagagccggctgaccatcatcaag
gacaacagcaagagccaggtgttcctgaagatgaacagcctgcagaccgacgacaccgccatctactactgcgc
caagcactactactacggcggcagctacgccatggactactggggccagggcaccagcgtgaccgtgagcagc
(CD19scFv) (SEQ ID NO:3)
Gaatctaagtacggaccgccctgccccccttgccct inge) (SEQ ID NO:4)
Atgttctgggtgctggtggtggtcggaggcgtgctggcctgctacagcctgctggtcaccgtggccttcatcatctt
ttgggtg m-)(SEQ ID NO:5)
Aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagagg
aagatggctgtagctgccgatttccagaagaagaagaaggaggatgtgaactg (41BB) (SEQ ID
NO:6)
Cgggtgaagttcagcagaagcgccgacgcccctgcctaccagcagggccagaatcagctgtacaacgagctga
acctgggcagaagggaagagtacgacgtcctggataagcggagaggccgggaccctgagatgggcggcaagc
ctcggcggaagaacccccaggaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcg
agatcggcatgaagggcgagcggaggcggggcaagggccacgacggcctgtatcagggcctgtccaccgcca
ccaaggatacctacgacgccctgcacatgcaggccctgcccccaagg (CD3Zeta)- (SEQ ID NO:7)
Ctcgagggcggcggagagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctagg
(T2A) (SEQ ID NO:9)
Atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccacgcaaagtgtg
aataggtattggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaaaactgc
acctccatcagtggcgatctccacatcctgccggtggcatttaggggtgactccttcacacatactcctcctctggat
ccacaggaactggatattctgaaaaccgtaaaggaaatcacagggtttttgctgattcaggcttggcctgaaaac
aggacggacctccatgcctttgagaacctagaaatcatacgcggcaggaccaagcaacatggtcagttttctctt
gcagtcgtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggagatgtgataattt
caggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaacc
aaaattataagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgctcccccga
gggctgctggggcccggagcccagggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggac
aagtgcaaccttctggagggtgagccaagggagtttgtggagaactctgagtgcatacagtgccacccagagtg
tcaggccatgaacatcacctgcacaggacggggaccagacaactgtatccagtgtgcccactacattga
cggcccccactgcgtcaagacctgcccggcaggagtcatgggagaaaacaacaccctggtctggaagtacgca
gacgccggccatgtgtgccacctgtgccatccaaactgcacctacggatgcactgggccaggtcttgaaggctgt
ccaacgaatgggcctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtggccc
tggggatcggcctcttcatgtga (EGFRt) (SEQ ID NO:9)
Table 2
GMCSFRss
DNA: ATGCTGCTGCTGGTGACCAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCC
AA: M L L L V T S L L L C E L P H P A
CD19scFv
DNA: TTTCTGCTGATCCCC:GACATCCAGATGACCCAGACCACCTCCAGCCTGAGC
AA: F L L I P D I Q M T Q T T S S L S
DNA: GCCAGCCTGGGCGACCGGGTGACCATCAGCTGCCGGGCCAGCCAGGACATC
AA: A S L G D R V T I S C R A S Q D I
DNA: AGCAAGTACCTGAACTGGTATCAGCAGAAGCCCGACGGCACCGTCAAGCTG
AA: S K Y L N W Y Q Q K P D G T V K L
DNA: CTGATCTACCACACCAGCCGGCTGCACAGCGGCGTGCCCAGCCGGTTTAGC
AA: L I Y H T S R L H S G V P S R F S
DNA: GGCAGCGGCTCCGGCACCGACTACAGCCTGACCATCTCCAACCTGGAACAG
AA: G S G S G T D Y S L T I S N L E Q
DNA: GAAGATATCGCCACCTACTTTTGCCAGCAGGGCAACACACTGCCCTACACC
AA: E D I A T Y F C Q Q G N T L P Y T
DNA: TTTGGCGGCGGAACAAAGCTGGAAATCACCGGCAGCACCTCCGGCAGCGGC
AA: F G G G T K L E I T G S T S G S G
DNA: AAGCCTGGCAGCGGCGAGGGCAGCACCAAGGGCGAGGTGAAGCTGCAGGAA
AA: K P G S G E G S T K G E V K L Q E
DNA: AGCGGCCCTGGCCTGGTGGCCCCCAGCCAGAGCCTGAGCGTGACCTGCACC
AA: S G P G L V A P S Q S L S V T C T
DNA: GTGAGCGGCGTGAGCCTGCCCGACTACGGCGTGAGCTGGATCCGGCAGCCC
AA: V S G V S L P D Y G V S W I R Q P
DNA: AAGGGCCTGGAATGGCTGGGCGTGATCTGGGGCAGCGAGACCACC
AA: P R K G L E W L G V I W G S E T T
40 DNA: TACTACAACAGCGCCCTGAAGAGCCGGCTGACCATCATCAAGGACAACAGC
AA: Y Y N S A L K S R L T I I K D N S
DNA: AAGAGCCAGGTGTTCCTGAAGATGAACAGCCTGCAGACCGACGACACCGCC
AA: K S Q V F L K M N S L Q T D D T A
DNA: ATCTACTACTGCGCCAAGCACTACTACTACGGCGGCAGCTACGCCATGGAC
AA: I Y Y C A K H Y Y Y G G S Y A M D
50 DNA: TACTGGGGCCAGGGCACCAGCGTGACCGTGAGCAGC:GAGAGCAAGTACGGA
AA: Y W G Q G T S V T V S S E S K Y G
CD28tm
DNA: CCGCCCTGCCCCCCTTGCCCT:ATGTTCTGGGTGCTGGTGGTGGTCGGAGGC
55 AA: P P C P P C P M F W V L V V V G G
DNA: GTGCTGGCCTGCTACAGCCTGCTGGTCACCGTGGCCTTCATCATCTTTTGG
AA: V L A C Y S L L V T V A F I I F W
41BB
DNA: GTG:AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATG
AA: V K R G R K K L L Y I F K Q P F M
DNA: AGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCA
AA: R P V Q T T Q E E D G C S C R F P
CD3Zeta
DNA: GAAGAAGAAGAAGGAGGATGTGAACTGCGGGTGAAG:TTCAGCAGAAGCGCC
AA: E E E E G G C E L R V K F S R S A
DNA: GACGCCCCTGCCTACCAGCAGGGCCAGAATCAGCTGTACAACGAGCTGAAC
AA: D A P A Y Q Q G Q N Q L Y N E L N
DNA: CTGGGCAGAAGGGAAGAGTACGACGTCCTGGATAAGCGGAGAGGCCGGGAC
AA: L G R R E E Y D V L D K R R G R D
DNA: CCTGAGATGGGCGGCAAGCCTCGGCGGAAGAACCCCCAGGAAGGCCTGTAT
AA: P E M G G K P R R K N P Q E G L Y
DNA: AACGAACTGCAGAAAGACAAGATGGCCGAGGCCTACAGCGAGATCGGCATG
AA: N E L Q K D K M A E A Y S E I G M
DNA: GAGCGGAGGCGGGGCAAGGGCCACGACGGCCTGTATCAGGGCCTG
AA: K G E R R R G K G H D G L Y Q G L
DNA: TCCACCGCCACCAAGGATACCTACGACGCCCTGCACATGCAGGCCCTGCCC
AA: S T A T K D T Y D A L H M Q A L P
DNA: CCAAGG:CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGT
AA: P R L E G G G E G R G S L L T C G
EGFRt
DNA: GACGTGGAGGAGAATCCCGGCCCTAGG:ATGCTTCTCCTGGTGACAAGCCTT
AA: D V E E N P G P R M L L L V T S L
DNA: CTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTGATCCCACGCAAAGTG
AA: L L C E L P H P A F L L I P R K V
DNA: TGTAACGGAATAGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCT
AA: C N G I G I G E F K D S L S I N A
DNA: ACGAATATTAAACACTTCAAAAACTGCACCTCCATCAGTGGCGATCTCCAC
45 AA: T N I K H F K N C T S I S G D L H
DNA: ATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATACTCCTCCTCTG
AA: I L P V A F R G D S F T H T P P L
DNA: GATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCACAGGGTTT
AA: D P Q E L D I L K T V K E I T G F
DNA: TTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTTGAG
AA: L L I Q A W P E N R T D L H A F E
DNA: AACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTT
AA: N L E I I R G R T K Q H G Q F S L
DNA: GCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAG
AA: A V V S L N I T S L G L R S L K E
DNA: ATAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCA
AA: I S D G D V I I S G N K N L C Y A
DNA: ATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAA
AA: N T I N W K K L F G T S G Q K T K
DNA: ATTATAAGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGC
AA: I I S N R G E N S C K A T G Q V C
DNA: CATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGC
AA: H A L C S P E G C W G P E P R D C
DNA: GTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC
AA: V S C R N V S R G R E C V D K C N
DNA: CTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAG
AA: L L E G E P R E F V E N S E C I Q
DNA: TGCCACCCAGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGG
AA: C H P E C L P Q A M N I T C T G R
DNA: GGACCAGACAACTGTATCCAGTGTGCCCACTACATTGACGGCCCCCACTGC
AA: G P D N C I Q C A H Y I D G P H C
DNA: GTCAAGACCTGCCCGGCAGGAGTCATGGGAGAAAACAACACCCTGGTCTGG
AA: V K T C P A G V M G E N N T L V W
DNA: AAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGCCATCCAAACTGCACC
AA: K Y A D A G H V C H L C H P N C T
DNA: TACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGGCCTAAG
45 AA: Y G C T G P G L E G C P T N G P K
DNA: ATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTG
AA: I P S I A T G M V G A L L L L L V
50 DNA: GTGGCCCTGGGGATCGGCCTCTTCATGTGA (SEQ ID NO:10)
AA: V A L G I G L F M * (SEQ ID NO:11)
Table 3
ZXR-014 Nucleotide and amino acid sequences (map of sections)
GMCSFRss: nt2084-2149
CD19scFv: nt2150-2884
Igg4Hinge: nt2885-2920
CD28tm: nt2921-3004
41BB: nt3005-3130
Zeta: nt3131-3466
T2A: nt3467-3538
EGFRt: nt3539-4612
Primers for sequencing:
Oligo name Sequence Region
oJ02649 AGAATAGACCGAGATAGGGT (SEQ ID NO:22)
oJ02648 CCGTACCTTTAAGACCAATGACTTAC delU3(SEQ ID NO:23)
oJ02650 GTTTTCGCCCCG mid-Ampr(SEQ ID NO:24)
oJ02651 AATAGACAGATCGCTGAGATAGGT post-Ampr(SEQ ID NO:25)
oJ02652 TCCGGTAAGCGG CoE1 ori(SEQ ID NO:26)
oJ02653 CGACCAGCAACCATAGTCC SV40(SEQ ID NO:27)
oJ02654 TAGCGGTTTGACTCACGG Q ID NO:28)
oJ02655 GCAGGGAGCTAGAACGATTC psi(SEQ ID NO:29)
oJ02656 ATTGTCTGGTATAGTGCAGCAG RRE(SEQ ID NO:30)
oJ02657 TCGCAACGGGTTTGCC EF1p(SEQ ID NO:31)
oJ02658 AGGAAGATATCGCCACCTACT CD19Rop(SEQ ID NO:32)
oJ02601 CGGGTGAAGTTCAGCAGAAG Zeta(SEQ ID NO:33)
oJ02735 ACTGTGTTTGCTGACGCAAC WPRE(SEQ ID NO:34)
oJ02715 ATGCTTCTCCTGGTGACAAG EGFRt(SEQ ID NO:35)
Table 4 Uniprot P0861 IgG4-Fc(SEQ ID NO:13)
20 30 40 50 60
ASTKGPSVFP STSE CLVK DYFPEPVTVS WNSGALTSGV LQSS
70 80 90 100 110 120
GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPSCP APEFLGGPSV
130 140 150 160 170 180
FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY
190 200 210 220 230 240
RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK
250 260 270 280 290 300
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG
310 320
NVFSCSVMHE ALHNHYTQKS LSLSLGK
1-98 CH1
99-110 Hinge
111-220 CH2
221-327 CH3
Position 108 S→P
Table 5 Uniprot P10747 CD28(SEQ ID NO:14)
20 30 40 50 60
MLRLLLALNL FPSIQVTGNK ILVKQSPMLV AYDNAVNLSC KYSYNLFSRE FRASLHKGLD
70 80 90 100 110 120
SAVEVCVVYG NYSQQLQVYS KTGFNCDGKL GNESVTFYLQ NLYVNQTDIY FCKIEVMYPP
130 140 150 160 170 180
PYLDNEKSNG TIIHVKGKHL PGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR
190 200 210 220
SKRSRLLHSD RRPG PTRKHYQPYA PPRDFAAYRS
1-18 signal peptide
19-152 extracellular domain
153-179 transmembrane domain
0 intracellular domain
Position 186-187 LL→GG
Table 6 Uniprot Q07011 SEQ ID NO:15)
20 30 40 50 60
MGNSCYNIVA TLLLVLNFER TRSLQDPCSN CPAGTFCDNN RNQICSPCPP NSFSSAGGQR
70 80 90 100 110 120
TCDICRQCKG VFRTRKECSS TSNAECDCTP GFHCLGAGCS MCEQDCKQGQ ELTKKGCKDC
130 140 150 160 170 180
CFGTFNDQKR GICRPWTNCS LDGKSVLVNG TKERDVVCGP SPADLSPGAS SVTPPAPARE
190 200 210 220 230 240
IISF FLALTSTALL FLLFFLTLRF SVVKRGRKKL LYIFKQPFMR PVQTTQEEDG
CSCRFPEEEE GGCEL
1-23 signal peptide
24-186 extracellular domain
3 transmembrane domain
214-255 intracellular domain
Table 7 Uniprot P20963 human CD3ζ isoform 3 (SEQ ID NO:16)
20 30 40 50 60
MKWKALFTAA ILQAQLPITE AQSFGLLDPK LCYLLDGILF IYGVILTALF RSAD
70 80 90 100 110 120
APAYQQGQNQ LYNELNLGRR EEYDVLDKRR GGKP QRRKNPQEGL YNELQKDKMA
130 140 150 160
EAYSEIGMKG ERRRGKGHDG LYQGLSTATK DTYDALHMQA LPPR
1-21 signal peptide
22-30 extracellular
31-51 transmembrane
52-164 intracellular domain
61-89 ITAM1
100-128 ITAM2
131-159 ITAM3
Table 8 Exemplary Hinge region Sequences
Human IgG1 EPKSCDKTHTCPPCP (SEQ ID NO:17)
Human IgG2 ERKCCVECPPCP (SEQ ID NO:18)
Human IgG3 ELKTPLGDTHTCPRCP (EPKSCDTPPPCPRCP)3 (SEQ ID NO:19)
Human IgG4 ESKYGPPCPSCP (SEQ ID NO:20)
Modified Human IgG4 ESKYGPPCPPCP (SEQ ID NO:21)
Modified Human IgG4 YGPPCPPCP (SEQ ID NO:51)
ed Human IgG4 KYGPPCPPCP (SEQ ID NO:52)
Modified Human IgG4 EVVKYGPPCPPCP (SEQ ID NO:53)
Table 9
R12 long spacer CAR: PJ_R12-CH2-CH3-41BB-Z-T2A-tEGFR (SEQ ID NO:37)
GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT
TCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG
TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC
TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG
CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG
GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA
GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA
AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG
CAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA
CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA
GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG
CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA
AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA
CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA
AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT
AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA
AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC
AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA
GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC
TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG
ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG
CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC
AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA
GGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT
TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG
GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA
ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC
AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG
GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA
GTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG
GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT
GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT
GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG
CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA
GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC
TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC
40 CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT
GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT
TACAGATCCAAGCTGTGACCGGCGCCTACG
GCTAGC GAATTCCTCGAGGCC
ACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCC
45 TTTCTGCTGATCCCCCAGGAACAGCTCGTCGAAAGCGGCGGCAGACTGGTGACA
CCTGGCGGCAGCCTGACCCTGAGCTGCAAGGCCAGCGGCTTCGACTTCAGCGCC
TACTACATGAGCTGGGTCCGCCAGGCCCCTGGCAAGGGACTGGAATGGATCGCC
ACCATCTACCCCAGCAGCGGCAAGACCTACTACGCCACCTGGGTGAACGGACG
GTTCACCATCTCCAGCGACAACGCCCAGAACACCGTGGACCTGCAGATGAACA
GCCTGACAGCCGCCGACCGGGCCACCTACTTTTGCGCCAGAGACAGCTACGCCG
ACGACGGCGCCCTGTTCAACATCTGGGGCCCTGGCACCCTGGTGACAATCTCTA
GCGGCGGAGGCGGATCTGGTGGCGGAGGAAGTGGCGGCGGAGGATCTGAGCTG
GTGCTGACCCAGAGCCCCTCTGTGTCTGCTGCCCTGGGAAGCCCTGCCAAGATC
ACCTGTACCCTGAGCAGCGCCCACAAGACCGACACCATCGACTGGTATCAGCA
GCTGCAGGGCGAGGCCCCCAGATACCTGATGCAGGTGCAGAGCGACGGCAGCT
ACACCAAGAGGCCAGGCGTGCCCGACCGGTTCAGCGGATCTAGCTCTGGCGCC
GACCGCTACCTGATCATCCCCAGCGTGCAGGCCGATGACGAGGCCGATTACTAC
GCCGACTACATCGGCGGCTACGTGTTCGGCGGAGGCACCCAGCTGACC
GTGACCGGCGAGTCTAAG
IgG4 spacer
TA CGGACCGCCCTGCCCCCCTTGCCCT
GCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAG
CTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTG
AGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGT
CGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG
TGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACA
AGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGC
AAGGCCAAG
GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG
ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC
CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT
GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG
AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG
4-1BB
ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG
GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG
TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT
GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
CD3 zeta
CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA
TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG
ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC
40 CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA
CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC
CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG
CAGGCCCTGCCCCCAAGG
45 CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA
GGAGAATCCCGGCCCTAGG
tEGFR
ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC
TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT
CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA
GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA
CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA
CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT
TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC
TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA
TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA
CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA
AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT
GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG
GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG
AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC
CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA
GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT
GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA
AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG
GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA
GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC
AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC
TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT
CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT
GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT
GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG
GCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG
CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT
AATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT
GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT
GGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC
AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG
CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT
AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC
TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT
CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT
GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT
CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT
40 CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG
CCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA
TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG
CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT
AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT
45 CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT
CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA
GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG
GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG
ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA
GCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC
ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG
GCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT
CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG
AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA
TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT
CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT
CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT
CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA
AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC
ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG
TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA
TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA
CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG
GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT
GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA
TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC
ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG
AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG
CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG
GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG
GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG
ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA
GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
GAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA
AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC
ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
40 GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT
GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT
GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA
GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT
TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT
45 TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA
CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA
TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA
ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA
TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG
GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA
TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT
CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC
TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT
CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC
AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
CAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC
ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT
ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA
TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA
CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG
AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG
Table 10
Leader _R12- Hinge-CH2-CH3- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:38)
Leader
MLLLVTSLLLCELPHPAFLLIP
R12 scFv
QEQLVESGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGKGLEWIATIYPSSG
KTYYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGALFNI
VTISSGGGGSGGGGSGGGGSELVLTQSPSVSAALGSPAKITCTLSSAHKTD
QLQGEAPRYLMQVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDE
ADYYCGADYIGGYVFGGGTQLTVTG
Hinge Spacer
ESKYGPPCPPCP
APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHN
AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK
CD28
MFWVLVVVGGVLACYSLLVTVAFIIFWV
4-1BB
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
CD3 zeta
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP
QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
LEGGGEGRGSLLTCGDVEENPGPR
tEGFR
MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI
LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT
KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK
TKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE
GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL
LLLVVALGIGLFM
Table 11
R12 intermediate spacer CAR: PJ_R12-CH3-41BB-Z-T2A-tEGFR (SEQ ID NO:39)
CCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT
TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG
TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC
TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG
CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG
GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA
GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA
AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG
TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA
CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA
GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG
CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA
AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA
CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA
ACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT
AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA
AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC
AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA
GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC
TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG
ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG
CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC
AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA
GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT
TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG
GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA
ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC
AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG
GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA
GTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG
GAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT
GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT
GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG
CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA
CATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC
TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC
40 CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT
GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT
TACAGATCCAAGCTGTGACCGGCGCCTACG
GCTAGCGAATTCCTCGAGGCC
R12 ScFv
45 ACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCC
TTTCTGCTGATCCCCCAGGAACAGCTCGTCGAAAGCGGCGGCAGACTGGTGACA
CCTGGCGGCAGCCTGACCCTGAGCTGCAAGGCCAGCGGCTTCGACTTCAGCGCC
ATGAGCTGGGTCCGCCAGGCCCCTGGCAAGGGACTGGAATGGATCGCC
ACCATCTACCCCAGCAGCGGCAAGACCTACTACGCCACCTGGGTGAACGGACG
GTTCACCATCTCCAGCGACAACGCCCAGAACACCGTGGACCTGCAGATGAACA
GCCTGACAGCCGCCGACCGGGCCACCTACTTTTGCGCCAGAGACAGCTACGCCG
ACGACGGCGCCCTGTTCAACATCTGGGGCCCTGGCACCCTGGTGACAATCTCTA
GCGGCGGAGGCGGATCTGGTGGCGGAGGAAGTGGCGGCGGAGGATCTGAGCTG
GTGCTGACCCAGAGCCCCTCTGTGTCTGCTGCCCTGGGAAGCCCTGCCAAGATC
ACCTGTACCCTGAGCAGCGCCCACAAGACCGACACCATCGACTGGTATCAGCA
GCTGCAGGGCGAGGCCCCCAGATACCTGATGCAGGTGCAGAGCGACGGCAGCT
ACACCAAGAGGCCAGGCGTGCCCGACCGGTTCAGCGGATCTAGCTCTGGCGCC
GACCGCTACCTGATCATCCCCAGCGTGCAGGCCGATGACGAGGCCGATTACTAC
TGTGGCGCCGACTACATCGGCGGCTACGTGTTCGGCGGAGGCACCCAGCTGACC
GTGACCGGCGAGTCTAAG
Hinge Spacer
TA GCCCTGCCCCCCTTGCCCT
GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG
ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC
CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT
GAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG
AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG
4-1BB
ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG
GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG
TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT
GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
CD3zeta
CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA
TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG
ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC
CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA
CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC
CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG
CAGGCCCTGCCCCCAAGG
CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA
GGAGAATCCCGGCCCTAGG
40 tEGFR
ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC
TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT
CCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA
GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA
45 CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA
CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT
TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC
TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA
TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA
CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA
AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT
GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG
GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG
AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC
CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA
GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT
GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA
AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG
GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA
GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC
AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC
TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT
CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT
TTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT
ACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG
ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG
GCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT
CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT
GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT
TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC
AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG
CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT
AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC
TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT
CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT
GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT
CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT
CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG
GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA
TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG
CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT
AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT
CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT
40 CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA
GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG
GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG
ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA
GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC
45 ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT
CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG
AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA
TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT
CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT
CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT
CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA
AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC
ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG
TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA
TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA
CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG
GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT
GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA
TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC
ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG
AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG
CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG
GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG
GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG
ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA
AGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA
AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC
ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT
GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT
TTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA
GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT
TTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT
TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA
CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA
40 TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA
ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA
TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG
GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA
TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT
45 CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC
TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT
CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC
AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
CAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC
ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT
ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA
TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA
CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG
AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG
Table 12
Leader _R12- Hinge- CH3- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:40)
Leader
MLLLVTSLLLCELPHPAFLLIP
R12 scFV
SGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGKGLEWIATIYPSSG
KTYYATWVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGALFNI
WGPGTLVTISSGGGGSGGGGSGGGGSELVLTQSPSVSAALGSPAKITCTLSSAHKTD
TIDWYQQLQGEAPRYLMQVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDE
ADYYCGADYIGGYVFGGGTQLTVTG
Hinge Spacer
ESKYGPPCPPCP
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK
CD28tm
MFWVLVVVGGVLACYSLLVTVAFIIFWV
4-1BB
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
CD3 zeta
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP
QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
GRGSLLTCGDVEENPGPR
tEGFR
MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI
LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT
KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK
TKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE
GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL
LLLVVALGIGLFM
Table 13
R12 short spacer CAR: PJ_R12-Hinge-41BB-Z-T2A-tEGFR (SEQ ID NO:41)
GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT
TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG
TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC
AGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG
CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG
GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA
GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA
AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG
TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA
CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA
GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG
AGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA
AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA
CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA
AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT
GAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA
AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC
AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA
GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC
TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG
ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG
CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC
AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA
GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT
TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG
GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA
ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC
AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG
GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA
GTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG
GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT
GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT
GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG
CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA
GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC
TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC
CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT
40 GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT
TACAGATCCAAGCTGTGACCGGCGCCTACG
GCTAGF
R12 scFV
ACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCCCACCCCGCC
45 TTTCTGCTGATCCCCCAGGAACAGCTCGTCGAAAGCGGCGGCAGACTGGTGACA
CCTGGCGGCAGCCTGACCCTGAGCTGCAAGGCCAGCGGCTTCGACTTCAGCGCC
ATGAGCTGGGTCCGCCAGGCCCCTGGCAAGGGACTGGAATGGATCGCC
ACCATCTACCCCAGCAGCGGCAAGACCTACTACGCCACCTGGGTGAACGGACG
GTTCACCATCTCCAGCGACAACGCCCAGAACACCGTGGACCTGCAGATGAACA
GCCTGACAGCCGCCGACCGGGCCACCTACTTTTGCGCCAGAGACAGCTACGCCG
ACGACGGCGCCCTGTTCAACATCTGGGGCCCTGGCACCCTGGTGACAATCTCTA
GCGGCGGAGGCGGATCTGGTGGCGGAGGAAGTGGCGGCGGAGGATCTGAGCTG
ACCCAGAGCCCCTCTGTGTCTGCTGCCCTGGGAAGCCCTGCCAAGATC
ACCTGTACCCTGAGCAGCGCCCACAAGACCGACACCATCGACTGGTATCAGCA
GCTGCAGGGCGAGGCCCCCAGATACCTGATGCAGGTGCAGAGCGACGGCAGCT
ACACCAAGAGGCCAGGCGTGCCCGACCGGTTCAGCGGATCTAGCTCTGGCGCC
GACCGCTACCTGATCATCCCCAGCGTGCAGGCCGATGACGAGGCCGATTACTAC
TGTGGCGCCGACTACATCGGCGGCTACGTGTTCGGCGGAGGCACCCAGCTGACC
GTGACCGGCGAGTCTAAG
Hinge/Spacer
TA CGGACCGCCCTGCCCCCCTTGCCCT
4-1BB
ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG
GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG
TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT
GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
CD3 zeta
CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA
TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG
ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC
CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA
CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC
CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG
CAGGCCCTGCCCCCAAGG
CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA
GGAGAATCCCGGCCCTAGG
tEGFR
ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC
TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT
CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA
ATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA
CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA
CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT
ACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC
40 TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA
TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA
CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA
AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT
GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG
45 GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG
AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC
CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA
GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT
CCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA
AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG
GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA
GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC
AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC
TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT
CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT
GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT
GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG
ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG
CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT
CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT
GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT
TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC
AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG
CTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT
AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC
TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT
CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT
AGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT
CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT
CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG
GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA
TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG
CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT
AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT
CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT
CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA
GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG
GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG
ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA
GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC
ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT
CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG
40 AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA
TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT
CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT
CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT
45 ATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA
AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC
ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG
TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA
TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA
CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG
GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT
GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA
TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC
ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG
AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG
TTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG
GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG
GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG
ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA
GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
GAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA
AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC
TCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT
GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT
GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA
GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT
TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT
TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA
CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA
TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA
ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA
TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG
GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA
TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT
CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC
TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT
CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC
40 AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC
ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT
ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA
45 TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA
CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG
AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG
Table 14
Leader _R12 - CD28tm/41BB-Z-T2A-tEGFR(SEQ ID NO:42)
Leader
MLLLVTSLLLCELPHPAFLLIP
scFv R12
QEQLVESGGRLVTPGGSLTLSCKASGFDFSAYYMSWVRQAPGKGLEWIATIYPSSG
WVNGRFTISSDNAQNTVDLQMNSLTAADRATYFCARDSYADDGALFNI
WGPGTLVTISSGGGGSGGGGSGGGGSELVLTQSPSVSAALGSPAKITCTLSSAHKTD
TIDWYQQLQGEAPRYLMQVQSDGSYTKRPGVPDRFSGSSSGADRYLIIPSVQADDE
ADYYCGADYIGGYVFGGGTQLTVTG
Hinge/spacer
ESKYGPPCPPCP
CD28tm
MFWVLVVVGGVLACYSLLVTVAFIIFWV
4-1BB
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
CD3zeta
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP
QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
LEGGGEGRGSLLTCGDVEENPGPR
tEGFR
MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI
LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT
KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK
RGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE
GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL
LLLVVALGIGLFM
Table 15
R11 long spacer CAR: PJ_R11-CH2-CH3-41BB-Z-T2A-tEGFR (SEQ ID NO:43)
GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT
TCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG
TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC
TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG
CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG
ACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA
GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA
AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG
TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA
CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA
GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG
CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA
AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA
AATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA
AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT
AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA
AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC
AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA
GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC
TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG
ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG
CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC
AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA
GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT
TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG
GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA
ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC
AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG
GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA
GTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG
GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT
GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT
GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG
CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA
GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC
TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC
40 CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT
GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT
TACAGATCCAAGCTGTGACCGGCGCCTACG
GCTAGC
scFv R12
45 GAATTCGCCACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCC
CACCCCGCCTTTCTGCTGATCCCCCAGAGCGTGAAAGAGTCCGAGGGCGACCTG
GTCACACCAGCCGGCAACCTGACCCTGACCTGTACCGCCAGCGGCAGCGACATC
AACGACTACCCCATCTCTTGGGTCCGCCAGGCTCCTGGCAAGGGACTGGAATGG
ATCGGCTTCATCAACAGCGGCGGCAGCACTTGGTACGCCAGCTGGGTCAAAGGC
CGGTTCACCATCAGCCGGACCAGCACCACCGTGGACCTGAAGATGACAAGCCT
GACCACCGACGACACCGCCACCTACTTTTGCGCCAGAGGCTACAGCACCTACTA
CGGCGACTTCAACATCTGGGGCCCTGGCACCCTGGTCACAATCTCTAGCGGCGG
AGGCGGCAGCGGAGGTGGAGGAAGTGGCGGCGGAGGATCCGAGCTGGTCATGA
CCCAGACCCCCAGCAGCACATCTGGCGCCGTGGGCGGCACCGTGACCATCAATT
GCCAGGCCAGCCAGAGCATCGACAGCAACCTGGCCTGGTTCCAGCAGAAGCCC
GGCCAGCCCCCCACCCTGCTGATCTACAGAGCCTCCAACCTGGCCAGCGGCGTG
CCAAGCAGATTCAGCGGCAGCAGATCTGGCACCGAGTACACCCTGACCATCTCC
GGCGTGCAGAGAGAGGACGCCGCTACCTATTACTGCCTGGGCGGCGTGGGCAA
CGTGTCCTACAGAACCAGCTTCGGCGGAGGTACTGAGGTGGTCGTCAAA
Hinge/Spacer
TA CGGACCGCCCTGCCCCCCTTGCCCT
GAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAG
CTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTG
AGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGT
CGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG
TGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACA
AGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGC
GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG
ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC
CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT
GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG
AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG
4-1BB
ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG
GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG
TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT
GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
CD3zeta
CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA
TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG
ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC
40 CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA
CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC
CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG
CAGGCCCTGCCCCCAAGG
45 CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA
GGAGAATCCCGGCCCTAGG
tEGFR
CTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC
TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT
CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA
GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA
CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA
CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT
TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC
TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA
TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA
CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA
AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT
GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG
GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG
AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC
CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA
GGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT
GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA
TCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG
GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA
GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC
AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC
TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT
CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT
GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT
GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG
ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG
CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT
CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT
GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT
TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC
AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG
CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT
AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC
TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT
CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT
GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
TTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT
40 CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT
CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG
GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA
TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG
CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT
45 AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT
CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT
CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA
GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG
GTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG
ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA
GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC
CGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT
CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG
AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA
TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT
CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT
CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT
CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA
AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC
ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG
TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA
TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA
CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG
GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
CCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT
GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA
TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC
ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG
AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG
CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG
GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG
GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG
ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA
GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA
AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC
40 ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT
GGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT
GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA
GCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT
45 TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT
TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA
CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA
TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA
ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA
TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG
GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA
ACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT
CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC
TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT
CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC
AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC
ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT
ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA
TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA
CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG
AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG
Table 16
Leader _R11- Hinge-CH2-CH3- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:44)
Leader
SLLLCELPHPAFLLIP
R11 scFv
QSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPGKGLEWIGFINSGGSTW
YASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFNIWGPGTLVT
ISSGGGGSGGGGSGGGGSELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQ
KPGQPPTLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNV
SYRTSFGGGTEVVVK
Hinge/Spacer
ESKYGPPCPPCP
APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHN
AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
SFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK
CD28tm
MFWVLVVVGGVLACYSLLVTVAFIIFWV
4-1BB
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
CD3zeta
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP
QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
LEGGGEGRGSLLTCGDVEENPGPR
tEGFR
MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI
LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT
KQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK
TKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE
GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL
LLLVVALGIGLFM
Table 17
R11 intermediate spacer CAR: PJ_R11-CH3-41BB-Z-T2A-tEGFR (SEQ ID NO:45)
CCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT
TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG
TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC
AGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG
CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG
GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA
GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA
AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG
TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA
CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA
GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG
CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA
AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA
CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA
AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT
AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA
AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC
AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA
GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC
TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG
ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG
CTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC
AAGCAGCTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA
GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT
TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG
GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA
ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC
AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG
GTTAGGCGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA
AGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG
GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT
GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT
GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG
CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA
GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC
ACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC
40 CTTTGTCCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT
GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT
TACAGATCCAAGCTGTGACCGGCGCCTACG
GCTAGC
R11 scFV
45 GAATTCGCCACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCC
CACCCCGCCTTTCTGCTGATCCCCCAGAGCGTGAAAGAGTCCGAGGGCGACCTG
GTCACACCAGCCGGCAACCTGACCCTGACCTGTACCGCCAGCGGCAGCGACATC
AACGACTACCCCATCTCTTGGGTCCGCCAGGCTCCTGGCAAGGGACTGGAATGG
ATCGGCTTCATCAACAGCGGCGGCAGCACTTGGTACGCCAGCTGGGTCAAAGGC
CGGTTCACCATCAGCCGGACCAGCACCACCGTGGACCTGAAGATGACAAGCCT
GACCACCGACGACACCGCCACCTACTTTTGCGCCAGAGGCTACAGCACCTACTA
CGGCGACTTCAACATCTGGGGCCCTGGCACCCTGGTCACAATCTCTAGCGGCGG
AGGCGGCAGCGGAGGTGGAGGAAGTGGCGGCGGAGGATCCGAGCTGGTCATGA
CCCCCAGCAGCACATCTGGCGCCGTGGGCGGCACCGTGACCATCAATT
CCAGCCAGAGCATCGACAGCAACCTGGCCTGGTTCCAGCAGAAGCCC
GGCCAGCCCCCCACCCTGCTGATCTACAGAGCCTCCAACCTGGCCAGCGGCGTG
CCAAGCAGATTCAGCGGCAGCAGATCTGGCACCGAGTACACCCTGACCATCTCC
GGCGTGCAGAGAGAGGACGCCGCTACCTATTACTGCCTGGGCGGCGTGGGCAA
CGTGTCCTACAGAACCAGCTTCGGCGGAGGTACTGAGGTGGTCGTCAAA
Hinge/spacer
TAGGACCGCCCTGC TGCCCT
GCCCCCGAGTTCCTGGGCGGACCCAGCGTGTTCCTGTTCCCCCCCAAGCCCAAG
GACACCCTGATGATCAGCCGGACCCCCGAGGTGACCTGCGTGGTGGTGGACGTG
AGCCAGGAAGATCCCGAGGTCCAGTTCAATTGGTACGTGGACGGCGTGGAAGT
GCACAACGCCAAGACCAAGCCCAGAGAGGAACAGTTCAACAGCACCTACCGGG
TGGTGTCTGTGCTGACCGTGCTGCACCAGGACTGGCTGAACGGCAAAGAATACA
AGTGCAAGGTGTCCAACAAGGGCCTGCCCAGCAGCATCGAAAAGACCATCAGC
AAGGCCAAG
CH3
GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG
ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC
CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT
GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG
AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG
4-1BB
ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG
GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG
TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT
GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
CD3zeta
CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA
TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG
40 ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC
CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA
CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC
CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG
CAGGCCCTGCCCCCAAGG
45 T2A
GGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA
GGAGAATCCCGGCCCTAGG
tEGFR
ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC
TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT
CACTCTCCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA
GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA
CTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA
CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT
TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC
TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA
TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA
CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA
AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT
GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG
GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG
AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC
CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA
GGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT
GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA
AGGCTGTCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG
CCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA
GCGGCCGCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC
AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC
TACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT
CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT
TTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT
GACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG
ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG
CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT
CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT
GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT
TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC
AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG
CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT
AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC
TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT
CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT
GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT
40 CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT
CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG
GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA
TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG
CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT
45 AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT
CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT
CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA
GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG
TAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG
ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA
GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC
ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG
AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT
CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG
AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA
TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT
CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT
TGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT
CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA
AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC
ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG
TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA
TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA
CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG
GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG
AGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT
CCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA
TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC
ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG
AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG
CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
CTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG
GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG
GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG
ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA
GCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
TGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA
AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC
40 ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT
GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT
GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA
GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT
45 TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT
TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA
CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA
TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA
ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA
TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG
GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA
TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT
CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC
TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT
TGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC
AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC
ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT
ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
TGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA
TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA
CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG
AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG
Table 18
Leader _R11- CH3- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:46)
Leader
MLLLVTSLLLCELPHPAFLLIP
scFV R11
QSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPGKGLEWIGFINSGGSTW
YASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFNIWGPGTLVT
ISSGGGGSGGGGSGGGGSELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQ
KPGQPPTLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNV
SYRTSFGGGTEVVVK
Hinge/spacer
ESKYGPPCPPCP
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK
CD28tm
MFWVLVVVGGVLACYSLLVTVAFIIFWV
4-1BB
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
CD3zeta
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP
QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
LEGGGEGRGSLLTCGDVEENPGPRM
tEGFR
LLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHIL
PVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTK
QHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKT
KIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEG
ENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMG
ENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLL
LLVVALGIGLFM
Table 19
R11 short spacer CAR: PJ_R11- 41BB-Z-T2A-tEGFR(SEQ ID NO:47)
GTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCT
TAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG
TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATC
TCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGAAACCAGAGGAG
CTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGAGGG
GCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGA
GAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGATGGGA
AAAAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAG
TATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAA
CATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACA
GGATCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTG
CATCAAAGGATAGAGATAAAAGACACCAAGGAAGCTTTAGACAAGATAGAGGA
AGAGCAAAACAAAAGTAAGAAAAAAGCACAGCAAGCAGCAGCTGACACAGGA
CACAGCAATCAGGTCAGCCAAAATTACCCTATAGTGCAGAACATCCAGGGGCA
AATGGTACATCAGGCCATATCACCTAGAACTTTAAATGCATGGGTAAAAGTAGT
AGAAGAGAAGGCTTTCAGCCCAGAAGTGATACCCATGTTTTCAGCATTATCAGA
AGGAGCCACCCCACAAGATTTAAACACCATGCTAAACACAGTGGGGGGACATC
AAGCAGCCATGCAAATGTTAAAAGAGACCATCAATGAGGAAGCTGCAGGCAAA
GAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTTGTTCC
TTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG
ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTG
GCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATC
CTCCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACA
GCTCCTGGGGATTTGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCT
TGGATCTACAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTG
GGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAA
ACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTTATTAC
AGGGACAGCAGAGATCCAGTTTGGGGATCAATTGCATGAAGAATCTGCTTAGG
CGTTTTGCGCTGCTTCGCGAGGATCTGCGATCGCTCCGGTGCCCGTCA
GTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCG
GCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGAT
GTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGT
GCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAG
CTGAAGCTTCGAGGGGCTCGCATCTCTCCTTCACGCGCCCGCCGCCCTACCTGA
GGCCGCCATCCACGCCGGTTGAGTCGCGTTCTGCCGCCTCCCGCCTGTGGTGCC
TCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCGAGACCGGGC
40 CCGGCGCTCCCTTGGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTT
GCCTGACCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGT
TACAGATCCAAGCTGTGACCGGCGCCTACG
GCTAGC
scFV R11
45 GAATTCGCCACCATGCTGCTGCTGGTGACAAGCCTGCTGCTGTGCGAGCTGCCC
CACCCCGCCTTTCTGCTGATCCCCCAGAGCGTGAAAGAGTCCGAGGGCGACCTG
GTCACACCAGCCGGCAACCTGACCCTGACCTGTACCGCCAGCGGCAGCGACATC
AACGACTACCCCATCTCTTGGGTCCGCCAGGCTCCTGGCAAGGGACTGGAATGG
ATCGGCTTCATCAACAGCGGCGGCAGCACTTGGTACGCCAGCTGGGTCAAAGGC
CGGTTCACCATCAGCCGGACCAGCACCACCGTGGACCTGAAGATGACAAGCCT
GACCACCGACGACACCGCCACCTACTTTTGCGCCAGAGGCTACAGCACCTACTA
CGGCGACTTCAACATCTGGGGCCCTGGCACCCTGGTCACAATCTCTAGCGGCGG
AGGCGGCAGCGGAGGTGGAGGAAGTGGCGGCGGAGGATCCGAGCTGGTCATGA
CCCAGACCCCCAGCAGCACATCTGGCGCCGTGGGCGGCACCGTGACCATCAATT
GCCAGGCCAGCCAGAGCATCGACAGCAACCTGGCCTGGTTCCAGCAGAAGCCC
GGCCAGCCCCCCACCCTGCTGATCTACAGAGCCTCCAACCTGGCCAGCGGCGTG
AGATTCAGCGGCAGCAGATCTGGCACCGAGTACACCCTGACCATCTCC
GGCGTGCAGAGAGAGGACGCCGCTACCTATTACTGCCTGGGCGGCGTGGGCAA
CGTGTCCTACAGAACCAGCTTCGGCGGAGGTACTGAGGTGGTCGTCAAA
Hinge/spacer
TACGGACCGCCCTGCCCCCCTTGCCCT
GGCCAGCCTCGCGAGCCCCAGGTGTACACCCTGCCTCCCTCCCAGGAAGAGATG
ACCAAGAACCAGGTGTCCCTGACCTGCCTGGTGAAGGGCTTCTACCCCAGCGAC
ATCGCCGTGGAGTGGGAGAGCAACGGCCAGCCTGAGAACAACTACAAGACCAC
CCCTCCCGTGCTGGACAGCGACGGCAGCTTCTTCCTGTACAGCCGGCTGACCGT
GGACAAGAGCCGGTGGCAGGAAGGCAACGTCTTTAGCTGCAGCGTGATGCACG
AGGCCCTGCACAACCACTACACCCAGAAGAGCCTGAGCCTGTCCCTGGGCAAG
4-1BB
ATGTTCTGGGTGCTGGTGGTGGTGGGCGGGGTGCTGGCCTGCTACAGCCTGCTG
GTGACAGTGGCCTTCATCATCTTTTGGGTGAAACGGGGCAGAAAGAAACTCCTG
TATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGAT
GGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
CD3zeta
CGGGTGAAGTTCAGCAGAAGCGCCGACGCCCCTGCCTACCAGCAGGGCCAGAA
TCAGCTGTACAACGAGCTGAACCTGGGCAGAAGGGAAGAGTACGACGTCCTGG
ATAAGCGGAGAGGCCGGGACCCTGAGATGGGCGGCAAGCCTCGGCGGAAGAAC
CCCCAGGAAGGCCTGTATAACGAACTGCAGAAAGACAAGATGGCCGAGGCCTA
CAGCGAGATCGGCATGAAGGGCGAGCGGAGGCGGGGCAAGGGCCACGACGGC
CTGTATCAGGGCCTGTCCACCGCCACCAAGGATACCTACGACGCCCTGCACATG
CTGCCCCCAAGG
CTCGAGGGCGGCGGAGAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGA
GGAGAATCCCGGCCCTAGG
tEGFR
40 ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCC
TCCTGATCCCACGCAAAGTGTGTAACGGAATAGGTATTGGTGAATTTAAAGACT
CCATAAATGCTACGAATATTAAACACTTCAAAAACTGCACCTCCATCA
GTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCCTTCACACATA
CTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAAATCA
45 CAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCT
TTGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTC
TTGCAGTCGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGA
TAAGTGATGGAGATGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATA
CAATAAACTGGAAAAAACTGTTTGGGACCTCCGGTCAGAAAACCAAAATTATA
AGCAACAGAGGTGAAAACAGCTGCAAGGCCACAGGCCAGGTCTGCCATGCCTT
GTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCCAGGGACTGCGTCTCTTGCCG
GAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAACCTTCTGGAGGGTG
AGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCAGAGTGC
CTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC
CAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGA
GTCATGGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGT
GTGCCACCTGTGCCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGA
TCCAACGAATGGGCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGG
GGCCCTCCTCTTGCTGCTGGTGGTGGCCCTGGGGATCGGCCTCTTCATGTGA
GCTCTAGACCCGGGCTGCAGGAATTCGATATCAAGCTTATCGATAATC
AACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGC
TCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTT
CCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTAT
GAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCT
ACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGG
ACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTG
CCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGT
CGGGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCT
GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCT
TCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTC
AGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCGATACCGTCGACTAG
CCGTACCTTTAAGACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTT
AAAAGAAAAGGGGGGACTGGAAGGGCTAATTCACTCCCAAAGAAGACAAGATC
TGCTTTTTGCCTGTACTGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCT
CTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGT
GCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTC
AGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGAATTCGATATCAAGCTTAT
CGATACCGTCGACCTCGAGGGGGGGCCCGGTACCCAATTCGCCCTATAGTGAGT
CGTATTACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTG
GCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAA
TAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGG
CGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTT
AAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAAT
CAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT
CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCA
40 GGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAG
TAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTG
ACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGA
GCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGCGTAACCACCAC
ACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTTCGGGG
45 AAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT
CCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAG
AGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA
TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGAT
CCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAAAGTT
CTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGT
CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAA
AAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACC
ATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAA
GGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCG
TTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGA
TGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTA
CTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAG
GACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGG
TGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAA
GCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGA
ACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACT
GTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAA
TTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTT
AACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGAT
CTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACC
ACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCG
AAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAG
CCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCT
ATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCG
GGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACG
GGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAG
ATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGG
CGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGA
AGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTC
GAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAA
AACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTC
ACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTT
GAGTGAGCTGATACCGCTCGCCGCAGCCGAACGACCGAGCGCAGCGAGTCAGT
GAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT
GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCA
GTGAGCGCAACGCAATTAATGTGAGTTAGCTCACTCATTAGGCACCCCAGGCTT
TACACTTTATGCTTCCGGCTCGTATGTTGTGTGGAATTGTGAGCGGATAACAATT
TCACACAGGAAACAGCTATGACCATGATTACGCCAAGCTCGAAATTAACCCTCA
CTAAAGGGAACAAAAGCTGGAGCTCCACCGCGGTGGCGGCCTCGAGGTCGAGA
TCCGGTCGACCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTA
40 ACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTA
TGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAGTAGTGAGGAG
GCTTTTTTGGAGGCCTAGGCTTTTGCAAAAAGCTTCGACGGTATCGATTGGCTCA
TGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAAT
CAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC
45 TTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGT
CAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTC
AATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATC
ATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGC
ATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGT
ATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCG
GCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA
TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAA
CTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGAATTCGGAGTGGCG
AGCCCTCAGATCCTGCATATAAGCAGCTGCTTTTTGCCTGTACTGGGTCTCTCTG
Table 20
Leader _R11- Hinge- CD28tm/41BB-Z-T2A-tEGFR (SEQ ID NO:48)
Leader
MLLLVTSLLLCELPHPAFLLIP
ScFv R11
QSVKESEGDLVTPAGNLTLTCTASGSDINDYPISWVRQAPGKGLEWIGFINSGGSTW
YASWVKGRFTISRTSTTVDLKMTSLTTDDTATYFCARGYSTYYGDFNIWGPGTLVT
ISSGGGGSGGGGSGGGGSELVMTQTPSSTSGAVGGTVTINCQASQSIDSNLAWFQQ
KPGQPPTLLIYRASNLASGVPSRFSGSRSGTEYTLTISGVQREDAATYYCLGGVGNV
SYRTSFGGGTEVVVK
Spacer/Hinge
PCPPCP
CD28tm
MFWVLVVVGGVLACYSLLVTVAFIIFWV
4-1BB
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
CD3zeta
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP
QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ
ALPPR
LEGGGEGRGSLLTCGDVEENPGPR
tEGFR
MLLLVTSLLLCELPHPAFLLIPRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHI
LPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRT
SLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQK
TKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLE
GEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALL
LLLVVALGIGLFM
Table 21
Intermediate Spacer (SEQ ID NO:49)
Hinge/spacer
PCPPCP
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK
Long spacer (SEQ ID NO:50)
Hinge
ESKYGPPCPPCP
APEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWY VDGVEVHN
AKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAK
GQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPP
VLDSDGSFFLYSRLTVDKSRWQE GNVFSCSVMHEALHNHYTQKSLSLSLGK
Table 22 Her2 uct-short spacer (SEQ Id No:54 )
GMCSFss-Her2scFv-IgG4hinge-CD28tm-41BB-Zeta-T2A-EGFRt
Leader
Atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatccca
Her2scFV
gatatccagatgacccagtccccgagctccctgtccgcctctgtgggcgatagggtcaccatcacctgccgtgccagtcaggatgtg
aatactgctgtagcctggtatcaacagaaaccaggaaaagctccgaaactactgatttactcggcatccttcctctactctggagtccct
tctcgcttctctggttccagatctgggacggatttcactctgaccatcagcagtctgcagccggaagacttcgcaacttattactgtcag
caacattatactactcctcccacgttcggacagggtaccaaggtggagatcaaaggcagtactagcggcggtggctccgggggcg
gatccggtgggggcggcagcagcgaggttcagctggtggagtctggcggtggcctggtgcagccagggggctcactccgtttgtc
agcttctggcttcaacattaaagacacctatatacactgggtgcgtcaggccccgggtaagggcctggaatgggttgcaag
gatttatcctacgaatggttatactagatatgccgatagcgtcaagggccgtttcactataagcgcagacacatccaaaaacacagcct
acctgcagatgaacagcctgcgtgctgaggacactgccgtctattattgttctagatggggaggggacggcttctatgctatggacta
ctggggtcaaggaaccctggtcaccgtctcgagt
Hinge spacer
Gagagcaagtacggaccgccctgccccccttgccct
CD28tm
atgttctgggtgctggtggtggtcggaggcgtgctggcctgctacagcctgctggtcaccgtggccttcatcatcttttgggtg
4-1BB
Aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagc
tgccgatttccagaagaagaagaaggaggatgtgaactg
CD3 zeta
Cgggtgaagttcagcagaagcgccgacgcccctgcctaccagcagggccagaatcagctgtacaacgagctgaacctgggcag
aagggaagagtacgacgtcctggataagcggagaggccgggaccctgagatgggcggcaagcctcggcggaagaacccccag
ctgtataacgaactgcagaaagacaagatggccgaggcctacagcgagatcggcatgaagggcgagcggaggcggg
gcaagggccacgacggcctgtatcagggcctgtccaccgccaccaaggatacctacgacgccctgcacatgcaggccctgcccc
caagg
Ctcgagggcggcggagagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctagg
tEGFR
atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccacgcaaagtgtgtaacggaataggt
attggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaaaactgcacctccatcagtggcgatctccacatcc
tgccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactggatattctgaaaaccgtaaaggaaatc
acagggtttttgctgattcaggcttggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggacc
aagcaacatggtcagttttctcttgcagtcgtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggaga
tgtgataatttcaggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaaccaaaa
ttataagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgctcccccgagggctgctggggccc
ggagcccagggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggacaagtgcaaccttctggagggtgagcc
40 aagggagtttgtggagaactctgagtgcatacagtgccacccagagtgcctgcctcaggccatgaacatcacctgcacaggacgg
ggaccagacaactgtatccagtgtgcccactacattgacggcccccactgcgtcaagacctgcccggcaggagtcatgggagaaa
acaacaccctggtctggaagtacgcagacgccggccatgtgtgccacctgtgccatccaaactgcacctacggatgcactgggcca
ggtcttgaaggctgtccaacgaatgggcctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtg
gccctggggatcggcctcttcatgtga
Table 23
Her2 construct-intermediate spacer (SEQ Id No:55 )
Leader
Atgcttctcctggtgacaagccttctgctctgtgagttaccacaccca
Her2scFv
Gcattcctcctgatcccagatatccagatgacccagtccccgagctccctgtccgcctctgtgggcgatagggtcaccatcacctgc
cgtgccagtcaggatgtgaatactgctgtagcctggtatcaacagaaaccaggaaaagctccgaaactactgatttactcggcatcct
tcctctactctggagtcccttctcgcttctctggttccagatctgggacggatttcactctgaccatcagcagtctgcagccggaagactt
ttattactgtcagcaacattatactactcctcccacgttcggacagggtaccaaggtggagatcaaaggcagtactagcggc
ggtggctccgggggcggatccggtgggggcggcagcagcgaggttcagctggtggagtctggcggtggcctggtgcagccagg
gggctcactccgtttgtcctgtgcagcttctggcttcaacattaaagacacctatatacactgggtgcgtcaggccccgggtaagggc
ctggaatgggttgcaaggatttatcctacgaatggttatactagatatgccgatagcgtcaagggccgtttcactataagcgcagacac
atccaaaaacacagcctacctgcagatgaacagcctgcgtgctgaggacactgccgtctattattgttctagatggggaggggacgg
cttctatgctatggactactggggtcaaggaaccctggtcaccgtctcgagt
Hinge spacer
aagtacggaccgccctgccccccttgccctGgccagcctagagaaccccaggtgtacaccctgcctcccagccagga
agagatgaccaagaaccaggtgtccctgacctgcctggtcaaaggcttctaccccagcgatatcgccgtggaatgggagagcaac
ggccagcccgagaacaactacaagaccaccccccctgtgctggacagcgacggcagcttcttcctgtactcccggctgaccgtgg
acaagagccggtggcaggaaggcaacgtcttcagctgcagcgtgatgcacgaggccctgcacaaccactacacccagaagtccc
tgagcctgagcctgggcaag
CD28tm
Atgttctgggtgctggtggtggtcggaggcgtgctggcctgctacagcctgctggtcaccgtggccttcatcatcttttgggtg
4-1BB
Aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagc
tttccagaagaagaagaaggaggatgtgaactg
CD3 zeta
Cgggtgaagttcagcagaagcgccgacgcccctgcctaccagcagggccagaatcagctgtacaacgagctgaacctgggcag
aagggaagagtacgacgtcctggataagcggagaggccgggaccctgagatgggcggcaagcctcggcggaagaacccccag
gaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcgagatcggcatgaagggcgagcggaggcggg
gcaagggccacgacggcctgtatcagggcctgtccaccgccaccaaggatacctacgacgccctgcacatgcaggccctgcccc
caagg
Ctcgagggcggcggagagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctagg
tEGFR
atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccacgcaaagtgtgtaacggaataggt
attggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaaaactgcacctccatcagtggcgatctccacatcc
tgccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactggatattctgaaaaccgtaaaggaaatc
acagggtttttgctgattcaggcttggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggacc
aagcaacatggtcagttttctcttgcagtcgtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggaga
40 tgtgataatttcaggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaaccaaaa
ttataagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgctcccccgagggctgctggggccc
ggagcccagggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggacaagtgcaaccttctggagggtgagcc
aagggagtttgtggagaactctgagtgcatacagtgccacccagagtgcctgcctcaggccatgaacatcacctgcacaggacgg
ggaccagacaactgtatccagtgtgcccactacattgacggcccccactgcgtcaagacctgcccggcaggagtcatgggagaaa
45 acaacaccctggtctggaagtacgcagacgccggccatgtgtgccacctgtgccatccaaactgcacctacggatgcactgggcca
ggtcttgaaggctgtccaacgaatgggcctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtg
gccctggggatcggcctcttcatgtga
Table 24
Her2 construct-long spacer (SEQ Id No:56 )
leader
ctcctggtgacaagccttctgctctgtgagttaccacaccca
Her2scFV
ctcctgatcccagatatccagatgacccagtccccgagctccctgtccgcctctgtgggcgatagggtcaccatcacctgcc
gtgccagtcaggatgtgaatactgctgtagcctggtatcaacagaaaccaggaaaagctccgaaactactgatttactcggcatcctt
cctctactctggagtcccttctcgcttctctggttccagatctgggacggatttcactctgaccatcagcagtctgcagccggaagactt
cgcaacttattactgtcagcaacattatactactcctcccacgttcggacagggtaccaaggtggagatcaaaggcagtactagcggc
ggtggctccgggggcggatccggtgggggcggcagcagcgaggttcagctggtggagtctggcggtggcctggtgcagccagg
gggctcactccgtttgtcctgtgcagcttctggcttcaacattaaagacacctatatacactgggtgcgtcaggccccgggtaagggc
ctggaatgggttgcaaggatttatcctacgaatggttatactagatatgccgatagcgtcaagggccgtttcactataagcgcagacac
atccaaaaacacagcctacctgcagatgaacagcctgcgtgctgaggacactgccgtctattattgttctagatggggaggggacgg
cttctatgctatggactactggggtcaaggaaccctggtcaccgtctcgagt
long spacer
gagagcaagtacggaccgccctgccccccttgccctgcccccgagttcctgggcggacccagcgtgttcctgttcccccccaagcc
caaggacaccctgatgatcagccggacccccgaggtgacctgcgtggtggtggacgtgagccaggaagatcccgaggtccagtt
caattggtacgtggacggcgtggaagtgcacaacgccaagaccaagcccagagaggaacagttcaacagcacctaccgggtggt
gtctgtgctgaccgtgctgcaccaggactggctgaacggcaaagaatacaagtgcaaggtgtccaacaagggcctgcccagcagc
atcgaaaagaccatcagcaaggccaagggccagcctcgcgagccccaggtgtacaccctgcctccctcccaggaagagatgacc
aagaaccaggtgtccctgacctgcctggtgaagggcttctaccccagcgacatcgccgtggagtgggagagcaacggccagcct
gagaacaactacaagaccacccctcccgtgctggacagcgacggcagcttcttcctgtacagccggctgaccgtggacaagagcc
ggtggcaggaaggcaacgtctttagctgcagcgtgatgcacgaggccctgcacaaccactacacccagaagagcctgagcctgtc
cctgggcaag
CD28tm
atgttctgggtgctggtggtggtgggcggggtgctggcctgctacagcctgctggtgacagtggccttcatcatcttttgggtg
4-1BB
aaacggggcagaaagaaactcctgtatatattcaaacaaccatttatgagaccagtacaaactactcaagaggaagatggctgtagct
gccgatttccagaagaagaagaaggaggatgtgaactg
CD3zeta
Cgggtgaagttcagcagaagcgccgacgcccctgcctaccagcagggccagaatcagctgtacaacgagctgaacctgggcag
aagggaagagtacgacgtcctggataagcggagaggccgggaccctgagatgggcggcaagcctcggcggaagaacccccag
gaaggcctgtataacgaactgcagaaagacaagatggccgaggcctacagcgagatcggcatgaagggcgagcggaggcggg
gcaagggccacgacggcctgtatcagggcctgtccaccgccaccaaggatacctacgacgccctgcacatgcaggccctgcccc
caagg
Ctcgagggcggcggagagggcagaggaagtcttctaacatgcggtgacgtggaggagaatcccggccctagg
tEGFR
atgcttctcctggtgacaagccttctgctctgtgagttaccacacccagcattcctcctgatcccacgcaaagtgtgtaacggaataggt
40 attggtgaatttaaagactcactctccataaatgctacgaatattaaacacttcaaaaactgcacctccatcagtggcgatctccacatcc
tgccggtggcatttaggggtgactccttcacacatactcctcctctggatccacaggaactggatattctgaaaaccgtaaaggaaatc
acagggtttttgctgattcaggcttggcctgaaaacaggacggacctccatgcctttgagaacctagaaatcatacgcggcaggacc
aagcaacatggtcagttttctcttgcagtcgtcagcctgaacataacatccttgggattacgctccctcaaggagataagtgatggaga
tgtgataatttcaggaaacaaaaatttgtgctatgcaaatacaataaactggaaaaaactgtttgggacctccggtcagaaaaccaaaa
45 ttataagcaacagaggtgaaaacagctgcaaggccacaggccaggtctgccatgccttgtgctcccccgagggctgctggggccc
ggagcccagggactgcgtctcttgccggaatgtcagccgaggcagggaatgcgtggacaagtgcaaccttctggagggtgagcc
aagggagtttgtggagaactctgagtgcatacagtgccacccagagtgcctgcctcaggccatgaacatcacctgcacaggacgg
gacaactgtatccagtgtgcccactacattgacggcccccactgcgtcaagacctgcccggcaggagtcatgggagaaa
acaacaccctggtctggaagtacgcagacgccggccatgtgtgccacctgtgccatccaaactgcacctacggatgcactgggcca
ggtcttgaaggctgtccaacgaatgggcctaagatcccgtccatcgccactgggatggtgggggccctcctcttgctgctggtggtg
gccctggggatcggcctcttcatgtga
Claims (45)
1. A nucleic acid encoding a chimeric receptor, the chimeric receptor comprising: (a) an extracellular domain consisting of: 5 an extracellular ligand binding domain consisting of a single chain variable fragment (scFv) that binds to a CD19, wherein the scFv comprises a variable light chain (VL) domain comprising a CDRL1, a CDRL2, and a CDRL3 of the amino acid sequence encoded by SEQ ID NO:3, and a variable heavy chain (VH) domain comprising a CDRH1, a CDRH2, and a CDRH3 of the amino acid sequence 10 d by SEQ ID NO:3; and an extracellular polypeptide spacer that is about 15 amino acids or less in length and comprises an amino acid sequence of X1PPX2P, wherein X1 is a cysteine, glycine, or arginine and X2 is a cysteine or a threonine (SEQ ID NO:1); (b) a transmembrane domain; and 15 (c) an intracellular signaling domain that comprises a CD3ζ signaling domain and a costimulatory .
2. A nucleic acid encoding a chimeric receptor, the nucleic acid comprising: (a) a polynucleotide encoding a single chain variable fragment (scFv) 20 that binds to CD19, wherein the scFv ses: the amino acid sequence encoded by SEQ ID NO:3; (b) a polynucleotide encoding a transmembrane domain; (c) a polynucleotide ng a polypeptide spacer located between the scFv and the transmembrane domain, wherein the polypeptide spacer is about 15 25 amino acids or less in length and comprises an amino acid sequence of P, n X1 is a cysteine, glycine, or arginine and X2 is a ne or a threonine (SEQ ID NO:1); and (d) a polynucleotide encoding an intracellular signaling domain that comprises a CD3ζ signaling domain and a costimulatory domain.
3. The nucleic acid of claim 1 or 2, wherein the polypeptide spacer comprises a human IgG1, IgG2, or IgG4 hinge region or a modified version of a human IgG1, IgG2, or IgG4 hinge region.
4. The nucleic acid of any one of claims 1-3, wherein the polypeptide 5 spacer comprises the amino acid ce set forth in SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:51, SEQ ID NO:52, or SEQ ID NO:53.
5. The nucleic acid of any one of claims 1-3, n the polypeptide spacer comprises a ed human IgG4 hinge . 10
6. The nucleic acid of any one of claims 1-5, wherein the polypeptide spacer comprises the amino acid sequence set forth in SEQ ID NO:51.
7. The nucleic acid of any one of claims 1-6, wherein the polypeptide spacer is 10 to 15 amino acids in length.
8. The nucleic acid of any one of claims 1-7, wherein the polypeptide 15 spacer is about 12 amino acids in length.
9. The nucleic acid of any one of claims 1-8, wherein the polypeptide spacer consists of the amino acid sequence set forth in SEQ ID NO:21.
10. The c acid of any one of claims 1 and 3-9, wherein the VL domain comprises a VL domain present in the amino acid sequence encoded by SEQ ID 20 NO:3; and theVH domain comprises a VH domain present in the amino acid sequence encoded by SEQ ID NO:3.
11. The nucleic acid of any one of claims 1 and 3-10, wherein theVL domain comprises a CDRL1 sequence of RASQDISKYLN, a CDRL2 sequence of SRLHSGV, and a CDRL3 sequence of GNTLPYTFG, and theVH domain comprises a CDRH1 sequence of DYGVS, a CDRH2 sequence of VIWGSETTYYNSALKS, and a CDRH3 sequence of YAMDYWG.
12. The nucleic acid of any one of claims 1 and 3-11, wherein the VH 5 domain and theVL domain are separated by a peptide linker.
13. The nucleic acid of claim 12, wherein the peptide linker comprises the amino acid ce set forth in SEQ ID NO:36.
14. The nucleic acid of claim 12 or 13, wherein the scFv has a VL-linker-VH orientation. 10
15. The nucleic acid of any one of claims 1-14, wherein the transmembrane domain comprises a transmembrane domain of a CD8 or of a CD28.
16. The nucleic acid of any one of claims 1-15, wherein the transmembrane domain ses a transmembrane domain of a CD28 comprising the amino acid sequence encoded by SEQ ID NO:5, or the amino acid sequence 15 MFWVLVVVGGVLACYSLLVTVAFIIFWV.
17. The nucleic acid of any one of claims 1-16, wherein the mulatory domain comprises: the signaling domain of a 4-1BB or a modified version thereof; or the signaling domain of a CD28 or a modified version thereof. 20
18. The nucleic acid of claim 17, wherein the 4-1BB signaling domain ses amino acids 214-255 of SEQ ID NO:15 or comprises the amino acid sequence encoded by SEQ ID NO:6.
19. The nucleic acid of claim 17, wherein the CD28 signaling domain comprises amino acids 180-220 of SEQ ID NO:14 or comprises a modified version thereof comprising an LL → GG substitution located at ons 186-187 of SEQ ID NO:14. 5
20. The nucleic acid of any one of claims 1-19, wherein the CD3ζ signaling domain comprises the amino acid ce encoded by SEQ ID NO:7.
21. The nucleic acid of any one of claims 1, 3-18 and 20, wherein: the VL domain comprises the VL domain present in the amino acid sequence encoded by SEQ ID NO:3; and the VH domain comprises the VH domain present in 10 the amino acid sequence encoded by SEQ ID NO:3; the polypeptide spacer comprises the amino acid sequence set forth in SEQ ID NO:51; the transmembrane domain comprises the amino acid sequence d by SEQ ID NO:5; and 15 the intracellular signaling domain comprises the amino acid sequence encoded by SEQ ID NO:6 and the amino acid sequence encoded by SEQ ID NO:7.
22. The nucleic acid of any one of claims 1, 3-18, 20 and 21, wherein: the VL domain comprises the VL domain present in the amino acid sequence d by SEQ ID NO:3; and the VH domain comprises the VH domain present in 20 the amino acid sequence encoded by SEQ ID NO:3; the polypeptide spacer consists of the amino acid sequence encoded by SEQ ID NO:4 or consists of the amino acid ce set forth inf SEQ ID NO:21; the transmembrane domain comprises the amino acid sequence encoded by SEQ ID NO:5; and 25 the intracellular ing domain comprises the amino acid ce encoded by SEQ ID NO:6 and the amino acid sequence encoded by SEQ ID NO:7.
23. The nucleic acid of any one of claims 1, 3, 7, 8, 10, 18 and 20, wherein: the scFv has a VL-linker-VH orientation; the polypeptide spacer comprises a modified IgG4 hinge region; 5 the transmembrane domain comprises the amino acid sequence encoded by SEQ ID NO:5; and the ellular signaling domain comprises the amino acid sequence encoded by SEQ ID NO:6 and the amino acid ce encoded by SEQ ID NO:7.
24. The nucleic acid of any one of claims 1 and 3-23, wherein the scFv is 10 encoded by the sequence set forth in SEQ ID NO:3.
25. The nucleic acid of any one of claims 1-18 and 20-24, wherein the nucleic acid ses: (a) the sequence set forth in SEQ ID NO:3 encoding the scFv; (b) the sequence set forth in SEQ ID NO:4 encoding the polypeptide 15 spacer; (c) the sequence set forth in SEQ ID NO:5 ng the transmembrane domain; (d) the sequence set forth in SEQ ID NO:6 encoding the costimulatory domain; and 20 (e) the sequence set forth in SEQ ID NO:7 encoding the CD3ζ signaling domain.
26. The nucleic acid of any one of claims 1-18 and 20-25, wherein the nucleic acid encodes a chimeric receptor encoded by a nucleic acid comprising the ce set forth in SEQ ID NO:10. 25
27. An expression vector, comprising the nucleic acid of any one of claims 1-26.
28. The sion vector of claim 27, r comprising a polynucleotide encoding a marker sequence, wherein the polynucleotide encoding the marker ce is operably linked in frame with the nucleic acid encoding the chimeric receptor. 5
29. The expression vector of claim 28, wherein the nucleic acid ng the chimeric receptor and the polynucleotide encoding the marker sequence are separated by a polynucleotide encoding a cleavable linker.
30. The expression vector of claim 28 or 29, wherein the marker sequence is a truncated EGFR sequence. 10
31. The expression vector of claim 30, wherein the truncated EGFR ce is encoded by the polynucleotide of SEQ ID NO:9.
32. The expression vector of any one of claims 29-31, wherein the cleavable linker comprises a T2A peptide.
33. The expression vector of claim 32, wherein the T2A peptide is 15 encoded by the polynucleotide of SEQ ID NO:8.
34. An expression vector ng the amino acid sequence MLLLVTSLLLCELPHPAFLLIPDIQMTQTTSSLSASLGDRVTISCRASQDISKY LNWYQQKPDGTVKLLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIAT YFCQQGNTLPYTFGGGTKLEITGSTSGSGKPGSGEGSTKGEVKLQESGPGLV 20 APSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTYYNSAL KSRLTIIKDNSKSQVFLKMNSLQTDDTAIYYCAKHYYYGGSYAMDYWGQG TSVTVSSESKYGPPCPPCPMFWVLVVVGGVLACYSLLVTVAFIIFWVKRGR KKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQ QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQ 25 KDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR LEGGGEGRGSLLTCGDVEENPGPRMLLLVTSLLLCELPHPAFLLIPRKVCNGI GIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDIL TGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSL GLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKA 5 ALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVEN SECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGEN NTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGA LLLLLVVALGIGLFM.
35. An in vitro method for preparing an isolated host cell, sing: 10 introducing the nucleic acid of any one of claims 1-26 or the expression vector of any one of claims 27-34 into cells of a lymphocyte population and culturing the cells in the presence of anti-CD3 and/or anti-CD28, and at least one homeostatic cytokine.
36. The method of claim 35, wherein the lymphocyte population 15 comprises a lymphocyte that is CD45RA-, CD45RO+, and CD62L+.
37. The method of claim 35 or 36, wherein the lymphocyte population comprises a T cell.
38. The method of claim 37, wherein the T cell is a CD8+ T cell or a CD4+ T cell. 20
39. The method of claim 38, wherein the CD8+ T cell is selected from the group consisting of a naïve CD8+ T cell, a central memory CD8+ T cell, an effector memory CD8+ T cell, and a bulk CD8+ T cell.
40. The method of claim 39, wherein the CD8+ T cell is a central memory CD8+ T cell, wherein the l memory CD8+ T cell is CD45RO+ and 25 CD62L+.
41. The method of claim 38, wherein the CD4+ T cell is selected from the group consisting of a naïve CD4+ T cell, a central memory CD4+ T cell, an effector memory CD4+ T cell, and a bulk CD4+ T cell.
42. The method of claim 41, n the CD4+ T cell is a naïve CD4+ T 5 cell, wherein the naïve CD4+ T cell is CD45RA+, CD62L+, and CD45RO-.
43. A nucleic acid encoding a ic receptor as claimed in any one of claims 1-26 substantially as herein described and with reference to any example thereof.
44. An expression vector as claimed in any one of claims 27-34 10 substantially as herein described and with reference to any e thereof.
45. An in vitro method as claimed in any one of claims 35-42 substantially as herein described and with reference to any example thereof. PCT/U
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ745376A NZ745376B2 (en) | 2012-08-20 | 2013-08-20 | Method and compositions for cellular immunotherapy |
NZ745372A NZ745372B2 (en) | 2012-08-20 | 2013-08-20 | Method and compositions for cellular immunotherapy |
NZ745375A NZ745375B2 (en) | 2012-08-20 | 2013-08-20 | Method and compositions for cellular immunotherapy |
NZ745374A NZ745374B2 (en) | 2012-08-20 | 2013-08-20 | Method and compositions for cellular immunotherapy |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261691117P | 2012-08-20 | 2012-08-20 | |
US61/691,117 | 2012-08-20 | ||
NZ70547513 | 2013-08-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ738636A NZ738636A (en) | 2020-09-25 |
NZ738636B2 true NZ738636B2 (en) | 2021-01-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10869889B2 (en) | Method and compositions for cellular immunotherapy | |
JP7402933B2 (en) | Genetic tags for transgenes and their use | |
NZ738636B2 (en) | Method and compositions for cellular immunotherapy | |
NZ738636A (en) | Method and compositions for cellular immunotherapy | |
NZ745372B2 (en) | Method and compositions for cellular immunotherapy | |
NZ745376B2 (en) | Method and compositions for cellular immunotherapy | |
NZ745375B2 (en) | Method and compositions for cellular immunotherapy | |
NZ745374B2 (en) | Method and compositions for cellular immunotherapy |